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ii SUMMARY 
Thioesterases hydrolyze thioester bonds in a variety of substrates, including fatty 
acid CoA esters, and palmitoylated or myristoylated proteins, and participate in lipid 
metabolism, α- and β-oxidation, cholesterol metabolism, and other processes. 
According to their folding and the catalytic reaction mechanism, thioesterases are 
subdivided into two groups: α/β-hydrolases and hotdog-fold thioesterases. Whereas 
α/β hydrolases have been well characterized in mammals, the second group of 
enzymes, mammalian hotdog thioesterases have been studied to a much lesser 
extent (Hunt and Alexson, 2002). 
CTMP/Them4 protein has been identified in a yeast two-hybrid screening as an 
interactor and negative regulator of PKB (Maira et al., 2001). We have recently 
shown that CTMP/Them4 is a mitochondrial protein which is released form 
mitochondria after apoptosis induction and promotes cell death (Parcellier et al., 
2009a). Other reports have implicated CTMP/Them4 in glioblastoma development 
and in ischemia-induced neuronal cell death (Knobbe et al., 2004; Miyawaki et al., 
2009). CTMP is located in the intramembrane space and is associated with the inner 
mitochondrial membrane. Proper processing of CTMP is important for maintaining 
mitochondrial morphology. In a knock-out mouse model we have shown that 
mitochondria from CTMP1-/-
Parcellier et al., 2009b
 mice are more elongated and interconnected; these 
results were confirmed in a cell culture system by using siRNA against CTMP 
( ).   
Human CTMP2/Them5 protein shares 38% similarity with Them4, which has 
previously been shown to be an acyl-CoA thioesterase with a broad substrate range 
(Zhao et al., 2009). Interestingly, while Them4 orthologs have been found in yeast 
and lower eukaryotes, Them5 orthologs have only been found in higher eukaryotes.  
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Therefore, we were keen to investigate CTMP2/Them5. We have determined 
structures of both human Them4 and Them5 and confirmed that these proteins 
belong to the hotdog class of thioesterases. Previous reports have shown that 
mammalian hotdog proteins are organized in tetrameric or higher-order structures. 
However, both CTMP/Them4 and CTMP2/Them5 form homodimers, and thus seem 
to be more closely related to bacterial hotdog thioesterases. We also identified 
residues which participate in the formation of active centers and are important for the 
acyl-CoA hydrolysis. Although Them4 and Them5 have very similar folding, they 
exhibit structural differences and different substrate specificity. For example, Them4 
reacts with acetyl-CoA, whereas Them5 does not hydrolyze it. 
Hotdog-fold thioesterases play very diverse biological roles, and their function in 
mammals has not been fully studied. We could show that Them5-deficient mice are 
viable and fertile, and show no gross developmental abnormalities. Similarly to 
Them4, which has been reported to localize in mitochondria, Them5 is also a 
mitochondrial protein. Them5 is located in the mitochondrial matrix and the inner 
mitochondrial membrane, facing the matrix side. We therefore analyzed the 
morphology of mitochondria in Them5 knock-out mice. We demonstrate that Them5-
/- mice are characterized by a highly interconnected and elongated mitochondrial 
network compared to wildtype control mice. However, loss of Them5 does not affect 
the biogenesis of mitochondria. More importantly, we show that overexpression of a 
thioesterase-dead version of Them5 in a cell culture system leads to the appearance 
of a more elongated and interconnected mitochondrial network, similar to the 
phenotype observed in Them5-/-
In order to assess the lipid profile after Them5 ablation, we performed a detailed 
mass spectrometry analysis of lipid extracts from Them5
 tissues, indicating that the enzymatic activity of 
Them5 is important for maintaining normal mitochondrial morphology.  
-/- and control mitochondria. 
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We found that loss of Them5 leads to a two-fold increase in major species of 
monolysocardiolipin (MCL), which act as upstream metabolites in the remodeling 
cycle of cardiolipin (CL). CL is a phospholipid localized predominantly within the 
inner mitochondrial membrane (Esposti et al., 2003). On the basis of these results, 
we propose that Them5 has a rather specific action in vivo, namely that of regulating 
the initial metabolism of mitochondrial CL by maintaining, in particular, the pool of 
acyl groups used to re-acetylate one metabolic intermediate of cardiolipin, SP2-MCL 
(stearoyl-di-palmitoyl-monolysocardiolipin). More importantly, Them5 knock-out mice 
develop fatty livers and show deregulation of enzymes participating in lipid 
metabolism. Interestingly, young Them5-/-
  
 males are insulin-hypersensitive, which we 
have shown in both in vivo and in vitro settings. We were able to demonstrate that 
insulin-induced PKB phosphorylation is stronger and more sustained in knock-out 
tissues, and this led us to suggest that Them5/CTMP2, in addition to CTMP/Them4, 
also participates in regulation of PKB signaling. 
This work presents a structural and functional analysis of two members of a 
previously uncharacterized class of mammalian hotdog-fold enzymes. In addition, 
our data indicate for the first time a connection between the loss of thioesterase 
activity, mitochondrial morphology and function, and development of fatty liver 
disease. Considering that very limited information is available about the biological 
role of mitochondrial hotdog-fold thioesterases in mammals, our work provides a 
framework for future research in this area.  
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1. GENERAL INTRODUCTION 
 
1.1 MITOCHONDRIA: CONNECTION OF MORPHOLOGY AND SIGNALING 
Mitochondria are cellular organelles that are believed to be a result of a symbiotic 
relationship between eubacteria and the eukaryotic cell. This allowed cells to survive 
in a new environment, utilizing aerobic metabolism (Green and Reed, 1998). 
Following endosymbiosis, genes were rapidly lost or transfered to the nuclear 
genome, which was important for the survival of the endosymbiont. This had to be 
compensated either by the transfer of some of these gene products from the 
nucleus, or by the transport of other proteins to replace them. As a consequence of 
some genes’ integration into the nuclear genome, proteins had to acquire 
mitochondrial targeting sequences. This also led to the development of protein 
import machinery into the mitochondria.  
Without oxidative phosphorylation, animal cells would have depended on anaerobic 
glycolysis for all their ATP production; aerobic mitochondria produce up to 95% of 
the cells’ ATP via oxidative phosphorylation (da Fonseca et al., 2008).  
The role of mitochondria as “powerhouses” in the cell is crucial. They are the location 
of three of the most important energy-generating pathways in humans: oxidative 
phosphorylation (OXPHOS), fatty-acid β-oxidation, and the tricarboxylic acid (TCA) 
cycle. However, they are also important components of signaling cascades. In 
addition to their role as amplifiers in apoptotic events, they also produce reactive 
oxygen species (ROS) that act as second messengers. The localization of 
mitochondria in the cell is also not random: they accumulate mainly in the places 
where high amounts of ATP are needed, or where regulation of Ca2+ signaling is 
required. To ensure the good performance of all these functions, mitochondrial 
populations should be very dynamic. They constantly undergo processes of fusion 
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and fission, maintaining a balance between tubular highly interconnected and 
fragmented morphology.  
 
 
 
 
 
Mitochondria have two membranes, the outer mitochondrial membrane (OMM) and 
the inner mitochondrial membrane (IMM), which have different functions and 
composition. These two membranes, in turn, define the intramembrane space (IMS) 
and the mitochondrial matrix. The organelle plasticity is achieved by the ability of the 
IMM and OMM membranes to fuse in a coordinated manner. By regulating the 
relative rates of fusion and fission, the morphology of the mitochondrial population 
can be significantly altered, which has important consequences for mitochondrial 
functions.  
 
 
 
Figure 1.1 
Schematic view of mitochondria. Mitochondria are composed of an outer membrane surrounding an inner 
membrane folded into cristae that increase the surface area available to membrane-bound molecules 
involved in energy transfer. The mitochondrial matrix contains enzymes, circular DNA, and ribosomes. 
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1.1.1 Fusion and fission proteins 
A number of fusion/fission machinery components have been identified, first in yeast 
and then later in mammalian cells (see Figure 1.5). Two dynamin-like GTPases, 
mitofusins 1 and 2 (Mfn1/2), are located at the outer mitochondrial membrane and 
are principal regulators of the fusion process (Chen et al., 2003). Another protein 
involved in fusion is the GTPase OPA1, which also belongs to the dynamin family. It 
is located in the intramembrane space and is associated with the inner mitochondrial 
membrane (Spinazzi et al., 2008). Both Mfn2 and OPA1 are known to be involved in 
neurodegenerative diseases (Alexander et al., 2000; Engelfried et al., 2006; 
Verhoeven et al., 2006),  
Mitochondrial fission depends on the dynamin-related protein 1 (Drp1). It is located 
in the cytoplasm and translocates to mitochondria in response to cellular and 
mitochondrial cues. Fis1 is an outer membrane protein that faces the intramembrane 
space, and its overexpression leads to mitochondrial fragmentation. Additionally, 
Fis1 and Drp1 interact with each other (Yoon et al., 2003). This is rather a transient 
event, and dissociation of the complex is required for efficient fission. However, the 
above interaction process has been described more complete in yeast, which have 
another adaptor protein of the interaction process, Mdv1 (Naylor et al., 2006). 
Mammalian are lacking its ortholog (or it has not been identified yet), and the fission 
process mechanics is still to be fully described.  
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1.2.2 Mitochondrial phospholipids  
1.1.2 Phospholipids of mitochondria 
Phospholipids (PL) are important components of mitochondrial membranes. The 
relative abundance of different PLs varies little among different cell types, indicating 
that major changes cannot be tolerated. Indeed, changes in the PL spectrum have 
been associated with altered mitochondrial structure and function. The most 
abundant proteins in mitochondria are cardiolipin (CL) and phosphatidylinositol, 
which comprise ca. 40% and 30% of total mitochondrial PLs, respectively (see 
Figure 1.6). In mammalian cells, mutations in phosphatidylglycerol phosphate 
synthase eliminate phosphatidylglycerol and CL pools, leading to alterations in 
mitochondrial structure and functions (Ohtsuka et al., 1993).  
CLs are particularly interesting phospholipids, located in the inner mitochondrial 
membrane. CL is a dimeric phospholipid, composed of a glycerol backbone and four 
acyl chains. CL is an important regulator of the biophysical properties of cellular 
membranes; it is known to favor membrane fold creation. Also, CL forms clusters 
Figure 1.2  
Mitochondrial fusion and fission molecules. (A) Fusion molecules. Mfn is a mitochondrial outer 
membrane protein with a cytosolic GTPase domain (orange oval) and two coiled coil regions (coils). The C-
terminal coiled coil mediates oligomerization between Mfn molecules on adjacent mitochondria. OPA1 
(white oval) is a GTPase in the intermembrane space. Mfns and OPA1 coordinate mitochondrial fusion, as 
shown by the mixing of green and red matrix markers to produce yellow. (B) Fission molecules. Fis1 is 
localized uniformly to the mitochondrial outer membrane, whereas Drp1 is localized to the cytosol and 
punctate spots on mitochondria[or Fis1?]. Some of these spots are constriction sites that lead to 
mitochondrial fission. Taken from (Chen and Chan, 2005) 
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and non-bilayer structures. Additionally, it strongly interacts with many different 
proteins, including mitochondrial membrane transport complexes, the fusion protein 
OPA1, cytochrome c, and components of respiratory complexes, which leads to 
specific features of CL-associated disorders. 
        
 
                         
 
 
 
 
 
1.1.3 Synthesis and remodeling of cardiolipin 
Cardiolipin is synthesized from its precursors PG and CDP-DAG, and after primary 
synthesis CL chains are remodeled and CL achieves its final maturation. The 
enzymes responsible for CL synthesis and remodeling are outlined in Figure 1.4   
The mature acyl chain composition of CL cannot be explained by the substrate-
specificity of CL synthase. This implies that additional mechanisms are involved in 
achieving the final composition by acyl chain remodeling. Remodeling can occur 
either by the deacylation-reacylation cycle, or by transacylation. Deacylation is 
Figure 1.3  
Phospholipids in mitochondrial membranes. (A) The central structural element of phospholipids is a 
glycerol backbone. Acyl chains that can vary in length and saturation are attached to the sn-1 and sn-2 
hydroxyl groups. Distinct hydrophilic head groups can be attached at the sn-3 position of the glycerol 
backbone via a phosphodiester bond and confer unique biophysical properties that distinguish the different 
phospholipid classes: phosphatidic acid (PA), phosphatidylserine (PS), phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI), and CDP-DAG. CDP-DAG 
is an intermediate that does not accumulate in significant amounts in mitochondrial membranes under normal 
conditions. (B) CL is a lipid unique to mitochondria, which consists of two PA moieties covalently linked to 
each other by a glycerol bridge, with phosphodiester bonds at the sn-1 and sn-3 positions of the bridging 
glycerol. Taken from (Osman et al., 2011). 
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mediated by phospholipase A, where the formation of monolyso-CL (MCL) is 
followed by CoA-dependent reacylation (Figre 1.4A) (Ma et al., 1999; Taylor and 
Hatch, 2003).  
 
 
 
 
 
 
 
 
The enzymes involved in this process are acyltranferases, which have been shown 
to exert specificity toward linoleic and oleic acyls, which are predominantly found in 
mature species of CL (Taylor and Hatch, 2009) (Cao et al., 2004). However, 
ALCAT1, the first identified CL-remodeling acyltransferase, lacks preference towards 
linoleic acid as a substrate. These enzymes are sensitive to the thyroid status and 
oxidative stress; ALCAT1 has been shown to be upregulated in diet-induced obesity, 
leading to pathological remodeling of CL due to its lack of preference towards linoleic 
Figure 1.4 
Phospholipid remodeling pathways (Schlame, 2008). (A) Phospholipid remodeling by the deacylation-
reacylation cycle (Lands cycle). This pathway is used for remodeling of other PLs (not CL). However, it may 
still be indirectly involved in CL remodeling, providing necessary turnover of fatty acids. (B) CL remodeling 
by phospholipid transacylation. CL remodeling is catalyzed by a single enzyme tafazzin, which mediates 
several transacylation reactions (highlighted in the grey box). Tafazzin is equally active with the substrates 1-
monolysocardiolipin (1-MLCL) and 2- monolysocardiolipin (2-MLCL). Because it can also transfer acyl 
groups from CL to MLCL, it can function as a positional isomerase. The acyl groups are directly transferred 
from the phospholipid (PL) to the lysophospholipid (LPL), and no acyl-enzyme intermediate is present, since 
free fatty acids are not released in the absence of an acyl acceptor. 
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acid as a substrate (Cao et al., 2009a), (Li et al., 2010). The second way of CL 
remodeling, transacylation, involves the transfer of an acyl chain from PC to MCL, 
forming lyso-PC and CL. This is mediated by the enzyme tafazzin. The acyl groups 
are transferred directly from the phospholipid to the lysophospholipid, with no acyl 
intermediate, because free fatty acids are not released in the absence of an acyl 
acceptor (Figure 1.4B).  
1.1.4 Role of cardiolipin in diseases  
Mutations in the tafazzin gene (chromosome Xq28) are associated with Barth 
syndrome, an X-linked recessive disorder, clinically characterized by 
cardiomyopathy, growth delay, and neutropenia (Vreken et al., 2000). As a result of 
the tafazzin mutations, CL remodeling is impaired, and abnormal profiles of CL can 
be detected. CL levels are lower, MCL levels are increased, and the acyl chain 
composition is shifted towards unsaturated species (Xu et al., 2006). As a 
consequence of CL/MCL imbalance, mitochondria of taz-deficient cells show 
abnormalities in the cristae and compromised bioenergetic mitochondrial coupling 
(van Gestel et al., 2010). Loss of the acyl-CoA binding protein Acb1p leads to a 
similar phenotype, resulting in the accumulation of short acyl chains (fewer than 16 
carbon atoms) in CL (Rijken et al., 2009). It has been proposed that CL is required 
for Bid/Bax activation and oligomerization during apoptosis (Kuwana et al., 2002). 
Bax oligomerization requires tBid and occurs after it has translocated to 
mitochondria. However, the data from Iverson et al. question the role of CL in this 
process (Iverson et al., 2004). In contrast, the authors suggest that CL is required for 
cytochrome c retention within the cristae, supporting the two-step mechanism of 
cytochrome c release, which states that CL is required for binding cytochrome c to 
the inner mitochondrial membrane (Ott et al., 2002) (See Figures 1.5 and 1.6).  
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Additionally, CLs are very prone to peroxidation by ROS due to the high content of 
unsaturated fatty acids and their location near the site of ROS production (Paradies 
et al., 2001). Reduction of mitochondrial phosphatydylethanolamine or CL leads to 
abnormal mitochondrial morphology and the appearance of more mitochondria with 
respiratory defects (Claypool et al., 2008a). CL stimulates OPA1 oligomerization and 
its GTPase activity (Ban et al., 2010). Lipid binding by the yeast OPA1 ortholog, 
Mgm-1, is required for mitochondrial membrane fusion (DeVay et al., 2009). 
Impaired processing of OPA1 leads to aberrant morphology, which emphasizes the 
importance of membrane composition for maintaining mitochondrial morphology.  
 
Figure 1.5  
Regulation of cytochrome c release from mitochondria. The mitochondrial outer membrane is 
permeabilized by tBid, which promotes the oligomerization and insertion of Bax and Bak. Cytochrome c 
release is initiated by the dissociation of the hemoprotein from its binding to cardiolipin in the inner 
mitochondrial membrane, which is stimulated by cardiolipin peroxidation (mediated by ROS). Once 
released into the cytosol, cytochrome c triggers pro-caspase-activation via the apoptosome mechanism. 
Taken from (Fariss et al., 2005).  
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1.2 ENERGY METABOLISOM IN THE CELL 
1.2.1 Fatty acid synthesis  
Once fatty acids (FAs) enter a cell, they either diffuse or are transported to the 
mitochondria, peroxisomes, or endoplasmic reticulum. Fatty Acid Binding Proteins 
(FASBPs), which regulate FA uptake and intracellular transport, may function as 
carriers of FAs in the cytoplasm. In animal cells, β-oxidation takes place in 
mitochondria and peroxisomes: this pathway is similar to a reversal of fatty acid 
synthesis. Similarly, FA synthesis takes place in at least two subcellular 
compartments in eukaryotic cells: cytoplasm and mitochondria. Cytosolic FAS in 
eukaryotes relies on the activity of a multifunctional, multidomain enzyme (FAS-I) to 
Figure 1.6. Cardiolipin peroxidation in mitochondria 
Increased production of ROS in mitochondria leads to oxidation of cardiolipin. Cardiolipin peroxidation, in 
turn, affects the binding of cytochrome c to the mitochondrial inner membrane, leading to an increased 
soluble pool of cytochrome c in the IMS. Consequently, upon permeabilization of the OMM by activated 
Bax, a larger amount of mitochondrial cytochrome c can be released, making it more likely for a cell to 
undergo apoptosis (adapted from (Perier et al., 2005)). 
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catalyze the repetitive FA synthesis steps, whereas the mitochondrial system (FAS-
II) depends on individual, monofunctional enzymes that catalyze individual reactions.  
Regulation of fatty acid synthesis, or lipogenesis, occurs via the action of lipogenic 
enzymes, namely fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and 
ATP citrate lyase (ACL). 
ACC is the rate-limiting enzyme in fatty acid synthesis. Two major isoforms of ACC 
exist: ACC1 and ACC2. ACC1 is cytosolic and is present in liver, adipose, and 
lactating mammary glands. ACC2 is expressed in heart, liver, and skeletal muscle. 
ACC2 associates with CPT1, thereby participating in CPT1 downregulation by 
malonyl-CoA, produced by ACC. ACC1 is activated upon polymerization, which is 
not the case for ACC2. However, both ACC1 and ACC2 are allosterically activated 
by citrate and inhibited by long- and short-chain fatty acids, products of fatty acid 
synthesis. Additionally, ACC activity can be affected by phosphorylation. Thus, 
ACC1 phosphorylation by AMPK leads to its inhibition. Also, increased levels of 
cAMP, mediated by glucagon, and the subsequent increase in PKA activity lead to 
ACC phosphorylation. As a result, insulin (re-feeding) stimulates ACC and FA 
synthesis, whereas starvation leads to a decrease in FA synthesis.  
At the transcriptional level, regulation of these lipogenic genes in response to 
glucose and insulin occurs via SREBP-1/2, liver X receptors, and ChREBP.  
Fatty acid synthesis plays an important role in animal development, as shown by 
knock-out studies: ACC1 and FAS full body deletion causes embryonic lethality 
(Abu-Elheiga et al., 2003) (Chirala et al., 2003).  
 
1.2.2 Fatty acid degradation/β-oxidation 
β-oxidation provides a lot of energy for essential cellular functions, and each cellular 
compartment metabolizes a specific set of FAs, e.g. very-long chain, long chain, 
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saturated, non-saturated, short- or medium-chain fatty acids, eicosanoids, and bile 
acid intermediates. Mitochondria receive shortened products from peroxisomes, 
which are either further oxidized, or utilized in the production of ketone bodies to 
provide energy for extrahepatic tissues (Hunt and Alexson, 2002) (see Figure 1.3).  
For degradation via the mitochondrial β-oxidation pathway, the acyl group of 
cytosolic acyl-CoA passes the mitochondrial membrane bound to carnitine via a 
carnitine shuttle operated by carnitine-acylcarnitine translocase. Then acyl groups 
are transferred to CoA. Mammalian carnitine acyltransferases are characterized by 
different chain-length specificity: carnitine O-palmitoyltransferase I and II (CPT-I/II), 
present on both sides of the mitochondrial inner membrane, react specifically with 
long-chain acyl-CoA compounds; carnitine O-acyl transferases, found in 
peroxisomes and mitochondria, react on C2---C10
The process of fatty-acid oxidation occurs through the sequential removal of 2-
carbon units by oxidation at the β-carbon position of the fatty acyl-CoA molecule.  
 from acyl-CoA.   
There are multiple enzymes, which vary in their chain-length specificity, for each of 
the β-oxidation steps. Schematically, the β-oxidation pathway is presented in Figure 
1.7. 
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Each round of β-oxidation produces one mole of NADH, one mole of FADH2, and 
one mole of acetyl-CoA. Acetyl-CoA then enters the TCA cycle, resulting in the 
production of an additional three moles of NADH, one mole of FADH2
β-oxidation regulation is very much dependent on the organ of interest. Thus, liver is 
capable of high rates of β-oxidation and ketogenesis. Under fed conditions, when 
glucose levels are high, free fatty acids levels are low and CPT1 is inhibited by high 
levels of malonyl-CoA. Thus, the carbon flux is from glucose to de novo lipogenesis 
, and one mole 
of ATP. The resultant NADH and FADH2 enter then the respiratory chain to produce 
ATP.  
Figure 1.7 
Mitochondrial β-oxidation. The mitochondrial fatty acid β-oxidation pathway contains four reaction steps 
including acyl-CoA dehydrogenases, enoyl-CoA hydratase, β-hydroacyl CoA dehydrogenase, and β-ketoacyl 
CoA thiolase. The last three steps of β-oxidation are performed by a highly organized single enzymatic 
complex, known as mitochondrial trifunctional protein, associated with the inner mitochondrial membrane.  
Completely independent enzymes responsible for β-oxidation of medium- and short-chain fatty acids are 
located in the mitochondrial matrix. 
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via citrate and malonyl-CoA (see Figure 1.8). During starvation, FFA levels in blood 
rise in response to a higher glucagon/insulin ratio, and activate adipose tissue 
triacylglycerol lipase. Hepatic malonyl-CoA levels are lowered due to both a slower 
efflux of citrate from mitochondria and to phosphorylation (i.e. inactivation) of ACC by 
AMPK, again in response to a higher glucagon/insulin ratio. Hence, β-oxidation and 
ketogenesis are activated and an increase in ketone bodies is observed.  
In extrahepatic tissues, where there is no active lipogenesis (heart and skeletal 
muscle), β-oxidation provides contractile energy. The rate of β-oxidation increases 
upon demand, e.g. an increased work rate and ATP demand lead to faster oxidative 
phosphorylation and TCA cycle activity. NADH and acetyl-CoA levels decrease and 
thus β-oxidation flux increases.  
Control of mitochondrial β-oxidation occurs at several levels. One of them is the 
entry of acyl groups into the mitochondria. This is achieved via regulation (inhibition) 
of CPTI by malonyl-CoA. Another is intramitochondrial, since β-oxidation consists of 
several enzymes with overlapping chain-specificities.   
Product inhibition is a potent way to regulate the activity of β-oxidation enzymes. 
Thus, acyl-CoA dehydrogenases are inhibited via their enoyl-CoA products, as well 
as via 3-oxoacyl-CoA esters (which are formed two steps down the pathway). 
Crotonase (enoyl-CoA hydratase) is similarly inhibited by acetoacetyl-CoA. 3-
oxoacyl-CoA thiolase is inhibited by acetyl-CoA, leading to feedback inhibition of β-
oxidation due to inhibition of acetyl-CoA disposal to ketogenesis, the TCA cycle, or 
acetyl-carnitine. However, 3-oxoacyl-CoA thiolase is not inhibited by its acyl-CoA 
product. Regulation also happens at the level of acetyl-CoA disposal to ketogenesis. 
Depletion of free CoA, which is limited in mitochondria, inhibits both CPTII and 3-
oxoacyl-CoA thiolase, as well as other mitochondrial enzymes which are dependent 
on free CoA.  
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The respiratory chain is also quite tightly linked to β-oxidation. β-oxidation supplies 
substrates used by complexes I and III, which are then used to generate energy in 
the form of ATP. Consequently, inhibition of either of the electron transfer chain 
stages results in β-oxidation inhibition. There are also data supporting not only the 
functional, but also the physical, association of ETC with fatty acid oxidation 
enzymes (Wang et al., 2010). This is not surprising, given the localization of both 
components of β-oxidation and OXPHOS in the IMM.  
 
 
 
 
 
1.2.3. Oxidative phosphorylation and the electron transfer chain 
Four major protein complexes that facilitate electron and proton flow are located in 
the inner mitochondrial membrane. Complexes I and II transfer electrons from the 
TCA cycle-generated NADH and FADH2 to CoQ, then to complex III (CoQ 
reductase), then to cytochrome c, then to complex IV (cytochrome c oxidase), and 
Figure 1.8. Fatty acid synthesis and degradation: modulation of CPTI activity 
See the text of the section 1.2.2 for explanations (modified from (Eaton et al., 1996)) 
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then to molecular oxygen, finally producing water (Figure 1.9). At the same time, 
protons cross the IMM at complexes I, III, and IV, generating an electrochemical 
gradient, which will be used by ATP synthase (complex V, but technically not a 
member of the respiratory chain). 
Two alternative models have been proposed for the organization of the OXPHOS 
system. The first is the random collision model, where all the components are 
independent of each other and the electron transfer is possible due to transient 
meeting by the complexes (Hackenbrock et al., 1986). The second, the “solid-state” 
model proposed more than 55 years ago, postulates that enzyme components are 
assembled into a huge supramolecular energy-converting machine (Chance and 
Williams, 1955). Recently it has been demonstrated that supercomplexes do indeed 
exist and can function as respirasomes (Acin-Perez et al., 2008). Thus, the solid-
state model should be reconsidered when developing a new model of the respiratory 
chain: coexistence of both individual complexes and various supercomplexes should 
be taken into account. This model also proposes that supercomplex composition 
may vary according to tissue type or energy demand.  
The proper assembly of respiratory complexes is mediated via the biophysical 
properties of the inner mitochondrial membrane. Cardiolipin (CL), the major 
phospholipid of the IMM, is associated with complexes I, III, IV, and V, and the major 
carrier proteins for adenine nucleotides and phosphates (Osman et al., 2011). Also, 
reconstruction of complex IV and the ADT/ATP carrier (ACC) activity in vitro 
demonstrated a strong need for CL (Hoffmann et al., 1994). Overall, it is accepted 
that CL, although not mandatory for OXPHOS, significantly improves the efficiency of 
this process (Claypool et al., 2008a; Claypool et al., 2008b). 
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 In yeast, structural changes in the organization of the respiratory complexes when 
CL is absent are directly associated with functional consequences, such as 
cooperation between the complexes or their stability (Zhang et al., 2002). Patients 
with Barth syndrome, a cardiomiopathy which involves mutation of tafazzin, are 
characterized by unstable OXPHOS complex association, and, as a consequence, 
by defects in respiratory chain activities (McKenzie et al., 2006).  
Mitochondrial morphology depends very much on the energetic state of the cell. For 
example, a decrease in mitochondrial membrane potential leads to organelle 
fragmentation. It has been suggested that compromised membrane potential blocks 
fusion by Opa1 degradation, which leads, in turn, to the activation of fission 
machinery (Cereghetti et al., 2008). Grown on glucose yeasts are characterized by 
low levels of respiration; however, when glucose is depleted cells increase their 
Figure 1.9 
Schematic view of the electron transfer chain. Reduced substrates (NADH and FADH2) are oxidized, 
with electrons passing to the enzyme complexes of the electron transfer chain (ETC) and the protons being 
pumped into the IMS of the mitochondria, forming a large proton motive force (PMF). The PMF consists of 
an electrical (Δψ) and a chemical (ΔP) component and is maintained by the ETC. Functionally, the ETC 
consists of four multitprotein complexes (CI-CIV) and the electron carrier coenzyme Q10 (CoQ) and 
cytochrome c (Cyt C). Electrons are extracted from NADH at complex I and FADH at complex II, and are 
transported by CoQ to complex III. Subsequently, electrons are transferred to complex IV by cytochrome c, 
where they are donated to molecular oxygen to form water. The energy released from electron transfer is 
used to drive trans-IMM proton efflux, establishing the PMF. By allowing backflow of protons, ATP is then 
produced by complex V (F0F1-ATP synthase). The ETC complexes, together with complex V, constitute the 
OXPHOS (oxidative phosphorylation) system. 
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respiratory capacity and mitochondria are forming interconnected network. Later, 
when culture reaches saturation, mitochondrial network tends to fragment (Sauvanet 
et al., 2010). On the other hand, changes in mitochondria-shaping proteins can affect 
the bioenergetic state of the cell. Impaired fusion and activated fission processes can 
cause mitochondrial dysfunction. Blockage of fission by downregulation of Drp1 may 
lead to a loss of mtDNA, a decrease of mitochondrial respiration, and an increase in 
ROS (Parone et al., 2008). In β-cells, for example, it has been shown that inhibition 
of the fission machinery may lead to decreased mitochondrial autophagy, 
accumulation of oxidized proteins and, in turn, impaired insulin secretion (Twig et al., 
2008).  
Phospholipids, in addition to the already known proteins such as Opa1, Mfn1/2, etc., 
have become new players in the field of mitochondrial dynamics. However, a recent 
publication from our group introduced another interesting molecule, CTMP/Them4, to 
the area of mitochondrial morphology (Parcellier et al., 2009b). 
 
1.3 THIOESTERASES AND THEIR ROLE IN THE CELL 
Thioesterases are ubiquitous and diverse enzymes; they are present in bacteria, 
archea, and up to eukaryotes. They hydrolyze thioester bonds in a variety of 
substrates, including fatty acid CoA esters, and palmitoylated or myristoylated 
proteins; they participate in lipid metabolism; they regulate levels of fatty acids and 
CoA, cell membrane composition, α- and β-oxidation, cholesterol metabolism (Hunt 
and Alexson, 2002).  
According to their folding and the catalytic reaction mechanism, thioesterases are 
subdivided into two groups: α/β-hydrolases and hotdog-fold thioesterases. There is 
no apparent sequence similarity between these two groups of enzymes; however, 
within the α/β-hydrolase group there is quite a high degree of sequence 
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conservation. Interestingly, hotdog-fold enzymes show no strong amino acid 
similarity. On the other hand, these enzymes have very conserved folding: β-sheets 
wrapped around a central α-helix, from where they received their name. However, 
both groups of enzymes hydrolyse a thioester bonds and release free fatty acids and 
CoASH (or any other moiety) (see Figure 1.10).  
 
 
 
 
Although the majority of mammalian thioesterases are α/β-hydrolases and have 
been relatively well studied, mammalian hotdog-fold enzymes have been less well 
described. Recent publications concerning hotdog-fold hydrolases in mammals 
include: Acot13/Them2, a thioesterase with dual (mitochondrial and cytoplasmic) 
localization; and Acot7, which has been implicated in eicosanoid synthesis in the 
cytoplasm and inflammatory processes (Cao et al., 2009b; Forwood et al., 2007). As 
well as there being only seven known hotdog-fold enzymes in mammals (Acot7-9, 
Acot11, Acot13, Them4 and Them5), published data describe mainly their 
cytoplasmic or peroxisomal forms. In contrast, α/β thioesterases have been studied 
considerably better. This group of enzymes includes Acot1 (known previously as 
Figure 1.10 
Examples of two major classes of thioesterases. (A) α/β hydrolase Acot2 with a classical Ser-Asp-His 
catalytic triad. From (Pidugu et al., 2009). (B) Hotdog-fold thioesterase Acot7 (in stylized representation 
with monomers in red and blue).Two putative active sites are present within each dual hotdog fold, site I and 
site II. From (Forwood et al., 2007). 
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CTE-1, cytoplasmic thioesterase 1), Acot2 (mitochondrial thioesterase 1, MTE1), the 
lysosomal protein palmitoyl thioesterase 1 (see Figure 1.11). 
 
 
 
1.3.1 α/β thioesterases 
α/β-thioesterases can act towards different types of substrates. Based on that, they 
can be subdivided into protein thioesterases and acyl-CoA thioesterases.  
 
Protein thioesterases 
Protein thioesterases act on palmitoylated or myristoylated proteins. This is 
particularly important for regulation of protein trafficking, protein-protein interactions, 
and signaling. One well characterized protein, palmitoylthioesterase 1 (PPT1), has 
been implicated in the development of infantile neuronal ceroid lipofuscinosis, a 
severe neurodegenerative disease in children (Ahtiainen et al., 2006; Waliany et al., 
Figure 1.11 
Domain organisation of (A) 
human type I (α/β) and (B) type II 
(hotdog fold) acyl-CoA 
thioesterases (ACOTs).  
Closest homologues (THEM4 and 
THEM5) are included for 
comparison. Abbreviations: ACTH, 
acyl-CoA thioester hydrolase 
domain; BAAT, bile acid 
CoA:amino acid N-acyltransferase; 
EL, esteraselipase domain; HD, 
“hotdog” fold domain; START, 
steroidogenic acute regulatory 
protein (StAR)-related lipid transfer  
domain; THEM, thioesterase 
superfamily member. Taken from 
(Brocker et al., 2010) 
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2000). Ppt1, a lysosomal enzyme, cleaves thioester linkages in S-acylated proteins 
and removes palmitate residues, facilitating the degradation of these proteins. Ppt1 
deficiency leads to the activation of an unfolded protein response, ER and oxidative 
stress, and neuronal apoptosis (Zhang et al., 2006) (Wei et al., 2008).  
α/β fold acyl-CoA thioesterases and their functions 
Acyl-CoA thioesterases are important participants in metabolic pathways in the cell. 
They are substrates for the majority of pathways that use fatty acids for energy 
production or for synthesis of complex lipids; they are substrates for β-oxidation in 
mitochondria and peroxisomes and ω-oxidation in the endoplasmic reticulum.  
Termination of fatty acid synthesis is one of the established functions of α/β-fold acyl-
CoA thioesterases. For example, thioesterase I is part of the multifunctioning 
enzyme fatty acid synthase (FAS), where it functions as an acyl-releasing domain. 
Induction of some of the thioesterases by peroxisome proliferators suggests that 
they are involved in lipid metabolism (Di Nunzio et al., 2009; Dongol et al., 2007; 
Westin et al., 2004).   
 
1.3.2 Hotdog-fold thioesterases 
Hotdog-fold proteins include a variety of enzymes, mainly thioesterases, which are 
involved in a number of metabolic processes, including cholesterol biosynthesis and  
plasma membrane composition. The hotdog fold, which is formed of several anti-
parallel β-sheets wrapped around an α-helix, is found in all branches of life. 
However, up to now few mammalian proteins of this group have been described.  
The key feature of such thioesterases is that the hotdog domain does not exist as a 
single entity: it must form at least dimeric structures. The proteins contain either one 
copy of the domain and form homodimers and/or more complex structures, or have 
two copies of the domain, which dimerize with each other. The tertiary structures 
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vary and can include either dimers, tetramers, or hexamers (Dillon and Bateman, 
2004) (Figure 1.12).  
Recently, Pidugu et al. presented an analysis of hotdog-fold proteins of known 
structures that allows classification of these proteins with regard to the nature of their 
substrate and oligomeric state (Pidugu et al., 2009). In this analysis, normal 
members of the PAAI family, like E. coli PAAI or human Them2, form tetramers in a 
back-to-back arrangement of the β-sheets, while other PAAI family members, like the 
hypothetical proteins with PDB codes 1IXl (P. horikoshii), 2HBO (C. crescentus), and 
2OV9 (Rhodococcus sp.), are present as homodimers only, with altered 
tetramerization sequence motifs. The catalytic machinery of this class of proteins is 
well conserved, and is composed of an HGG motif and Asp/Thr residues. The 
carboxylate moiety is thought to deprotonate a water molecule prior to its 
nucleophilic attack on the thioester bond of the CoA-coupled fatty acid substrate, 
while the HGG motif at the N-terminal end of the central hotdog helix places the 
substrate thioester carbonyl group in the right position (Zhao et al., 2009).  
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1.3.3 Functions of mammalian hotdog-fold thioesterases 
The biological role of hotdog-fold thioesterases has not been fully addressed. A 
sequence and structure analysis of the hotdog fold-containing proteins carried out 
recently showed that consensus motifs in proteins may define the function and give a 
hint of the biological relevance of the proteins (Pidugu et al., 2009). These results 
suggest the substrate type that may be used by enzymes; however, they cannot 
provide information about any potential physiological role. 
It has been suggested that Acot7 participates in the mediation of inflammatory 
reactions via involvement in eicosanoid metabolism (Forwood et al., 2007; Serek et 
Figure 1.12  
Various quaternary associations of hot dog fold proteins. D, dimer; dh, double hotdog; H1, hexamer with 
active site loops at interface; H2, hexamer with N-terminal helices at interface; H3, hexamer with head-to-
tail arrangement of dimers; TA, tetramer with central helix interactions; TB, tetramer with back-to-back 
stacking of the β-sheets. DdhA (dimer of double hotdog with central helix interactions) is similar to TA while 
DdhB (dimer of double hotdog with back-to-back interaction of the β-sheets) is similar to TB. Trdh (trimer of 
double hotdog) is similar to H2. Taken from (Pidugu et al., 2009). 
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al., 2006). It has multiple splice variants, resulting in proteins with different 
subcellular localization; however, the biological role has only been addressed for its 
cytoplasmic isoform (Forwood et al., 2007). Them2, another mammalian hotdog 
thioesterase, also displays dual localization, cytosolic and mitochondrial (Cheng et 
al., 2006; Wei et al., 2009). It has been identified among proteins regulated by 
HNF4α, raising the possibility that Them2 may be involved in renal cell carcinoma 
pathogenesis (Lucas et al., 2005). Another study has shown its interaction with the 
StarD2 protein (phosphatidylcholine transfer protein
Kanno et al., 2007
 (PC-TP, a.k.a. StarD2)), 
suggesting that it has a role in fatty acid metabolism ( ). 
 
Physiological roles of acyl-CoA and acyl-CoA thioesterases, and their deficiencies 
In mitochondria, acyl-CoA thioesterases (Acots) lower increased levels of acyl-CoA 
(which have been imported through CPTI/II across the mitochondrial membrane from 
the cytosol). As a consequence, they counteract enhanced β-oxidation and reduce 
mitochondrial stress caused by any imbalance between fatty acid oxidation and TCA 
cycle/electron transfer chain activity during fatty acid overload. During these periods, 
when levels of acyl-CoA are high, excessive amounts of esters are preferentially 
hydrolyzed by Acots. It has been shown that the major site of H2O2
Elsner et al., 
2011
 production 
during FA overload are the peroxisomes, and not the mitochondria (
). In addition, mitochondrial β-oxidation may not be able to cope with the 
elevated levels of long-chain fatty acids which are associated with obesity and type 2 
diabetes. This overload results in a larger proportion of fatty acids being metabolized 
via the peroxisomal β-oxidation system, leading to increased levels of toxic H2O2
Some inborn human disorders of mitochondrial fatty acid β-oxidation are known, and 
are characterized by fasting-induced episodes of hypoketonic-hypoglycemia, 
metabolic acidosis, hyperammonemia, and fatty livers (
.   
Roe, 2001).   
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During metabolic stress which induces hypoglycemia (fasting, thermal stress, viral 
infection), a “normal” infant should produce ketone bodies as a combined result of 
mitochondrial FAO and ketogenesis. This provides an alternate fuel to help spare 
glucose as metabolic requirements increase. In addition, β-oxidation is required to 
energize gluconeogenesis. Thus, in an infant with an inborn error in this pathway the 
glycogen stores are quickly depleted during metabolic stress. Due to an inadequate 
ketogenic response and other mechanisms, this infant would be unable to maintain 
blood glucose levels. These characteristic clinical symptoms are termed Reye-like 
syndrome (Gosalakkal and Kamoji, 2008). Patients have a varying phenotype 
ranging from no clinical signs to sudden death. 
Several mouse models have been generated to study different steps during 
mitochondrial β-oxidation of fatty acids (Spiekerkoetter and Wood, 2010); they 
include mainly different types of dehydrogenases, and CPT-Ia/b deficiencies 
(Spiekerkoetter and Wood, 2010).  
In general, when sufficient nutrients are available, fatty acids are stored as 
triacylglycerol (TAG), mainly in adipocytes, and are released during starvation or 
metabolic stress. However, other non-adipose tissues are also able to deposit TAG, 
e.g. liver, β-cells, muscle, heart, and this leads to lipotoxicity.  
Intracellular levels of acyl-CoA are known to correlate with insulin resistance and 
may lead to lipotoxicity in non-adipose tissues (Li et al., 2008a). The usual 
concentration of long-chain acyl-CoAs in the cytoplasm is between 1 and 20 μM, 
although local concentrations can also be higher. Furthermore, the concentration of 
acyl-CoA and ACBP are similar, which suggests that most acyl-CoA is bound to its 
carrier.   
The involvement of acyl-CoA in insulin sensitivity/resistance might be tissue-specific. 
In the pancreas, levels of acyl-CoA have been shown to regulate insulin secretion, 
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because in β-cells an increase in acyl-CoA levels enhances KATP
Herrero et al., 2005
 channel activity 
and reduces β-cell excitability ( ).  
Although there are a lot of indications of the importance of acyl-CoA levels in 
metabolic regulation, no direct mechanism has been proposed. In addition, the role 
of other fatty acid metabolites has not yet been completely resolved.  
CTMP/Them4 is part of the PKB signaling regulation network and, when released 
from mitochondria upon induction of apoptosis, sensitizes cells to death by 
negatively affecting PKB phosphorylation and, in turn, activation (Maira et al., 2001; 
Parcellier et al., 2009a). A recent publication has shown that Them4 is a 
mitochondrial acyl-CoA thioesterase, with its activity directed mainly towards long-
chain fatty acids (Zhao et al., 2009). Mitochondrial localization and the importance of 
correct CTMP/Them4 processing indicate the role this protein may play in the 
regulation of mitochondrial morphology (Parcellier et al., 2009b).  
 
1.3.4 CTMP/Them4: mitochondrial acyl-CoA thioesterase and negative 
regulator of PKB signaling 
The CTMP/Them4 protein has been identified in a yeast two-hybrid screening as 
interacting with and negatively regulating PKB (Maira et al., 2001). Additionally, there 
is information regarding hypermethylation of the CTMP promoter region in 
glioblastoma patients (Knobbe et al., 2004). Later, we showed that CTMP is a 
nuclear-encoded protein and is translocated to the mitochondria via its mitochondrial 
targeting sequence (MTS), which is cleaved off later on by mitochondrial peptidases 
(Parcellier et al., 2009a). The protein is located in the intramembrane space and is 
associated with the inner mitochondrial membrane. Cleavage of MTS, or, in other 
words, proper processing of CTMP, is important for maintaining mitochondrial 
morphology. In a knock-out mouse model we have shown that mitochondria from 
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CTMP1-/-
Parcellier et al., 2009b
 mice are more elongated and interconnected; these results were confirmed 
in a cell culture system using siRNA against CTMP ( ). CTMP 
interacts with Letm1, an inner mitochondrial membrane protein whose gene is 
located on chromosome 4 (4p16.3), in a region not present in patients suffering from 
Wolf-Hirschhorn syndrome (Endele et al., 1999; Piao et al., 2009) (see Figure 1.13). 
This syndrome is characterized by a neurological phenotype (seizures, mental 
retardation, etc.). Certain controversy exists concerning the Letm1 protein: it has 
been suggested as either a mitochondrial Ca2+/H+ antiporter, or K+/H+
Jiang et al., 2009
 exchanger 
( ; Nowikovsky et al., 2004). Nevertheless, Letm1 protein and its 
yeast homolog, products of the YOL027 gene, have also been implicated in the 
regulation of mitochondrial morphology.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 
Interaction of CTMP protein with Letm1. (A) The interaction between the CTMP protein and Letm1 was 
assessed by co-immunoprecipitation. HEK 293 cell extracts were incubated with anti-LETM1 antibody and 
bound CTMP was assessed by immunoblotting with anti-CTMP antibody. From (Piao et al., 2009). (B) The 
yeast homolog of the Letm1 protein, Mdm38, has been shown to have K+/H+ exchange activity. Its loss is 
shown to associate with a number of phenotypes, such as reduced content of respiratory chain complexes, 
altered mitochondrial morphology, and loss of mitochondrial K+/H+ exchange activity resulting in osmotic 
swelling. The addition of nigericin, a polyether ionophore, can rescue the observed mitochondrial 
phenotype. From (Nowikovsky et al., 2004). (C) The loss of the CTMP protein leads to changes in 
mitochondrial morphology, resulting in the appearance of more elongated and interconnected organelles. 
Taken from (Parcellier et al., 2009b). 
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CTMP is also known as Them4, which stands for thioesterase superfamily member 4 
(gene ID 117145 in Entrez/NCBI). The Pfam database shows the presence of a 
4HBT domain in the CTMP protein, which is named after the founding member of the 
hotdog thioesterase family, 4-hydroxybenzoyl-CoA thioesterase (
Zhao et al., 2009
PF03061 accession 
in Pfam). Recently, CTMP has been experimentally shown to have thioesterase 
activity directed mainly towards fatty acid CoA esters ( ). Based on a 
3D homology search, the authors proposed threading model of CTMP crystal 
structure which, together with the bioinformatics prediction, places CTMP into the 
thioesterase family, specifically hotdog-fold thioesterases.  
The role of the CTMP protein as a negative regulator of PKB has been corroborated 
in the settings of apoptosis. We have shown that CTMP processing is important for 
its subsequent release from mitochondria upon induction of apoptosis (Parcellier et 
al., 2009a). Once released, it negatively regulates PKB phosphorylation, thereby 
promoting cell survival. In addition to in vitro apoptosis stimulation, CTMP inhibits 
PKB in response to ischemia-induced cell death, and prevents hippocampal 
neuronal injury in mouse models (Miyawaki et al., 2009). Thus, we have shown that 
mitochondrial acyl-CoA thioesterase CTMP/Them4 is an important regulatory 
component of PI3K/PKB signaling.  
                     
1.4 PKB SIGNALING PATHWAY AND ITS REGULATION 
 
PKB/Akt is a ubiquitous and evolutionarily conserved serine/threonine kinase that is 
recognized as a major coordinator of various intracellular signals. It controls cell 
responses to extrinsic stimuli and regulates cell metabolism, proliferation, and 
survival. Proper tuning of PKB activity via direct or indirect mechanisms is of the 
utmost importance for stringent regulation of PKB-dependent cellular activities. Many 
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diseases, such as cancer or metabolic disorders, are the result of, or are associated 
with, aberrant activity of the PI3K/PTEN/PKB pathway. PKB has been implicated in 
the development of type 2 diabetes mellitus, non-alcoholic fatty liver disease, insulin 
resistance, liver tumors.  
Serine/threonine kinase PKB/Akt  is one of the major targets of phosphatidylinositol 
3-kinase (PI3K)-generated signals and is involved in the regulation of cell growth, 
proliferation, apoptosis, glucose metabolism, angiogenesis, and migration.  
The mammalian genome encodes three isoforms of Akt/PKB: Akt1/PKBα, 
Akt2/PKBβ, and Akt3/PKBγ, which are highly conserved despite being the products 
of three different genes located on different chromosomes. When PKB is fully 
activated and is exerting its biological functions, it is phosphorylated at two sites, one 
located within the activation loop of the kinase domain (Thr308 in PKBα) and the 
other within the HM (Ser473). 
 
1.4.1 Activating stimuli and upstream kinases 
Growth factor binding promotes the recruitment and activation of class I PI3K after 
autophosphorylation of the receptor on tyrosine residues. At the membrane, PI3K 
phosphorylates PtdIns(4,5)P2 to form PtdIns(3,4,5)P3, which then serves as the 
docking site for a subgroup of proteins with PH domains. PI3K is involved in the 
regulation of a wide range of cellular processes, such as cell growth, proliferation, 
differentiation, motility, survival, and intracellular trafficking: many of these PI3K 
effects are mediated by downstream PKB. The constitutive activation of class I PI3K 
due to a gain-of-function mutation (in the p110α catalytic subunit, for example) or the 
downregulation of its negative regulator PTEN (lipid phosphatase and tensin 
homolog deleted on chromosome 10) are striking features of many human cancers 
(Samuels et al., 2005).  
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Thus, inactive PKB/Akt is translocated to the plasma membrane (PM), undergoes a 
conformational change, attaches to a phospholipid through a PH domain and 
becomes phosphorylated (schematic representation of PKB activation is shown in 
Figure 1.14). Once recruited to the PM, PKB is activated in a two-step process that 
requires phosphorylation on both Thr308 in the activation loop of the kinase domain 
and Ser473 within the hydrophobic motif of the regulatory domain. Thr308 is 
phosphorylated by PDK1 kinase, which is recruited to the PM through its PH domain; 
there is also evidence that PKB may be pre-complexed with PDK1 in cytoplasm 
(Alessi et al., 1997; Calleja et al., 2007).  
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PKB monophosphorylated on Thr308 has ca. 10% of the activity of the fully 
phosphorylated enzyme. Additional Ser473 phosphorylation stabilizes the active 
conformation, allowing most PKB molecules to become fully active (Yang et al., 
2002). The PI3K-related protein kinase family TORC2 complex, DNA-PK, and ATM 
are responsible for PKB-S473 phosphorylation. The fact that mTORC2 is a Ser473 
kinase for PKB is widely recognized (Bhaskar and Hay, 2007; Sarbassov et al., 
2005). 
Work done on knock-out mice and Drosophila cells has provided genetic evidence 
favoring the hypothesis that components of the rapamycin-insensitive Rictor-mTOR 
complex have a shared positive role in the phosphorylation of the hydrophobic motif 
site of PKB (Sarbassov et al., 2005). DNA-PK has also been identified as an 
upstream Ser473 kinase of PKB (Bozulic et al., 2008; Feng et al., 2004); it 
phosphorylates PKB on Ser473 after DNA damage, thus promoting survival in 
response to genotoxic stress in vivo (Bozulic et al., 2008). 
 
 
Figure 1.14 
Schematic representation of PKB activation and regulation. Activation of growth factor receptors (GFR) 
by a ligand (insulin, growth factors (GF)) induces their autophosphorylation and recruits the p85 regulatory 
subunit of phosphatidylinositol 3-kinase (PI3K). Subsequent activation of the p110 catalytic subunit leads to 
phosphorylation of phosphoinositol-(4,5)-bis phosphate (PIP2) and formation of the phosphoinositol-(3,4,5)-
tris phosphate (PIP3). PIP3 is a substrate for lipid phosphatase, the tensin homolog PTEN, and the SH2-
domain-containing inositol polyphosphate 5-phosphatase SHIP, which act as endogenous inhibitors of the 
PI3K-dependent pathway, indirectly inhibiting PKB activity. Wortmannin and LY294002 also inhibit PI3K. 
Once formed, PIP3s serve as docking sites for the PH domains of PDK1 and PKB, which translocate to the 
plasma membrane from the cytoplasm. As a result of this translocation, inactive PKB is phosphorylated by 
PDK1 on Thr308 in a regulatory kinase domain. There are data to suggest that PKB is already pre-complexed 
with PDK1 in the cytoplasm. The second phosphorylation event on Ser473 in the hydrophobic motif (HM) by 
upstream kinases such as TORC2, DNA-PKc, and ATM is cell-type and stimulus specific. It leads to 
conformational changes in the PKB molecule and full activation of the kinase. Activated PKB then 
translocates to different subcellular compartments, such as the nucleus, ER, Golgi, and mitochondria, where it 
exerts its biological activity. Protein phosphatase 2A (PP2A) and a PH domain leucine-rich repeat protein 
phosphatase (PHLPP) dephosphorylate and inactivate PKB. Other negative regulators of PKB are Grb10, 
carboxyl-terminal modulator protein (CTMP), tribbles homolog 3 (Trb3), casein kinase 2-interacting protein-1 
(CKIP-1), and keratin 10. Positive regulation of PKB activity may be achieved through interaction with 
BTBD10 and the heat shock proteins Hsp90 and Hsp27, which protect the PKB molecule from 
dephosphorylation. T-cell leukemia antigen-1 (Tcl-1) and fused toes protein-1 (Ft1) may also function as 
positive PKB regulators. 
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1.4.2 Negative regulation of PKB by phosphatases 
Certain cellular mechanisms counteract PKB activation. Negative regulation of PKB 
could be mediated either by a direct mechanism, such as intra-molecular 
interactions, or indirectly by modulation of factors important for PKB activation.  
The best-studied negative regulator of the PI3K/PKB pathway is PTEN, a tumor 
suppressor protein that is often inactivated in many disorders characterized by PKB 
hyperactivation, such as cancers and some metabolic diseases (described in detail 
below). This molecule acts as a lipid phosphatase by dephosphorylating PIP3 at the 
D3 position, converting it to PIP2. This leads to inhibition of the PI3K pathway and 
reduces recruitment of PDK1 and PKB to the PM, and thus subsequently decreases 
PKB activity. At the transcriptional level, PTEN is positively regulated by p53, Myc, 
Egr-1, and PPARγ, whereas Ras, JNK, Notch, and miR-21 are negative regulators of 
PTEN transcription (reviewed in (Salmena et al., 2008)). Downregulation due to the 
loss of promoter activity or loss-of-function mutations of PTEN are distinct 
characteristics of many neoplastic diseases, including hepatocellular carcinoma 
(Horie et al., 2004; Hu et al., 2007).  
Given that PKB is activated by increased phosphorylation, protein phosphatases are 
direct negative regulators acting on phosphorylated PKB. Protein phosphatase 2A 
(PP2A) acts as a negative regulator by dephosphorylating PKB at both sites 
(Andjelkovic et al., 1996; Ugi et al., 2004), but particularly at Thr308 (Gao et al., 
2005). Heat shock protein 90 (Hsp90), a general chaperone to numerous targets, 
may inhibit PP2A-mediated dephosphorylation, offering PKB protection from 
inactivation. BTB (POZ) domain-containing protein 10 (BTBD10) has also been 
reported to interact with PKB and protect it from PP2A-mediated dephosphorylation 
(Nawa et al., 2008).  
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A further phosphatase directly dephosphorylating Ser473 is the PH domain leucine-
rich repeat protein phosphatase PHLPP, which has a PP2C-like catalytic core, is not 
sensitive to okadaic acid, and binds directly to PKB via a C-terminal PDZ motif (Gao 
et al., 2005). This phosphatase is markedly reduced in several colon cancer and 
glioblastoma cell lines with elevated PKB phosphorylation. Recently, a second 
PHLPP isoform, PHLPP2, has been cloned (Brognard et al., 2007). In parallel to the 
different tissue expression patterns and substrate specificities of the different PKB 
isoforms, the PHLPP isoforms have been reported to show specificity for distinct 
PKB isoforms. PHLPP1 was shown to affect PKBβ/γ, while PHLPP2 influences the 
activity of PKBα/γ, with marked differences in the affected PKB substrates. These 
data led to speculation that PHLPP1 may regulate PKBβ and affect glucose 
metabolism, whilst PHLPP2 may be involved mostly in the regulation of PKBα and 
cell survival (Brognard et al., 2007).  
 
Regulation of the PI3K/PKB pathway by reactive oxygen species 
Reactive oxygen species (ROS), which are now recognized as second messengers, 
play an important role in regulating the PI3K/PKB/PTEN pathway. At lower 
concentrations, they are required for normal cell functioning and intracellular 
signaling; “physiological” ROS are produced at the plasma membrane by NADP(H) 
oxidases in a response to stimulation of many growth factors (Rhee, 2006; Tonks, 
2006) (See Figure 1.15). Oxidative stress, which is prevalent in malignant, as well as 
diabetic, conditions, and impaired mitochondrial function lead to increased levels of 
intracellular ROS. 
The primary source of ROS is the superoxide O2−, which is generated by complex I 
and complex III of the electron transfer chain in the mitochondria; superoxide is then 
converted to hydrogen peroxide H2O2 by superoxide dismutase, and then to oxygen 
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and water by a number of enzymes that include catalase, glutathione peroxidases 
(Gpx), and thioredoxin. The highly reactive OH∙ radical is a product of H2O2 
transformation via Fenton’s reaction; it reacts instantaneously with the nearest 
molecules. H2O2 
Tonks, 2006
activity is directed towards redox-sensitive cysteine residues within 
proteins. It is a weak oxidizing agent, and its effects depend on the concentration. 
PTEN and PTP1B have been shown to be direct targets of ROS: oxidation of active 
Cys residues in their molecules leads to the formation of inactive configurations, 
which cannot function normally ( ).  
 
 
 
 
 
In addition to PTEN and PTP1B actively participating in PI3K/PKB signaling and 
promoting insulin sensitivity, it has been shown that ROS are important contributors 
to maintaining insulin sensitivity (Loh et al., 2009). Thus, Gpx1 activity has been 
Figure 1.15  
H2O2 production, protection, and signaling actions. The activation of various cell surface receptors 
activates Nox, situated either in the plasma membrane or in the membrane of organelles such as endosomes, 
to produce H2O2. To function as an intracellular signaling molecule, H2O2 must be imported into the cytosol. 
Cytosolic H2O2 enhances protein tyrosine phosphorylation by inactivating protein tyrosine phosphatases 
while activating protein tyrosine kinases. Transient protection of the H2O2 signal from abundant cytosolic 
peroxiredoxin appears to be caused by reversible inactivation of these enzymes through either 
hyperoxidation or phosphorylation. Taken from (Rhee, 2006).  
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shown to interfere with insulin function by substantially decreasing the amount of 
intracellular ROS required for insulin sensitizing. Mice overexpressing Gpx1 develop 
insulin resistance and obesity, whereas Gpx1 knock-out mice display insulin 
hypersensitivity as a result of enhanced PI3K/PKB signaling (McClung et al., 2004), 
(Loh et al., 2009). 
 
1.4.3 Role of PKB in insulin resistance, non-alcoholic fatty liver disease and 
hepatosteatosis 
Among liver diseases, non-alcoholic fatty liver disease (NAFLD) is becoming 
increasingly common; every third adult and tenth child/adolescent in the USA is 
affected by this condition (Angulo, 2007). NAFLD is considered to be a hepatic 
manifestation of a metabolic syndrome. The prerequisite feature of NAFLD is 
increased accumulation in hepatocytes of lipids, which can originate either from 
increased levels of non-esterified fatty acids (NEFA) circulating in the blood or from 
enhanced de novo synthesis of lipids in the cells. Although simple steatosis seems to 
have a relatively benign clinical course, a subgroup of patients develops 
inflammatory changes, known as non-alcoholic steatohepatitis (NASH) and, 
potentially, liver cirrhosis which carries an increased risk of hepatocellular carcinoma 
(Rector et al., 2008). An increase in intracellular lipid metabolites may lead to 
activation of the PI3K/PKB pathway. Initial overactivation of the signaling cascade 
then results in IRS-1 inhibition, which mediates a negative feedback effect on PI3K 
activation, leading finally to the inhibition of insulin signaling. Patients with NAFLD 
display lower levels of phosphorylated PKB and an increase in Bax/Bcl-2 ratio (Piro 
et al., 2008). A similar situation has been described for activated PKCε, which led to 
decrease in insulin-stimulated IRS-2 phosphorylation and hepatic insulin resistance 
(Samuel et al., 2004). Later, insulin resistance involves other peripheral organs, such 
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as skeletal muscle and adipose tissue, eventually becoming systemic. Under 
physiological conditions, insulin released from the pancreas decreases glucose 
output from the liver but stimulates glucose uptake by muscle and adipose tissue. In 
patients with insulin resistance, a syndrome associated with impaired metabolic 
clearance of glucose, the concentration of NEFA in the bloodstream increases due to 
the high lipogenic effect of insulin. NEFA act by reducing adipocyte and muscle 
glucose uptake and promoting hepatic glucose output, which leads to increased 
blood glucose concentration. Obesity worsens that situation and leads to increased 
levels of NEFA released directly into the portal vein from visceral adipose. This adds 
to the vicious cycle, leading to even higher insulin resistance.  
The current view of NAFLD development may be presented as a “two-hit theory”: 
Liver degeneration due to lipid accumulation occurs first and this condition is later 
boosted by inflammatory cytokines, endotoxins, iron accumulation, and oxidative 
stress (Mendez-Sanchez et al., 2007). To a large extent, the latter is caused by 
increased intracellular lipids. The effects of lipotoxicity on β cells (Joseph et al., 
2004; Lupi et al., 2002) and cardiomyocytes (Dyntar et al., 2001) have been studied 
most, but hepatocytes are also significantly affected, via a direct or an indirect 
mechanism, often displaying mitochondrial dysfunction (Li et al., 2008b). Key 
characteristics of mitochondrial dysfunction are respiratory chain defects that lead to 
an increase in ROS production. This, in turn, has damaging effects on cellular 
organelles and molecules. In addition to damaging mtDNA and respiratory chain 
enzymes, an increase in ROS leads to the oxidation of many cytoplasmic enzymes, 
including PTEN. Thus it is now clear that ROS are not only deleterious for the cell 
but are very important with respect to signaling molecules (Rhee, 1999). Their 
presence at low concentrations helps maintain certain basal levels of kinase activity, 
namely PI3K/PKB, in cells not supplemented with growth factors. However, when 
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cells are overloaded with ROS, this may lead to hyperactivation of the 
PI3K/PTEN/PKB pathway, inhibition of FoxO1 and PGC-1α, and transcription of 
adipogenic-, lipogenic-, and β-oxidation-related genes. This leads to liver steatosis 
and, potentially, to hepatic tumorigenesis.  
The role of cell types other than hepatocytes in insulin resistance should not be 
neglected. Sinusoidal liver cells are often ignored, but they are an important factor in 
the maintenance of the pathological situation of insulin resistance, exacerbating the 
oxidative damage of hepatocytes, as well as secreting the pro-inflammatory 
cytokines TNF-α and IL6 (Leclercq et al., 2007). It has been suggested that the 
degree of insulin sensitivity depends on the state of activation of stellate cells, which 
have phosphorylated IR and IRS1 when activated and do not respond further to 
insulin, thus failing in glucose uptake. Their activation brings hepatic tissue one step 
closer to the development of fibrosis and, ultimately, cirrhosis (Delibegovic et al., 
2007; Leclercq et al., 2007).  
 
Involvement of phosphatases in insulin sensitivity 
Targeting the PI3K/PKB pathway via a decrease in phosphatase activity, and 
negative regulation of PKB activity, is beneficial for the restoration of insulin 
sensitivity. This is shown by the protein tyrosine phosphatase 1 B (PTP1B), which 
negatively regulates insulin receptor and IRS-1 signaling knock-out mice. Disruption 
of the PTP1B gene in mice leads to enhanced insulin sensitivity and a decrease in 
adipose mass. In mice with polygenic insulin resistance, PTP1B deficiency results in 
improved glucose tolerance and a decrease in the occurrence of diabetes (Xue et 
al., 2007). Similarly, muscle-specific KO of PTP1B also has a beneficial effect on 
insulin sensitivity (Delibegovic et al., 2007).  
Another clear example of increased insulin sensitivity due to loss of lipid 
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phosphatase activity is PTEN knock-out mice. Quite unexpectedly, in addition to the 
insulin-hypersensitive phenotype, liver-specific PTEN knock-outs suffer from 
hepatomegaly and fatty livers, being at the same time leaner than their wildtype 
littermates (Stiles et al., 2004). These mice have low levels of NEFA in the plasma 
and relative hypoinsulinemia, concomitant with the higher PKB activity. They display 
an increased liver glycogen content and enhanced FA synthesis and secretion. 
PTEN null mice are, in principle, a further model of NAFLD that does not involve 
overnutrition, and is not polygenic in nature. These mice are valuable because of the 
absence of obesity/type 2 diabetes, which is not thought to be mandatory for insulin 
resistance but only an associated complication. PTEN null mice provide a new 
insight into the in vivo role of PTEN, underlying the importance of negative PKB 
regulators in the liver insulin-signaling pathway. Hepatocellular carcinoma (HCC), 
recognized as a complication of NAFLD, is often accompanied by PTEN 
downregulation, leading to a poor prognosis for HCC patients (Sato et al., 2000) 
Deregulation of PTEN activity may be due to hypermethylation of its promoter (Ping 
et al., 2006) or loss-of-function mutations (Wang et al., 2007). Alternatively, PTEN 
may be the target of increased ROS in cells, leading to its oxidation and the 
blockage of the catalytic cystein residues important for proper function (Lee et al., 
2002). In this context, PTEN heterozygous and liver-specific KOs are invaluable 
models for studying the pathogenesis of NAFLD, which later develops into 
steatohepatitis and progresses to liver carcinoma without any additional exogenous 
treatment.  
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2. AIM OF THE THESIS 
 
The aim of my thesis was to functionally characterize the novel protein 
CTMP2/Them5. This protein has been identified in the laboratory of Brian Hemmings 
as a paralog of the CTMP1/Them4 protein. CTMP1 was previously described as an 
interactor and negative regulator of protein kinase B (PKB)/Akt. We have shown that 
CTMP1 is a mitochondrial protein and exerts its function once released from 
mitochondria upon apoptosis induction. In addition, it has been shown to regulate 
mitochondrial morphology. The role of CTMP2/Them5 is currently largely unknown; 
in the databases both CTMP1/Them4 and CTMP2/Them5 are classified as hotdog-
fold thioesterase family members. Thus, the work focused on the functional and 
structural characterization of CTMP2/Them5 protein by using Them5-/- mouse 
models and in vitro approaches.   
 49 
3. RESULTS 
3.1  
Analysis of the novel acyl-CoA thioesterase Them5 reveals a role in 
mitochondrial morphology and fatty liver disease development. 
Elena Zhuravleva1, Heinz Gut1, Debby Hynx1, Christopher K. E. Bleck1,2, David 
Marcellin3, Christel Genoud1, Peter Cron1, Jeremy J. Keusch1, Bettina Dummler1, 
Mauro Degli Esposti4, Brian A. Hemmings1* 
1 Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, 
Switzerland 
2 Center for Cellular Imaging and Nano Analytics C-CINA, Focal Area Structural Biology and 
Biophysics, Biozentrum University Basel, WRO-1058 Mattenstrasse 26, 4058 Basel, 
Switzerland 
3 Novartis Pharma AG, Forum 1, Novartis Campus, 4056 Basel, Switzerland 
4
 
 Faculty of Life Sciences, The University of Manchester, Michael Smith building, Oxford 
Road, M13 9PT Manchester, UK 
50 
 
Analysis of the novel acyl-CoA thioesterase Them5 reveals a role in 
mitochondrial morphology and fatty liver disease development 
 
Elena Zhuravleva1, Heinz Gut1, Debby Hynx1, David Marcellin2, Christopher K. E. 
Bleck1,3, Christel Genoud1, Peter Cron1, Jeremy J. Keusch1, Bettina Dummler1, 
Mauro Degli Esposti4, Brian A. Hemmings1 
1 Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, 
Switzerland 
2 Novartis Pharma AG, Forum 1, Novartis Campus, 4056 Basel, Switzerland 
3 Center for Cellular Imaging and Nano Analytics C-CINA, Focal Area Structural Biology and 
Biophysics, Biozentrum University Basel, WRO-1058 Mattenstrasse 26, 4058 Basel, 
Switzerland 
4
 
 
 Faculty of Life Sciences, The University of Manchester, Michael Smith Building, Oxford 
Road, M13 9PT Manchester, UK 
 
 
 
 
 
 
 
 
51 
 
SUMMARY  
 
Acyl-CoA thioesterases hydrolyze thioester bonds in acyl-CoA metabolites. The majority of 
mammalian thioesterases are α/β-hydrolases and have been well studied, but Hotdog-fold 
enzymes have been less well described. Here, we present a structural and functional 
analysis of a new mammalian mitochondrial thioesterase, Them5. Them5 and its paralog 
Them4 adopt the classical Hotdog-fold structure and form homodimers in crystals, 
representing a new group of these enzymes. In vitro Them5 shows strong thioesterase 
activity with long-chain acyl-CoAs. Them5-/- mice have highly interconnected mitochondria; 
this effect depends on the enzymatic activity of Them5. Loss of Them5 specifically alters the 
remodeling process of the mitochondrial phospholipid cardiolipin. Them5-/- mice develop fatty 
livers, lipid metabolism is deregulated, and mitochondrial respiration and β-oxidation are 
impaired. 
This paper presents this novel mitochondrial thioesterase Them5 and its specific role in the 
cardiolipin remodeling process, connecting it to the development of fatty liver and related 
conditions. 
52 
 
Highlights 
• Them5 is a novel mitochondrial acyl-CoA thioesterase of the Hotdog-fold family 
• Them5 enzymatic activity is important for mitochondrial morphology and function 
• Loss of Them5 specifically alters re-acylation of cardiolipin with long acyl-CoAs  
• Them5-/- mice develop fatty livers due to the accumulation of acyl-CoAs  
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INTRODUCTION 
 
Thioesterases hydrolyze thioester bonds in a variety of substrates, including fatty acid CoA 
esters and palmitoylated or myristoylated proteins; and participate in lipid metabolism (Hunt 
and Alexson, 2002). According to their protein fold and the catalytic reaction mechanism, 
thioesterases are subdivided into two groups: α/β-hydrolases and Hotdog-fold thioesterases. 
Subcellular localization of thioesterases varies: they are found in the cytoplasm, 
peroxisomes, and mitochondria. Whereas the majority of mammalian thioesterases are α/β-
hydrolases and have been well studied, mammalian Hotdog-fold enzymes have only been 
described to a lesser extent. Here, we present a new mammalian mitochondrial thioesterase, 
Them5, that belongs to the Hotdog-fold enzyme family. It is encoded by the nuclear genome 
and is imported into mitochondria, where it resides in the matrix and is also found to 
associate with the inner mitochondrial membrane facing the matrix side. We show that 
Them5 is a thioesterase which directs its activities towards fatty acid-CoA esters. We have 
determined the crystal structure of Them4 and Them5 at resolutions of 1.6 Å and 1.45 Å 
respectively, and have shown that they adopt the classical Hotdog-fold, with six β-sheets 
wrapped around a central α-helix. Recent studies have shown that mammalian Hotdog 
proteins are organized in tetrameric or higher-order structures but both Them4 and Them5 
form independent homodimers in crystals, thus representing a new group of these enzymes. 
We have also identified residues which participate in the formation of the active center, and 
describe general structural features of these enzymes.  
The physiological role of mammalian Hotdog-fold thioesterases has not been well described, 
except in recent studies concerning Acot13/Them2, which have shown both mitochondrial 
and cytoplasmic localization, and Acot7, which has been implicated in inflammatory 
processes (Cao et al., 2009; Forwood et al., 2007). To study the physiological role of Them5, 
we generated knock-out mice which show a highly interconnected, elongated mitochondrial 
network compared to wildtype mice. Overexpression of a thioesterase-dead version of 
Them5 in cell culture leads to the appearance of an interconnected mitochondrial network as 
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in Them5-/- tissues, indicating that the enzymatic activity of Them5 is important for 
maintaining normal mitochondrial morphology. Them5-/- mice show increased levels of a 
specific metabolite of cardiolipin (CL) among their mitochondrial lipids, indicating that Them5 
activity is implicated in the remodeling of CL within mitochondria. Knock-out mice develop 
fatty liver disease and β-oxidation is impaired, accompanied by an overall deregulation of 
lipid metabolism. These phenotypic effects can be explained by the loss of thioesterase 
activity of Them5 in mitochondria, where long-chain acyl-CoAs cannot be hydrolyzed any 
more and are then exported into the cytosol, contributing to intracellular lipid accumulation. 
Hence, our study identifies Them5 as a novel enzyme participating in CL metabolism, whose 
removal progressively reverberates from mitochondria to the metabolism of fatty acids in the 
whole body. 
 
RESULTS 
 
Them4/5 are dimers of a Hotdog-fold 
Them4 and Them5 genes are located on chromosome 1 in humans, 20kb apart 
(chromosome 3 in mice, and 10kb apart) and share exon-intron structure (Figure S1A). A 
search of databases shows that Them4 orthologs are present in lower eukaryotes, including 
yeasts (FMP10, NC_001137.2), whereas Them5 orthologs have only been found in 
mammals (Figure S1B). Bioinformatics analysis of the Them5 protein suggests that it 
belongs to the Hotdog-fold thioesterase family of proteins. 
We used the molecular replacement method to determine the crystal structures of human 
Δ34Them5 and Δ36Them4 to a resolution of 1.45 Å and 1.6 Å, respectively (data collection 
and refinement statistics are given in Table S1). Δ34Them5 crystallized in space group 
C2221, with one molecule per asymmetric unit (a.u.) representing half of the biologically 
active homodimer, while Δ36Them4 crystallized in space group P1 with two independent 
homodimers per a.u. Clear electron density allowed model building of residues 52-247 
(Δ34Them5) and 42-234 (Δ36Them4), with a disordered stretch of residues that could not be 
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built in both structures due to lack of electron density (102-111 and 81-105 for Δ36Them4 
and Δ34Them5, respectively). Crystal structures of Δ36Them4 and Δ34Them5 show that 
both proteins do indeed belong to the Hotdog-fold superfamily typical of thiosterases (Figure 
1A). The core structure of the thioesterase Hotdog fold encompasses residues 119-231 and 
125-237 for Δ36Them4 and Δ34Them5, respectively, and consists of a long central α-helix 
surrounded by a six-stranded curved antiparallel β-sheet. In both proteins, two of these core 
domains form a stable homodimer related by a two-fold symmetry axis, and the extension of 
the β-sheets to a continuous anti-parallel 12-stranded β-sheet contributes the most to dimer 
stabilization. In both molecules, ~120 N-terminal residues are mostly in a coiled 
conformation, with the exception of extended α-helixes formed by residues 55-68 
(Δ36Them4) and 64-79 (Δ34Them5) that is tightly attached to the convex side of the curved 
β-sheet via hydrophobic interactions with the first and second strand. The two proteins have 
a very similar structure and have an r.m.s. deviation of only 0.8 Å (Cα atoms over 165 
residues) at a sequence identity of 38%. A search of the Protein Data Bank (PDB) using 
DALI identified the structures of a hypothetical P. aeruginosa protein PA5202 (1ZKI, 1.6Å, 
115), the T. thermophilus protein PAAI (1J1Y, 1.4Å, 110), and the human Them2 protein 
(3F5O, 2.1Å, 124) as being most similar to Δ36Them4 (PDB codes, r.m.s. deviations, and 
length of the structural alignments given in parentheses) (Holm and Sander, 1993). The 
same analysis for Δ34Them5 showed that the structures of a putative thioesterase YHDA 
from L. lactis (3GEK, 1.7Å, 120), human Them2 (3F5O, 2.0Å, 122), and the PAAI protein 
from T. thermophilus (1WLV, 1.9Å, 116) were structurally most related.  
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Figure 1. Them4 and Them5 are Hotdog-fold dimers 
(A) Crystal structures of Δ34Them5 (blue and orange) and Δ36Them4 (gray, transparent) are superimposed and 
displayed in a stylized representation. N- and C-terminal residues in the Δ34Them5 structure are labeled, and 
disordered stretches that are not included in the model are shown as dotted lines. 
(B) Surface representations of the Δ34Them5 crystal structure rotated through ~120° along a vertical axis. 
Surface-exposed residues conserved in both Them4 and Them5 (for the ClustalW multiple sequence alignment 
see Figure S2) are highlighted in red and orange (computed using ConSurf, http://consurf.tau.ac.il/, ConSurf 
color code 9, 8, respectively). A black circle indicates the putative binding site of the CoA-linked acyl chain, an 
asterisk marks the catalytic center, and an arrow points to Them5 residues Glu168 and Lys172 which interrupt 
the long open channel present in the Them4 structure. A blue circle shows conserved residues on the surface of 
the central β-sheet that are likely to be involved in binding the CoA phospho-ADP module. Them5 residues 89-
101 and 238-247 are not displayed to make the image clearer. 
(C) Stylized representation of the putative Δ36Them4 active site. Homodimer subunits are shown in cyan and 
gray, with those residues expected to be involved in catalysis and substrate recognition displayed as sticks (atom 
colors). 
(D) Stylized representation of the putative Δ34Them5 active site. Similar representation as in (C), but with 
homodimer subunits and active site residues in blue and orange. 
(E) ClustalW multiple sequence alignment of selected Them5 (human, mouse, giant panda, bovine) and Them4 
(bovine, rat, mouse, human) sequences (without predicted MTS). Conserved residues are boxed in red, and 
secondary structure elements present in the Δ34Them5 and Δ36Them4 crystal structures are indicated at the top 
and bottom of the alignment, respectively. The first residues present in the crystallographic models are 
highlighted with open arrows. Disordered stretches with no electron density, not included in the models, are 
shown in yellow shading; mutations used in this study are highlighted with red triangles (dimerization mutants) 
and a red asterisk (enzymatically inactive mutant). 
 
 
Them5 is a functional acyl-CoA thioesterase  
We analyzed the protein sequences of the Them4 and Them5 remote homologs in order to 
find conserved sequence motifs (Figure S2). By using structural information from 4HBT 
thioesterase from the founding family member Arthrobacter sp. SU, hTHEM2, Acot7 and 
comparing this with the Them5 protein sequence, we proposed residues that may be 
important for Them4/5 secondary and tertiary structure formation and enzymatic activity. Our 
analysis pointed to the presence of a highly conserved HGG…D motif, which has also 
recently been reported to be an important consensus sequence motif in many thioesterases, 
and which is present in all aligned sequences (Pidugu et al., 2009). As expected from our 
sequence analysis, both Δ36Them4 and Δ34Them5 crystal structures have two active sites 
per homodimer, located at the end of each Hotdog helix, with residues from both subunits 
contributing to catalysis. The main catalytic residues are indeed the HGG motif 152-154 and 
158-160 (for Δ36Them4 and Δ34Them5, respectively) on one subunit and Asp161/Thr177 
(Δ36Them4) and Asp167/Thr183 (Δ34Them5) located on the other subunit (Figure 1C,D). 
These residues are supposed to bind and hydrolyze the thioester moiety of the acyl-CoA 
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substrate. They are located in the middle of a long L-shaped channel which is limited in 
length by a stretch of residues from the N-terminal part (74-79 in Δ36Them4 and 83-88 in 
Δ34Them5) that likely defines the length of the CoA-coupled fatty acids accepted for 
turnover. This channel is less deep and less open in Them5, where the Them4 residues 
Ala162 and Met166 are positionally exchanged with Glu168 and Lys172 which, together with 
Asn91, form an extended and elevated hydrogen bond network.  
In order to characterize the Them4/5 molecules more closely, a ConSurf analysis was 
carried out and the functionally relevant residues were mapped onto the surface of the 
Them5 crystal structure (Figures 1B, S2). As expected, the catalytic machinery is fully 
conserved, and comparison with related structures reveals Asp161 (Them4) and Asp167 
(Them5) to be critically important.  
We next confirmed that Them5 is an active thioesterase in vitro. Full-length Them5 purified 
after expression in bacteria does hydrolyze acyl-CoAs (Figures 2A, S3A). Interestingly, 
Them5 showed high activity toward long-chain acyl-CoA esters, which was comparable to 
published data about Them4 (Figure 2C) (Zhao et al., 2009). However, in contrast to Them4 
(Zhao et al., 2009), Them5 showed very low activity with acetyl-CoA as a substrate (Figures 
2A,C, S3A,B). Thus, Them5 does indeed have a different substrate specificity, as suggested 
by our structural analysis of substrate binding channels (Figure 1B,C,D). The ConSurf 
analysis identified a conserved region at the end of the L-shaped acyl-CoA binding channel 
that consists of Ser78, Thr112, Arg113, and Tyr123 (Them4). In Them4, these residues 
define the end of the hydrophobic flat-shaped channel which is thought to bind the acyl 
group. The substrate binding channel of Them5 is strikingly different: side chains of Glu168 
and Lys172 form a polar, barrier-like elevation in the middle of this channel, restricting 
binding to the conserved residues (Ser87, Thr117, Arg118, Tyr129) that form a cavity 
(Figure 1B). These differences in acyl binding sites likely result in different affinities for 
substrates, thereby determining specificity. 
According to our crystallographic model of the active centers of Them4 and Them5 (Figure 1 
C,D), we propose that D167 in Them5 is the key catalytic residue. Indeed, when alanine was 
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substituted, the D167A Them5 mutant did not display any catalytic activity, which is 
consistent with our hypothesis (Figures 2B,C, S3B).  
We carried out size exclusion chromatography experiments to study the oligomeric states of 
Them4/5 in solution using highly purified recombinant proteins. Similarly to studies published 
previously, we found that Δ36Them4 elutes as a dimer of around 46 kDa, with a minor 
fraction present as a homotetramer (~105 kDa) (Zhao et al., 2009). Δ34Them5, on the other 
hand, elutes as a homodimer with an apparent molecular mass of ~45 kDa (Figure S4B). A 
strong argument for the dimeric state of Them4/5 in their native form is also the fact that they 
always appear as independent homodimers, irrespective of the crystal packing and number 
of molecules in the a.u. (Figure S4A). In all of these cases, neither molecules in the a.u. nor 
molecules related by crystallographic symmetry have any higher oligomeric state than 
independent homodimers. This finding was confirmed in an analysis of the quaternary 
structure of molecules in the crystals using the PISA software (Krissinel and Henrick, 2007). 
We transfected Them5 mutants cDNA lacking the mitochondrial targeting sequence (MTS) 
and having mutations in either the α-helix or the β-sheet needed for dimerization in HEK293 
cells, and found that they expressed at low levels only, probably due to their intrinsic 
instability (Figure S4C,D). Those results confirm that Them5 does indeed form dimers, and 
cannot exist as a monomer in solution. 
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Figure 2. Them5 is an acyl-CoA thioesterase  
(A) Saturation curves of reaction rate for acyl-CoA substrates obtained for wildtype hThem5 and (B) D167A 
hThem5 mutant at 37ºC. Lines indicate fitting of the experimental data to the Michaelis-Menten equation.  
(C) Them5 hydrolyses long-chain acyl-CoA esters. Steady-state kinetic constants for hThem5-catalyzed 
hydrolysis of selected acyl-CoAs obtained at pH7.5 and 22ºC or 37ºC. The reaction was carried out in the 
presence of 0.5 mM DTNB and followed at 412nm wavelength.  
 
Them5 is a mitochondrial protein  
Bioinformatical analysis of Them5 [MitoProt, TargetP, iPSORT] showed the presence of the 
mitochondrial targeting sequence in the N-terminal part of the human Them5 protein, and its 
orthologs in other species (Figure S2). Immunofluorescence analysis shows an overlap of 
the staining pattern of the protein with the mitochondria-specific marker MitoTracker Red 
(Figure 3A). Confocal image analysis showed 85.5% co-localization of endogenous protein 
with MitoTraker Red. According to the bioinformatical analysis using MitoProt II, the 
cleavage site is located after Ser32 (Claros and Vincens, 1996). Like the majority of nuclear-
encoded mitochondrial proteins, Them5 possesses a mitochondrial targeting signal which is 
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cleaved off by mitochondrial proteases once the protein has been imported into the 
mitochondria. This explains the appearance of the double band in western blot experiments. 
The Them5 sequence lacks a conserved consensus motif for MPP cleavage (RXX(X)SX), 
and we could not identify any residues important for that cleavage (data not shown). Besides, 
the MTS of Them4 and Them5 are different, which may be reflected in different 
intramitochondrial localization of the proteins (see below). Anti-Them5 antibodies detected 
two bands of protein on immunoblots, corresponding to the processed (faster migrating 
band) and non-processed forms of the Them5 protein (Figure 3B). Additionally, we were 
able to detect a band at around 17 kDa, which appears in the mitochondrial fraction samples 
(Figure 3B). It is most likely to be a product of further protein processing in mitochondria. 
However, the biological relevance of this cleaved form is not yet clear. By overexpressing a 
C-terminally HA-tagged version of Them5 we were able to confirm that the full-length protein 
resides specifically in the mitochondria (Figures 3C, S5A), whereas a mutant lacking the first 
37 N-terminally located amino acids (ΔMTS) is excluded from mitochondria (Figure 3D). We 
chose to delete the first 37 amino acids because of the secondary structure prediction of a 
positively charged random coil from this region (Combet et al., 2000). To assess 
mitochondrial localization of Them5 in more detail, we performed immunogold electron 
microscopy. The 2D-EM analysis of cells overexpressing HA-tagged Them5 and 
endogenous Them5 in U2OS cells (Figure 3E) showed that Them5 is located mainly in the 
matrix of mitochondria and on the internal face of the inner mitochondrial membrane (IMM). 
The intramitochondrial localization of Them5 is different from that of Them4, which has been 
previously shown to reside in the intermembrane space of mitochondria (Parcellier et al., 
2009a). 
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Figure 3. Them5 is a mitochondrial protein localized in the mitochondrial matrix, and is associated with 
the matrix side of the inner mitochondrial membrane 
(A) Immunofluorescence analysis of mitochondrial localization of hThem5. U2OS cells were fixed and stained 
with antibodies against hThem5. Mitotracker Red was used for mitochondria visualization. Co-localization of 
Them5 with Mitotracker Red is 85.5%, as assessed by Imaris analysis of the confocal images. 
(B) HEK293 cells were transfected with hThem5 and 30 micrograms of total lysate or 
mitochondrial/cytoplasmic fractions were separated by SDS-PAGE and immunoblotted for hThem5, tubulin and 
mitochondrial Grp75. Note the presence of an upper double band, indicating full length Them5 (FL) and Them5 
without mitochondrial targeting sequence (ΔMTS). The presence of an additional lower band in the 
mitochondrial fraction suggests further Them5 processing in mitochondria. T - total, M - mitochondrial, C - 
cytoplasmic fraction. 
(C) U2OS cells expressing full-length hThem5-HA and (D) ΔMTS Them5-HA were fixed and stained with 
antibodies against HA-tag, hThem5, TOM20, and tubulin. Full-length Them5 is localized in mitochondria (C), 
whereas the mutant lacking MTS is excluded from the mitochondria (D, Figure S5C). Images were taken using 
the confocal microscope LSM700. Scale bar is 10μm. At least four independent experiments were performed, 
with a minimum of 10 transfected cells analyzed. 
(E) Immunogold-electronmicroscopy staining of U2OS cells transfected with HA-tagged hThem5. Sections 
were probed with anti-HA antibodies, and images were taken at high resolution (left and middle panels). To 
detect endogenous protein, sections of non-transfected cells were probed with anti-hThem5 antibodies (right 
panel). Staining was mainly detected in mitochondria. Positive signals of anti-Them5 labeling were quantified in 
different cellular compartments. Two independent preparations of grids were quantified according to the 
procedure described elsewhere (Lucocq et al., 2004; Mayhew and Lucocq, 2008). Quantification shows 
prevalence of the signal in mitochondria, with some background in other cellular compartments for both 
endogenous and transfected proteins (bottom left and middle panels, correspondingly).  
 
 
Loss of thioesterease activity of Them5 leads to changes in mitochondrial 
morphology 
To investigate the physiological role of Them5, we generated mice deficient in the Them5 
protein (Figure S6). Considering the mitochondrial localization of Them5, we looked at 
whether its absence affected mitochondrial morphology by performing a serial block-face 
scanning electron microscopy analysis of hepatocytes. 2D electron microscopy images 
showed elongated, predominantly filamentous mitochondria in Them5-mutant mice (Figure 
4A). Subsequent 3D reconstruction of the mitochondria showed a 2-fold increase in the 
volume of mitochondria from Them5-/-, and the formation of a highly interconnected network, 
which was dramatically different from the wildtype mitochondria (Figure 4B). Starvation 
affected both wildtype and Them5-/- mitochondria, resulting in an increased volume of 
organelles and the formation of a more interconnected network. Additionally, starvation 
increased the morphological differences between WT and KO cells, leading to a nearly 3-fold 
difference (Figure 4B,C).  
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Given that mitochondria from Them5 knock-out mice are more interconnected than wildtype 
organelles, we checked whether the mtDNA copy number was affected in Them5-/- mice. To 
analyze this, we assessed mRNA levels of ND1 and COX1, single-copy mitochondrial genes, 
and TFAM, a mitochondrial transcription factor, in mice at 6 and 12 months of age (Figures 4, 
S7A). Quantification of mitochondrial number in the EM stacks also showed a similar trend 
toward reduced numbers of mitochondria. However, the difference was not statistically 
significant (data not shown). This suggests that the loss of Them5 affects mitochondrial 
morphology, but not biogenesis.  
We next asked whether changes in mitochondrial morphology are caused by the loss of 
Them5 thioesterase activity. To answer this question, we analyzed mitochondrial 
morphology in cells transfected with wildtype or thioesterase-dead hThem5, or a vector 
control (Figure 4E). Analysis of reconstructed mitochondria in cells overexpressing a 
thioesterase-dead D167A mutant of Them5 showed an increase in volume (by 45%), and an 
elongated and more interconnected mitochondrial network compared to the cells transfected 
with wildtype protein (Figure 4F,G). The length of mitochondria increased by almost 35% 
upon D167A mutant overexpression, while overexpression of wildtype protein did not lead to 
any significant change, indicating the importance of Them5 enzymatic activity in maintaining 
mitochondrial morphology. 
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Figure 4. Loss of the enzymatic activity of Them5 protein results in more interconnected and elongated 
mitochondria 
(A-B) Electron micrographs of Them5 wildtype and mutant hepatocytes (8000× magnification) obtained by 
serial block-face scanning EM, and 3D reconstruction of mitochondria showing elongated and interconnected 
mitochondria in Them5KO mice (A right panels and B right panels) compared to wildtype littermates (A left 
panels and B left panels) in fasted (A) and fed (B) state (males, 3 months old).  
(C) Quantification of the mitochondria volume in Them5 wildtype and knock-out hepatocytes. A minimum of 
15 mitochondria per cell were reconstructed in a minimum of three cells per mouse per genotype. Data is 
presented as mean and S.E.M. p<10-6.  
(D) Mitochondrial DNA copy number in Them5 wildtype and knock-out hepatocytes, as assessed by real-time 
PCR of single-copy mitochondrial genes (NADH dehydrogenase subunit 1 (ND1) and cytochrome c oxidase 
subunit 1 (COX1)) and normalized to GAPDH levels (n=3).  
(E) U2OS cells were transfected with wildtype Them5, D167A-Them5 mutant, or vector control coupled with 
IRES-GFP expression; mitochondria were visualized with anti-TOM20 staining. Confocal images were taken 
with 0.5×0.5×0.2 µm pixel size. 3D reconstruction and object splitting (bottom panels) were performed with 
Imaris software. Scale bar 10µm. 
(F-G) Length (F) and volume (G) of 3D reconstructed mitochondria in cells transfected with wildtype, D167A-
Them5, or vector control were quantified. Data from three independent experiments are presented as mean and 
S.E.M. (minimum 10 cells per experiment were analyzed). *** p<0.001. 
 
Them5 knock-out mice develop non-alcoholic fatty liver disease 
Mice lacking the Them5 protein are born in an expected Mendelian ratio and have no gross 
developmental abnormalities. However, Them5 knock-out mice have increased liver weight 
with no changes in total body weight (Figure 5A). Analysis of liver sections and primary 
hepatocytes from knock-out mice revealed lipid accumulation, which explains the increased 
liver weights (Figure 5B). Lipid accumulation develops with age: young mice have no signs 
of it even though they already show changes in mitochondrial morphology (Figures 5B, 4A). 
In contrast to the chow diet, a high fat diet leads to an increase in body weight (with no 
changes in food intake) of Them5-/- mice, indicating reduced ability to cope with increased 
fatty acid load, compared to Them5+/+ mice (Figure S8A). The loss of Them5 exacerbates 
fatty liver development, leading to pronounced lipid accumulation, inflammatory infiltration, 
and further increases in UCP2 expression, compared to the wildtype control (Figure S8C,D).  
By the age of 6-9 months, Them5-/- mice develop fatty livers. The accumulation of lipids in 
the liver is accompanied by hypoketonia and impaired β-oxidation (Figure 5C,D). Plasma 
levels of free fatty acids also increase significantly in Them5-/- upon fasting (Figure 5E). 
Additionally, fatty acid synthase (FAS) mRNA levels are similar between mutant and control 
mice in the fasted state, but are not induced in Them5-/- upon re-feeding (Figure 5F). 
Upregulation of FAS normally occurs in response to elevated levels of acetyl-CoA, a product 
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of β-oxidation, and is negatively regulated by fatty acids. Hence, impaired β-oxidation and 
lipid steatosis may explain the failure of FAS induction. In line with hypoketosis and reduced 
oxidation of 14C-palmitic acid, the levels of carnitine palmitoyl transferease 1 (CPT1) are not 
increased after fasting (Figure 5G). However, CPT1 mRNA is upregulated in Them5-/- when 
mice are normally fed, probably as a consequence of higher intracellular levels of fatty acids. 
Also as a result of lipid accumulation, expression of the UCP2 protein is considerably 
increased in Them5-/- (Figure 5H).  
Analysis of respiration of Them5-/- mitochondria revealed no major changes in basal 
respiration, but significant decreases in state 3, state 4o, and state 3u (Figure 5I). The 
respiratory control ratio, RCR, is lower in both Them5-/- liver mitochondria and MEFs (35% 
and 20%, respectively) (Figures 5J, S8), indicating an increased uncoupling of knock-out 
mitochondria, which could be explained by elevated UCP2 expression (Figures 5I, S9D). An 
electron flow assay revealed reduced coupling of OXPHOS both in sites I (pyruvate+malate) 
and II (succinate) in Them5-/- mice (Figure 5K). Also, the impaired β-oxidation and TCA cycle 
resulting from Them5 loss can be accounted for by the observed decrease (almost 50%) in 
maximal respiratory rates attained by the oxidation of endogenous substrates (Figure 5I).   
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Figure 5. Loss of Them5 leads to the development of fatty liver 
(A) Increased liver weight/body weight ratio (left panel), but no changes in total body weight (right panel) are 
detected between Them5+/+ and Them5-/- (n=8-11). 
(B) Age-dependent accumulation of lipids in liver. Oil Red O (ORO) staining of liver sections from wildtype or 
Them5-/- mice at the age of 6 months (right panel). Phase-contrast images (middle panel) and ORO staining (left 
panel) of primary hepatocytes from wildtype and Them5-/- mice at the age of 9 months.  
(C) Decreased levels of serum 3-hydroxybutyrate (3-HB) in Them5-/- upon fasting (males, 12 months old, n=5-6) 
and (D) lower rates of 1-14C-palmitic acid oxidation by primary hepatocytes indicate impaired β-oxidation.  
(E) Increased plasma levels of non-esterified fatty acids in Them5-/- mice compared to wildtype (6-7 months old) 
were detected after 8 hours of starvation (n=5). 
(F) Fatty acid synthase and (G) CPT1 mRNA in liver of fasted and fed Them5-/- and wildtype mice (6-7 months 
of age) was determined by qRT-PCR and normalized to GAPDH mRNA (n=3-4 per group). 
(H) Increased levels of UCP2 mRNA were measured by qRT-PCR in liver samples from Them5-/- mice, as 
compared to controls (males, 6-7 months of age, n=4 per group). 
(I) Oxygen consumption rates were measured for Them5-/- and wildtype liver mitochondria using a Seahorse 
XF24 analyzer in the presence of rotenone and succinate in the initial mix. A – ADP, B – Oligomycin, C – 
FCCP, D – Antimycin D (n=10).  
(J) Respiratory Control Ratio (RCR, state3/state4) is significantly reduced in Them5KO liver mitochondria and 
MEFs compare to wildtype controls (35% and 20% decrease, respectively, n=8-10). For respirometry analysis of 
MEFs see Figure S9. 
(K) Impaired electron transport and reduced coupling of OXPHOS in Them5-/- liver mitochondria, as assessed by 
electron flow assay, measured with a Seahorse XF24 analyzer. Pyruvate+malate+FCCP were present in the mix 
from the start. A – rotenone, B – succinate, C – antimycin A, D – ascorbate/TMPD.  
* p<0.05, ** p<0.01, *** p<0.001.  
 
Them5 ablation modifies the metabolism of mitochondrial cardiolipin 
In order to ascertain the specific metabolic defect which results in FFA accumulation, we 
carried out a detailed mass spectrometry (MS) analysis of mitochondrial lipids extracted from 
Them5-/- and control mice. The MS results showed very specific changes in the lipid profile 
of cardiolipin (CL) and its metabolites (Figure 6A). Loss of Them5 leads to a two-fold 
increase in major species of monolyso-cardiolipin (MCL) (Figure 6B), which act as upstream 
metabolites in the remodeling cycle of CL. CL is a phospholipid localized predominantly 
within the inner mitochondrial membrane (Esposti et al., 2003). On the basis of these results, 
we propose that Them5 has a rather specific role in vivo, namely that of regulating the initial 
metabolism of mitochondrial CL by maintaining, in particular, the pool of acyl groups used to 
re-acetylate one metabolic intermediate of cardiolipin, SP2-MCL (stearoyl-di-palmitoyl-
monolysocardiolipin) (Figure 6A,B). It is likely that the accumulation of this and other 
palmitoyl-containing MCL species reflects an early impairment in the remodeling cycle of CL, 
which progressively adds long unsaturated fatty acids to the saturated precursors, producing 
the mature forms enriched in linoleyl (Schlame, 2008). Reduction of thioesterase activity as 
a consequence of Them5 loss results in an almost two-fold decrease in free fatty acids 
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detected in mitochondria. The free fatty acids are trapped in long acyl-CoA molecules that 
are not normally required for CL remodeling (Figure 6C,D).  
 
 
Figure 6. Them5 is a new player in cardiolipin remodeling  
(A) Mass spectrometry (MS) profiles of Them5KO (top) and wildtype (bottom) mitochondrial lipids. SP2 – 
Stearoyl-di-Palmitoyl-Monolysocardiolipin/Na2H. 
(B) Quantification of an increase in major monolysocardiolipin (MCL) over cardiolipin (CL) levels upon Them5 
ablation.  
(C) Quantification of a total mitochondrial content of free fatty acids and (D) detailed composition of FFA from 
Them5 wildtype and KO liver mitochondria, as assayed by MS. Note the strong decrease in linolenic acid in 
Them5-/- samples compared to widltype. 
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DISCUSSION 
 
We have shown that Them5 is a novel protein that belongs to the mitochondrial proteome. 
Our results show that Them5 is involved in the metabolism of cardiolipin, a mitochondrial 
phospholipid, specifically in its early remodeling with long acyl-CoA species. This new 
evidence provides a chemical and metabolic explanation for the observed mitochondrial 
phenotype associated with the genetic ablation of Them 5, also throwing new light on the 
biological function of its paralog Them 4. 
Indeed, we became interested in Them5 due to its similarity to CTMP/Them4, whose gene is 
located just 20kb away from that of Them5. Analysis of the phylogenetic tree shows that the 
Them5 gene appeared only in mammals, whereas Them4 orthologs can be found as far 
back as yeasts. Them5 seems to have appeared as a result of gene duplication, and thus 
Them4/5 may be paralogs. Them5 has a mitochondrial targeting sequence at the N-terminal 
and is imported into the mitochondria, where further processing occurs. It is localized only 
inside the mitochondrial organelle (both matrix and IMM), in contrast to Them 4 (Parcellier et 
al., 2009a). Indeed, the N-terminal pre-sequences are not conserved between the Them4 
and Them5 proteins. 
We determined the structures of Δ36Them4 and Δ34Them5 at high resolution, and showed 
that both Them4 and Them5 belong to the Hotdog-fold class of proteins. Those proteins 
include a variety of enzymes, mainly thioesterases, which participate in the metabolism of 
fatty acids and cholesterol (Hunt and Alexson, 2002). The Hotdog fold, which is formed by 
several anti-parallel β-sheets wrapped around an α-helix, is found in all branches of life. 
However, up to now few mammalian proteins have been described in this group.  
In our experiments, we found that Them4 is mainly present as a homodimer, with a small 
fraction forming tetramers, while Them5 forms homodimers only. Them4/5 would be the only 
characterized mammalian 4HBT thioesterases which have a dimeric quaternary structure, 
but it is still possible that Them4/5 can form higher order oligomers in their specific 
environment in the mitochondria, either upon interaction with membranes or proteins, or 
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upon substrate binding. It has been shown that members of the PAAI family, like E. coli PAAI 
or human Them2, form tetramers in a back-to-back arrangement of the β-sheets, while other 
PAAI family members, like the hypothetical proteins with PDB codes 1IXl (P. horikoshii), 
2HBO (C. crescentus), or 2OV9 (Rhodococcus sp.), are present as homodimers only, with 
altered tetramerization sequence motifs. Given that the predominant oligomeric species of 
both human Them4 and Them5 is homodimeric, they seem to be most related to the 
homodimer subclass of the PAAI family. Thus, taken together, our results suggest that 
Them4 and Them5 form a separate group of mammalian thioesterases.  
Analysis of functionally relevant residues revealed the catalytic machinery, composed of the 
HGG motif and the Asp/Thr residues, to be conserved. The carboxylate moiety is thought to 
deprotonate a water molecule prior to its nucleophilic attack on the thioester bond of the 
CoA-coupled fatty acid substrate, while the HGG motif at the N-terminal end of the central 
Hotdog helix places the substrate thioester carbonyl group in the right position (Zhao et al., 
2009).  
Them4 and Them5 proteins contain a highly variable sequence stretch (~83-109 and ~91-
114 for Them4 and Them5, respectively) that is partially disordered in both crystal structures. 
Residues 81-105 could not be built in the Them4 structure due to low electron density, 
whereas the corresponding region in Them5 extends much further. In the Them5 structure, 
12 additional residues could be modeled (Ser90-Pro101), but the conformation is likely to be 
influenced by the crystal packing. In the C2221 crystal layers of Them5 molecules are 
stabilized by a β-sheet-like crystal contact formed by neighboring C-termini, as well as 
stretches of the variable sequence region between symmetry related molecules. Despite the 
fact that these residues partially close the active site cavity, it is unlikely that the 
conformation represents a snapshot of a lid-like closure of the acyl binding site, thereby 
controlling substrate access. The function of this highly variable sequence stretch remains 
unclear, but we suggest that it adopts a stable conformation upon substrate binding or 
interaction with another protein. Interestingly, a study carried out with a Them4 peptide 
(residues 95-119) that contains parts of this variable sequence, including the highly 
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conserved FTR motif, showed that it induced apoptosis in pancreatic adenocarcinoma cell 
lines by interfering with the PKB/Akt pathway (Simon et al., 2009). Although parts of the 
peptide map to surface-exposed and disordered Them4 residues, we found Phe111, the 
residue to which the effect was attributed, to be buried in the protein core at the dimerization 
interface. 
The biological role of thioesterases has not been fully addressed. Consensus motifs and 
structural analysis can propose substrate types, but cannot provide information about the 
potential physiological roles of the Hotdog-fold proteins (Pidugu et al., 2009). Cytoplasmic 
Acot7 is thought to be involved in eicosanoid metabolism (Forwood et al., 2007; Serek et al., 
2006). Them2 is thought to participate in the pathogenesis of renal cell carcinoma (Lucas et 
al., 2005), and in fatty acid metabolism (Kanno et al., 2007). 
CTMP/Them4 has been reported to be a part of the PKB signaling regulation network (Maira 
et al., 2001; Parcellier et al., 2009a). Recently, it has been shown that Them4 is a 
mitochondrial acyl-CoA thioesterase with a preference for long-chain fatty acids (Zhao et al., 
2009). Data obtained from Them5 knock-out mice suggest that it has a role in the regulation 
of mitochondrial morphology. Our analysis showed a 2-fold increase in mitochondrial volume, 
most likely as a result of the formation of a highly interconnected network. This becomes 
more pronounced upon starvation, which leads to an almost 3-fold difference in volume. 
However, mitochondrial biogenesis is not affected by the loss of the Them5 protein. Previous 
analysis of Them4-deficient cells has shown similar changes in mitochondrial morphology 
without any affect on number, suggesting that Them4 may be involved in mitochondrial 
fusion processes (Parcellier et al., 2009b). However, the new evidence presented here for its 
paralog Them5 suggests that the alteration in mitochondrial morphology may well derive 
from an alteration in mitochondrial lipid metabolism.  
Sequence analysis shows 38% similarity between hThem4 and hThem5 proteins, which is 
reflected in highly similar 3D-structures. Differences between the proteins are localized 
primarily to the N-terminus and the MTS. Mapping these sequence differences onto the 
structures reveals distinct structural features, highlighting potential functional differences 
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between Them4 and Them5. The main sequence differences map onto the partially 
disordered loop covering the active site cleft, as well as onto the bottom of this same cleft, 
the putative binding site for the CoA-linked fatty acid alkyl chain. This might provide a 
structural explanation for the differential substrate preferences exhibited by Them4 and 
Them5. Hence, Them5 may be a prominent thioesterase for long-chain acyl-CoA molecules 
in mitochondria.  
Our results show that changes in mitochondrial morphology due to a lack of Them5 protein 
are most likely linked to its enzymatic activity. Considering the late appearance of Them4 in 
evolution, and the even later appearance of Them5, one can speculate that these proteins 
evolved to perform specific and non-overlapping functions in the mitochondria.  
Analysis of Them5 knock-out mice revealed an age-dependant progression of fatty liver 
disease. Mutant mice displayed hypoketosis and showed decreased β-oxidation rates. They 
failed to upregulate FAS upon fasting, which is also indicative of impaired β-oxidation and 
TCA cycle, and may be a consequence of the increase in cytoplasmic fatty acids. As a 
consequence of decreased β-oxidation and increased levels of UCP2, the maximal 
respiratory capacity and respiratory control ratio are lower in Them5-/- cells. Additionally, 
Them5KO mitochondria show reduced coupling of OXPHOS. Detailed MS analysis of lipid 
metabolites indicated that ablation of Them5 induced the accumulation of a major species of 
monolysocardiolipin (MCL), which acts as an upstream metabolite in the remodeling cycle of 
cardiolipin (CL). CL is the major phospholipid of the inner mitochondrial membrane, whose 
synthesis and remodeling occurs predominantly within mitochondria (Esposti et al., 2003; 
Schlame, 2008). We propose that Them5 thioesterase activity may regulate the initial 
metabolism of CL by maintaining the pool of acyl groups that re-acylate, in particular 
stearoyl- and palmitoyl-containing MCL species that lie upstream in the CL remodeling cycle 
(Figure 7A). Remodeling is essential for CL functions, which include the regulation of 
mitochondrial bioenergetic processes and mitochondrial dynamics (Osman et al., 2011; 
Schlame, 2008). The plasticity and dynamics of mitochondria are highly dependent on the 
content of CL and other lipids. In particular, the balance between CL and MCL is essential to 
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dynamically maintain cristae homeostasis (Acehan et al., 2011; Ban et al., 2010; Rujiviphat 
et al., 2009). Thus, our initial observation that thioesterase activity of Them5 is important for 
mitochondrial morphology (Figure 4) can be rationalized by the results of subsequent MS 
analysis showing more than a two-fold increase in major MCL species relative to CL species 
(Fig. 6). The membrane tubulation propensity of MCL would probably account for the 
elongated appearance of Them5-deficient mitochondria. Additionally, reduced thioesterase 
activity as a consequence of Them5 ablation (Figure 7B) will trap a portion of the 
mitochondrial pool of CoA into long acyl-CoA molecules. Those that are not normally used in 
the local CL remodeling metabolism (e.g. stearoyl-CoA) will then leave the mitochondria and 
subsequently be hydrolyzed to free fatty acids by cytosolic or peroxisomal thioesterases. 
The process will produce extra-mitochondrial accumulation of free fatty acids, which will 
build up in hepatocytes once their release capacity as cholesterol esters or triglycerides is 
saturated. In support of this interpretation, we found only minimal changes in the acyl group 
distribution of phospholipids synthesized outside mitochondria (Figure S10). Of note, a 
recent study has shown that altering the supply of acyl-CoA metabolites modifies CL 
remodeling (Rijken et al., 2009). The cytosolic accumulation of free fatty acids, again due to 
the above mechanism, would induce feedback inhibition of FAS by its product palmitate. 
Moreover, our finding of impaired β-oxidation in Them5-/- implies a reduced production of 
acetyl-CoA, with consequent reduction in mitochondrial citrate and its export into the cytosol, 
where it is required for FAS initiation. Ultimately, the accumulation of fatty acids, observed in 
Them5-/- animals, originates from the alteration in CL remodeling within mitochondria, due to 
the reduced capacity of utilizing long acyl-CoA metabolites caused by Them5 loss. We have 
identified a novel class of mitochondrial thioesterases, Them4 and Them5, and proposed 
their likely biological function. Further research on the involvement of Them5 in the 
regulation of mitochondrial lipid metabolism and mitochondrial dynamics will shed more light 
on these and related topics, such as oxidative stress. 
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Figure 7. Proposed scheme of Them5 function in mitochondria 
(A) Fatty acids are imported into mitochondria from cytosol via CPT transporters (1). Acyl-CoAs are 
hydrolyzed by Them5 (2), releasing acyl chains used for re-acylation of the CL precursor, SP2-MCL, by 
ALCAT or MCLAT (3). The other steps of CL remodeling are mediated by Taz (tafazzin), a transacylase that 
catalyzes transfer of one acyl from a PL donor (like PC) to an MCL precursor (4). Normally, strearoyl and 
palmitoyl acyls are re-esterified and can be used in β-oxidation and, subsequently, TCA (5). The final product 
acetyl-CoA is then transported to the cytosol (6), where it becomes a substrate for fatty acid synthesis (7,8).  
(B) Them5 ablation (1) leads to accumulation of the CL precursor SP2-MCL (2). However, short and saturated 
acyl species of CL are still produced by CL synthase and are degraded by local phospholipases (3), leading to 
the accumulation of palmitic and stearic fatty acids (4) and concomitant depletion of the limited mitochondrial 
CoA pool. Overall, it results in β-oxidation inhibition (5), upregulation of UCP2 (6), and increased export of 
these acids to the cytosol and storage of them as lipid droplets (7). This will cause an increase in basal levels of 
CPT1 (8), and eventually release lipids into the bloodstream. 
CL – cardiolipin; LPC – lysophosphatidylcholine; MCL – monolysocardiolipin; CPT – carnitine-palmitoyl 
transferase; UCP2 – uncoupling protein 2; CoA – coenzyme A; ALCAT – acyl-CoA:lysocardiolipin 
acyltransferase; MCLAT – monolysocardiolipin acyltransferase; TCA – tricarboxylic acid cycle. 
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EXPERIMENTAL PROCEDURES  
 
Immunostaining 
For immunostaining experiments, cells were plated on coverslips and optionally transfected 
with corresponding DNA the next day. 24 h later, cells were either fixed with 4% FA and 
permeabilized with 0.2% Triton X-100 as described elsewhere (Parcellier et al., 2009a), or 
were fixed and permeabilized with methanol/acetone (1:1 v/v) for 5 min at −20°C. To 
visualize mitochondria, cells were stained with 20 nM Mitotracker Red prior to fixation for 15 
min at 37°C. Afterwards, cells were washed with PBS and incubated with primary antibodies 
of appropriate dilution in 1% BSA/1% goat serum overnight. This was followed by incubation 
with secondary anti-mouse conjugated with Alexa488 or Alexa568, together with 1 µM To-
Pro-3 iodide (Molecular Probes Inc) for 30 min at room temperature. Afterwards, slides were 
washed, mounted with Prolong Gold mounting media (Invitrogen), and visualized using an 
LSM510/LSM700 laser scanning microscope. 
  
Immuno-electronmicroscopy 
This was performed according to the protocol described elsewhere with slight modifications 
(Slot and Geuze, 2007). Immunolabeling was carried out using anti-hThem5 at a dilution of 
1/50 and anti-HA at 1/200 (Clontech, Cat. No. 631207); 10 nm protein A-gold (UMC-Utrecht 
University, Utrecht, The Netherlands) was used at 1:50 dilution. 
 
Crystallization and structure determination 
Crystallographic methods are described in the Supplementary material section. Data 
collection and refinement statistics are given in Table S1.Thioesterase activity assay 
The reaction mixture contained recombinant protein, fatty acyl-CoA substrate (Larodan Fine 
Chemicals, Sweden) at concentrations ranging from 1 to 200 µM, 50 mM HEPES, 50 mM 
KCl, and 0.5 mM DTNB (5,5′ -Dithiobis(2-nitrobenzoic acid)) in 1 ml total volume. Reactions 
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were observed spectrophotometrically at 412 nm (ε=13.6 mM-1 cm-1) at 22°C or 37°C using a 
UV1800 spectrophotometer controlled by UVPro2.33 software (Shimadzu Schweiz GmbH).  
 
Lipid extraction and MS analysis 
Phospholipids were extracted from purified mitochondria and analyzed by electrospray mass 
spectrometry as described previously (Moisoi et al., 2009), (Esposti et al., 2003). 
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Supplemental Information 
Analysis of novel Acyl-CoA thioesterase Them5 reveals a role in 
mitochondrial morphology and fatty liver disease development. 
Elena Zhuravleva, Heinz Gut, Debby Hynx, David Marcellin, Christopher K. E. 
Bleck, Christel Genoud, Peter Cron, Jeremy J. Keusch, Bettina Dummler, Mauro 
Degli Esposti, Brian A. Hemmings 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Crystallization, X-ray data collection, and structure determination. Crystals of 
∆36Them4 were obtained via the vapor diffusion method by mixing 100 nl of protein 
solution (4.3 mg/ml ∆36Them4, 50 mM CHES pH 9.5, 200 mM NaCl, 5 mM TCEP) with 
100 nl of reservoir solution containing 100 mM Tris pH 7.0, 200 mM NaCl and 30 % Peg 
3000. Crystals were cryoprotected with 20 % ethylene glycol and frozen in liquid nitrogen 
before data collection at the Swiss Light Source (SLS) synchrotron, Villigen, Switzerland. 
The structure of ∆36Them4 was solved by the molecular replacement method using 
PHASER (McCoy et al., 2005). A homology model of the conserved thioesterase hot-
dog fold was constructed with the MODELLER software  and used as a search model 
(Sali and Blundell, 1993). Clear solutions for four molecules per asymmetric unit forming 
together two homodimers of the thioesterase fold were obtained. Phases calculated from 
this initial model were used for automated model building of the full molecule in PHENIX 
and BUCCANEER (Adams et al.). (Ref BUCCANEER) 
Crystals of ∆34Them5 were obtained by mixing 100 nl of protein solution (4.0 mg/ml 
∆34Them5, 20 mM Tris pH 7.5, 200 mM NaCl, 5 mM TCEP) with 100 nl of reservoir 
solution (100 mM Phosphate-citrate pH 4.2, 10 % PEG 3000, 200 mM NaCl). Crystals 
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were cryoprotected with 30 % ethylene glycol and frozen in liquid nitrogen before data 
collection at the SLS. The structure of ∆34Them5 was solved by the molecular 
replacement method using PHASER with the structure of ∆36Them4 as search model 
(McCoy et al., 2005). One Them5 chain per asymmetric unit was found representing half 
of the homodimeric thioesterase molecule. Phases from this solution were calculated 
and used for automatic model building with PHENIX (Adams et al.). Them4 and Them5 
models were further improved by the crystallographic simulated annealing routine 
followed by individual B-factor refinement in PHENIX (Adams et al.). All structures were 
refined by several rounds of manual rebuilding in COOT (Emsley and Cowtan, 2004) 
followed by refinement in PHENIX (Adams et al.). Final structures were validated using 
the molprobity server (http://molprobity.biochem.duke.edu/) and COOT (Emsley and 
Cowtan, 2004). Structural images for figures were prepared with PyMOL 
(http://pymol.sourceforge.net/). 
 
Analytical gel-filtration studies. Human THEM4 (amino acids 37-240) and THEM5 
(amino acids 35-247) proteins were expressed with C-terminal His6
Berrow et al., 2007
 tags using a 
pOPINE vector and E. coli Rosetta2 DE3 cells ( ). The target proteins 
were purified on nickel-nitrilotriacetic acid beads (Qiagen) followed by gel-filtration on a 
HiLoad 16/60 Superdex 200 column (GE Healthcare) and concentrated to 6 mg/ml in 
gel-filtration buffer (50 mM Tris, pH 8.5, 200 mM NaCl, 10 mM TCEP and 0.02% NaN3). 
Analytical gel-filtration runs were performed in the same buffer on a Tricorn Superdex 
200 10/300 GL (GE Healthcare) column, previously calibrated with molecular weight 
standards (ferritin 440 kDa, catalase 232 kDa, aldolase 158 kDa, albumin 67 kDa, 
ovalbumin 43 kDa, chymotrypsinogen A 25 kDa and ribonuclease A 13.7 kDa). A total 
volume of 100 µl containing THEM proteins (at a final concentration of 0.9 mg/ ml) was 
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injected onto the Superdex 200 10/300 column and separated at a flow rate of 0.75 ml/ 
min. 
 
Sequences: 
Human THEM4 37-240 (24,252.2 Da) 
MSSEEVILKDCSVPNPSWNKDLRLLFDQFMKKCEDGSWKRLPSYKRTPTEWIQDFKTH
FLDPKLMKEEQMSQAQLFTRSFDDGLGFEYVMFYNDIEKRMVCLFQGGPYLEGPPGFI
HGGAIATMIDATVGMCAMMAGGIVMTANLNINYKRPIPLCSVVMINSQLDKVEGRKFFV
SCNVQSVDEKTLYSEATSLFIKLNPAKSLTKHHHHHH 
 
Human THEM5 35-247 (24,894.5 Da) 
MGSSTDSMFSRFLPEKTDLKDYALPNASWCSDMLSLYQEFLEKTKSSGWIKLPSFKSN
RDHIRGLKLPSGLAVSSDKGDCRIFTRCIQVEGQGFEYVIFFQPTQKKSVCLFQPGSYL
EGPPGFAHGGSLAAMMDETFSKTAFLAGEGLFTLSLNIRFKNLPVDSLVVMDVEVDKIE
DQKLYMSCIAHSRDQQTVYAKSSGVFLQLQLEEESPQKHHHHHH 
 
 
Cell culture 
HEK293 and U2OS were grown in DMEM in the presence of 10% serum bovine serum. 
For transfection experiments, cells were plated in 6-well plates or 6-or 10-cm dishes and 
transfected the next day using JetPEI reagent (Polyplus Transfection™) for HEK293, 
and Fugene 6 (Roche) for U2OS cell lines. 
 
RNA extraction, reverse transcription reaction and qRT-PCR analysis 
Total RNA was extracted from tissues or cells using TRIzol Reagent (Invitrogen, Life 
Technologies) according to the manufacturer’s protocol. The concentration of RNA was 
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determined with NanoDrop Spectrophotometer (Nanodrop Technologies) and 2μg of 
RNA were used for reverse transcription reaction. qRT-PCR was performed using an 
Applied Biosystems ABI7000 Sequnce Detection  system. A 25 μl of reaction mixture 
included 12.5 μl of 2x SYBR Green Master mix (Applied Biosystems), oligos and cDNA 
in appropriate concentrations.  
 
Subcellular fractionation of cells was performed according to procedure described 
elsewhere (Parcellier et al., 2009a). 
 
Western blotting 
For Western blot analysis, protein lysates were prepared using a lysis buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 40 mM β-glycerophosphate, 10% glycerol, 4 
μM leupeptin, 0.05 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 50 mM NaF, 1 
mM Na3VO4
 
, 5 mM EDTA, 1 μM Microcystin LR). Homogenates were centrifuged 
(14,000 rpm for 20 min at 4°C) to remove cell debris. Protein concentrations were 
determined using the Bradford assay, and proteins separated with 15%, 12.5%, or 10% 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transfered to 
Immobilon-P PVDF membranes (Millipore). 
Antibodies   
hThem5 monoclonal antibodies were generated by repeated immunization of BALB/c 
mice with 50–100 µg of purified full-length GST-hThem5 protein (produced in E. coli), 
using Stimune (Prionics AG, Schlieren, Switzerland) as an adjuvant. Two months after 
the priming injection, splenic lymphocyte cells were fused with the P3AG8.653 
myelanoma cell line (ATCC) and cultured according to standard procedures. Monoclonal 
anti-Them5 antibodies are IgG1. 
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Anti-Myc (9E10), anti-HA (12CA5), α-tubulin (YL 1/2) were used as hybridoma 
supernatants. The commercial mouse anti-mHsp70 was from Affinity BioReagents, 
rabbit anti-cytochrome c was from Cell Signaling Technology, rabbit anti-Tom20 and 
rabbit anti-HA (Y11) were purchased from Santa Cruz Biotechnology. 
 
Imaging 
For the analysis of mitochondrial morphology, the images were 0.5μm×0.5μm×0.2μm, 
and were deconvolved afterwards with the Huygens Software (Scientific Volume Imaging 
B.V.) via Hygens Remote Manager. Image analysis was performed with the Imaris 
software (Bitplane, Zurich).  
 
Electron microscopy  
Samples we prepared according to standard procedures. Briefly, tissues or cells were 
fixed in 2.0% PFA/2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, washed in 
0.1 M cacodylate buffer (pH 7.4), subsequently postfixed in 1% OsO4/1.5% KFeCN and 
then 1% OsO4 in cacodylate buffer, rinsed in ddH2
 
O, stained with 1% uranil acetate in 
water for 20 min, then rinsed in water, gradually dehydrated in ethanol (50%-100%), and 
embedded in Durcupan resin. Serial block-face scanning electron microscopy was 
performed using the 3View™ SBFSEM system (Gatan, Inc.) under low-vacuum 
conditions. Images were taken at a resolution of 4096×4096 pixels with 50 nm slices, all 
controlled by DigitalMicrograph software (Gatan, Inc.) and then processed using Imaris 
software.  
Generation of Them5 knock-out mouse  
A targeting vector was generated that contains a 3.7 kb 5’ homology region, an 
IRES/lacZ/neo cassette, and a 5 kb 3’ homology region. A genomic DNA fragment of 
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about 1.3 kb, including the ATG start codon in exon 1 and the full sequence of exon2, is 
deleted in the targeting vector. The targeting vector was linearized with NotI and 
electroporated into 129/Ola ES cells. Screening of ES cell clones was performed by 
Southern Blotting. DNA was digested with EcoRV and probed with an external probe 
(green box spanning sequence 16980-17663, Figure S6C). An internal probe was then 
used on NdeI digested DNA (green box spanning sequence 9652-10154, Figure S6D) 
for further characterization of ES cell clones positive for homologous recombination. 
Correctly targeted ES cells were used to generate chimeras. Male chimeras were mated 
with wild type C57BL/6 females to obtain Them5-/-
 
 mice, which were intercrossed to 
produce Them5 homozygous mutants. 
Free fatty acids measurement 
Levels of free fatty acids in plasma of Them5-/-
 
 and wildtype mice were measured using 
ZenBio serum/plasma Fatty Acid detection kit (ZenBio, Inc.).  
Ketone bodies measurement 
Levels of 3-Hydroxybutyrate (3-HB) were determined with Autokit 3-HB test  for 
quantitative determination of 3-hydroxybutyrate (3-HB) in serum or plasma (WAKO). 
 
Cellular fatty acid oxidation 
Isolated hepatocytes were incubated for 1 h in scintillation vials in Krebs Ringer buffer 
with 3% fatty acid free BSA, with 1 mM 1-14C-palmitic acid with specific activity 1 
mCi/mmol (Hartmann Analytic GmbH). Radiolabeled CO2 was collected in center wells 
with Whatman #1 filter paper and 200 µl of 1 M methylbenzethonium hydroxide in 
methanol. At the end of the incubation, 300 µl of 5M H2SO4 was added to volatilize the 
remaining CO2, and the solution was incubated for another 30 min. The center wells 
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were then placed in other scintillation vials and 8 ml of scintillation liquid were added and 
counted on a β-counter.  
 
Preparation and culture of primary mouse embryonic fibroblasts (MEFs) 
Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos. Cells were 
cultured in DMEM containing 10% fetal calf serum under low oxygen conditions (3%) at 
37˚C (vom Brocke et al., 2006). All experiments were performed with primary MEFs 
(passages 3-15). 
 
Respirometry analysis was performed with Seahorse XF24 analyzer (Seahorse 
Bioscience, Billerica, MA, USA). Mitochondria were isolated from liver of Them5 WT and 
KO mice, protein was quantified using BCA (Pierce), and 5μg of protein per well were 
plated on polyethyleneimine–treated plates (1:15000 dilution from a 50% solution from 
Sigma-Aldrich). For coupling assay an initial mix contained succinate and rotenone 
(10mM and 2μM, correspondingly). After an Oxygen Consumption Rate (OCR) baseline 
measurement, ADP, oligomycin, carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone 
(FCCP), and antimycin A were sequentially added to each well to the final 
concentrations of 4mM, 2.5 μg/ml, 4 µM and 4 µM respectively, and changes in the OCR 
were analyzed. For electron flow assay the initial mix contained malate, pyruvate, and 
FCCP (2mM, 10mM, 4μM final concentrations, correspondingly). After the initial OCR 
measurement, subsequent injections of rotenone, succinate, antimycin A and 
ascorbate/N1,N1,N1,N1
 
-tetramethyl-1,4-phenylene diamine (TMPD) (2μM, 10mM, 4μM, 
10mM/100μM final concentrations, respectively) were performed, and changes in OCR 
were analyzed. The measurement was performed accordingly to the protocol provided 
by manufacturer.  
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Mice  
Mice were housed in groups of 3 with 12 hour-dark/light cycles and free access to food 
and water, in accordance to the Swiss Animal Protection Ordinance. All procedures were 
performed with approval of the appropriate authorities. 
For the high fat diet experiments mice were housed according to their genotypes, but not 
more that in groups of 3.  After weaning mice were kept on high fat diet for 13-15 weeks. 
High fat diet was from KLIBA NAFAG  #2126 (Kaiseraugst, Switzerland) and contained 
45 % kcal % fat.   
 
Statistical analysis  
Data are provided as means ± standard errors of the means (SEM), where n is the 
number of independent experiments. All data were subjected to the one-way analysis of 
variance (ANOVA), Student t-test, or Mann-Whitney test, as applicable. The significance 
is indicated as *** for p<0.001, ** for p<0.01 and * for p<0.05 
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SUPPLEMENTAL FIGURES 
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Figure S1. Them5 gene appears later in evolution but shares similar structure with Them4 
(A) Cartoon representation of hThem4 and hThem5 genes.  
Genomic (upper panel) and exon-intron structure and mRNA cartoon representation (lower panel) of 
hThem4 and hThem5 genes (4HBT - 4-hydroxybenzoyl-CoA thioesterase domain, MTS - mitochondrial 
targeting sequence).  
(B) Philogenetic tree of Them4 and Them5 orthologs in different species. 
Them4 othologs are found in lower eukaryotes, such as yeasts and chordata (Them4 orthologues upper 
group); Them5 orthologs, however, are present only in mammals (lower group). 
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Table S1. Data collection and refinement statistics 
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Figure S3. Wild-type hThem5 has a hydrolase activity directed towards myristoyl-CoA, but not 
acetyl-CoA 
(A) Time-dependent change of absorbance (selected time points) reflecting hydrolysis of 20μM myristoyl- 
and acetyl-CoA by wild-type hThem5. Reaction was monitored at 412nm at 37˚ C in the presence of 5μg of 
enzyme. 
(B) Efficiency of substrate hydrolysis (acetyl- and myristoyl-CoA) by wild type hThem5 after 20min of 
reaction.  
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Figure S4. Them4 and Them5 are forming homodimers 
(A) Crystal packing of Δ36Them4 (left panel) and Δ34Them5 (right panel) molecules in the P1 and in the 
C2221
The structure of Δ36Them4 was solved in space group P1 (two homodimers in the a.u.) and C222
 crystal lattice, respectively. Adjacent layers of symmetry-related molecules forming the crystal are 
displayed in cyan and red in cartoon representation. Δ34Them5 molecules are shown in cartoon 
representation with the content of the asymmetric unit colored in cyan (1/2 of the Δ34Them5 homodimer) 
and the symmetry-related molecules displayed in red.  
1 (one 
homodimer in the a.u., data not shown), while the structure of Δ34Them5 was solved in space group C2221 
(1/2 homodimer in the a.u.), C2 (three homodimers in the a.u., data not shown), and P21
(B) Analytical size-exclusion chromatography experiments displaying the oligomeric states of Δ36Them4 
(left panel) and Δ34Them5 (right panel) in solution. Δ36Them4 shows an equilibrium between a 
homodimeric species (15.22 ml, 45.80 kDa, 48.50 kDa) and a tetrameric species (dimer of homodimers, 
13.68 ml, 105.01 kDa, 97.01 kDa) whereas Δ34Them5 elutes as a homodimer only (15.23 ml, 45.56 kDa, 
49.79 kDa). Elution volumes, approximate molecular weight and expected molecular weight are given in 
parentheses, respectively. 
 (one homodimer in 
the a.u., data not shown). In all of these cases  Δ36Them4 and Δ34Them5 are independent homodimers. 
(C) Detailed view of Them5 mutation sites created to disrupt the homodimer. Sites are located at the 
homodimer interface and mapped onto the Δ34Them5 crystal structure (side view, left upper panel; top 
view, left bottom). The Them5 subunits are shown as cartoon models (blue and gray) while mutated 
residues are shown as sticks and colored in red (Ile188), orange (Gly160), and cyan (Ala163). The most C-
terminal α-strand of both subunits is not shown in the bottom view for clarity reasons. 
(D) Co-immunoprecipitation experiments with ΔMTS-Them5 wild-type and mutants with HA and myc-
RFP tags. HEK293cells were transfected with the corresponding cDNAs, 24hours after lyzed and proteins 
were precipitated with anti-myc antibodies and then probed with indicated antibodies. Mutations were 
introduced in the central helix, leading to instability of a dimer due to the electrostatic repulsion or steric 
hindrance (G160W/E, A163W/E); another mutation was made in order to disturb anti-parallel β-sheet 
formation (I188R). Double 160E163E and 160W163W mutants have very low levels of expression, but still 
can be co-precipitated with wildtype Them5 (lanes 5 and 6). However, co-transfection of two differently 
tagged mutants greatly diminishes their expression levels and abolishes interaction/co-precipitation (lanes 9 
and 10). 
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Figure S5. Mitochondrial localization of Them5 protein   
(A) Immunofluorescence analysis of endogenous Them5. U2OS cells were fixed and stained with 
antibodies against hThem5 protein. Mitochondria were visualized with TOM20 protein.  
(B) Examples of quantifications, carried out for Them5 and TOM20 (upper panel) and Them5 and tubulin 
(lower panel). Images were taken with the confocal microscope and analyzed with the Imaris Coloc 
software. The threshold of each channel was determined and percentage of colocalized pixels was 
quantified. Quantification showed 58.4% of colocalization of FL_Them5 with TOM20, 1.89% with tubulin 
(for Figure 3C); 12.5% colocalization of ΔMTS_Them5 with TOM20, 88.2% with tubulin (for Figure 3D).  
(C) Immunofluorescence analysis of overexpressed ΔMTS_Them5 and N-cadherin. 
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Figure S6. Generation of Them5 knock-out mouse 
(A) Presence of mThem5 genomic DNA in BAC clone was verified by PCR of individual exons (cloned 
mThem5 cDNA is positive control). BAC clone was used as PCR template for generating left and right 
homology region of targeting vector.  
(B) Transcript structure of mTHEM5 gene in mice. White areas represent untranslated regions (Ensembl 
database).  
(C) Targeted mThem5 allele. A targeting vector was generated that contains a 3.7 kb 5’ homology region, 
an IRES/lacZ/neo cassette, and a 5 kb 3’ homology region. A genomic DNA fragment of about 1.3 kb, 
including the ATG start codon in exon 1 and the full sequence of exon2, is deleted in the targeting vector. 
The targeting vector was linearized with NotI and electroporated into 129/Ola ES cells.  
(D) Screening of ES cell clones was performed by Southern Blotting. DNA was digested with EcoRV and 
probed with an external probe (green box spanning sequence 16980-17663). An internal probe was then 
used on NdeI digested DNA (green box spanning sequence 9652-10154) for further characterization of ES 
cell clones positive for homologous recombination. Correctly targeted ES cells (highlighted in red) were 
used to generate chimeras. Male chimeras were mated with wildtype C57BL/6 females to obtain Them5+/-
(E) Progeny were genotyped for the presence of a targeted allele by multiplex PCR. The following primers 
were used for genotyping: P1-as 5’-GCA GCA GGC TGA ACT GAC TGA GG-3’; P2/KO-s 5'- GCT GCC 
TCG TCC TGC AGT TCA TTC-3’'; P3/WT-s 5'-CAG GCG GCT GGA TTA AAC TAC C-3’. One 
reaction amplifies a 500 bp fragment from the targeted allele and the second reaction amplifies a 330 bp 
fragment from the wildtype allele. 
 
mice, which were intercrossed to produce Them5 homozygous mutants.  
(F) Total RNA was extracted from Them5-/- and Them+/+
(G) mRNA levels of CTMP/Them4 were assessed by real-time PCR in Them5 WT and KO mice (n=4-5). 
No significant changes in Them4 mRNA level were detected upon Them5 knock-out. 
 liver, and Them5 was amplified with specific 
primers. Each lane represents separate animal. 
(H) Western blot analysis of mitochondrial fractions from Them5 WT and KO liver (each lane represents 
separate animal). 30 μg of protein lysate were loaded on the gel and probed with anti-CTMP1/Them4 
antibodies and Grp75 as a loading control.  
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Figure S7. Them5-/-
Them5
 mice show no changes in mtDNA copy number and mitochondrial fusion genes 
expression 
+/+ and Them5-/- mice (males, 12 months old, random fed) were sacrificed and gene expression was 
measured by real-time PCR. No changes in mRNA expression between samples from Them5+/+
Them5
 and  
-/- were detected in neither (A) nuclear encoded mitochondrial transcription factor TFAM and single 
copy mitochondrial genes COX1 and ND1, nor in (B) expression of mitochondrial fusion genes (OPA1, 
MFN1, MFN2). 
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Figure S8. Loss of Them5 exacerbates fatty liver development upon high fat diet (HFD) treatment 
Mice (males, n=6-8) were kept on HFD for 15 weeks and analyzed afterwards. 
(A) Increase in body weights and liver weights of Them5-/-
(B) Hematoxilin-eosin staining of liver sections from Them5
 mice (left panels), but no significant changes in 
food intake (measured as per gram per body weight and gram/mouse/day – right panels) were detected. 
+/+ (left panels) and Them5-/- mice (right 
panels) kept on high fat diet for 15 weeks. Lipid accumulation is indicated with green arrows, lymphocytic 
infiltration - with black arrows. Note more pronounces inflammatory changes in Them5-/- 
 (C) Lipid accumulation was assessed by staining with BODIPY 493/503 of liver sections (10μm thickness). 
Nuclei were stained with TO-PRO 3 (both from Molecular Probes, Invitrogen). Images were taken with 
LSM700 and analyzed with Imaris software (Bitplane, Zurich). Quantification (bottom panel) shows almost 
2-fold increase in BODIPY-positive area in Them5
samples.  
-/-
(D-E) RNA was extracted from livers of random fed Them5
 samples. 
-/- and Them5+/+
 
 mice after 15 weeks of HFD  
and mRNA of (D) interleukin 6  and (E) UCP2 expression levels were measured by real-time PCR. 
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Figure S9. Them5-/-
(A) Primary MEFs from Them5 
 mouse embryonic fibroblasts (MEFs) show elongated mitochondrial morphology 
and decreased respiratory capacity 
-/-
(B) Primary MEFs were co-stained with anti-mouse Them5 and anti-Grp75 (mortallin) antibodies. Images 
were taken with LSM700 microscope. The staining pattern shows colocalization of Them5 and Grp75.  
 and wild-type controls (gender matched siblings) were stained with anti-
mouse Them5 antibodies and visualized with LSM700 microscope.  
(C) Primary MEFs from Them5 -/-
(D) UCP2 expression was measured by real-time PCR in primary MEFs from Them5
 and wild-type control were fixed and stained with anti-TOM20 
antibodies. Confocal images were taken with the LSM700 microscope and mitochondria were 
reconstructed and their length was quantified with Imaris software (Bitplane, Zurich). Minimum 3 
experiments were performed with at least 10 cells in each analyzed. 
-/- 
(E) Oxygen consumption rates were measured for Them5
and WT controls 
(from gender-matched siblings). 
-/- 
(F) Quantification of the integral maximum respiration rate presented as area under curve (AUC) shows 
20% decrease in Them5
and WT primary MEFs using a Seahorse XF24 
analyzer. A – Oligomycin, B – FCCP, C – Rotenone+Antimycin D (n=10 for each genotype). 
-/-
 
.   
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Figure S10. MS profiling of mitochondrial phospholipids  
Lipid extracts were prepared from Them5 WT (upper panel) and KO mouse mitochondria (lower panel) 
and analyzed by mass spectrometry in a positive mode (Moisoi et al., 2009). Species composition in the 
phospholipid region does not show major differences between WT and KO samples. Representative MS 
profiles are shown.  PE – phosphatidylethanolamine,  PC – phosphatidylcholine, PI – phosphatidylinositol 
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3.2 THE ROLE OF THE CTMP2/THEM5 PROTEIN IN PKB SIGNALING: FURTHER 
CHARACTERIZATION OF THEM5-/-
This part of the results includes work with Them5 KO mouse that was not included in 
the manuscript presented in section 3.1.  
 MICE 
 
3.2.1 Interconnected mitochondria in Them5-/- primary hepatocytes and β-cells 
We performed serial block-face scanning electron microscopy of primary 
hepatocytes from Them5 wildtype and knock-out mice, and observed more 
interconnected, elongated mitochondria in Them5-/- tissues. Them5-/- mitochondria 
had almost twice the volume of Them5+/+ mitochondria, reflecting their more 
interconnected phenotype. We analyzed samples from 2- and 6-month-old mice and 
found that the phenotype was more pronounced in the older mice. At 2 months the 
difference was statistically significant, although visually mitochondrial morphology 
had not changed considerably. However, at 6 months the difference in mitochondrial 
shape was striking. We also analyzed whether mitochondrial morphology changed 
upon fasting in Them5-/- and Them5+/+
The increased volume/interconnectivity may also be partially explained by an 
increase in the number of mitochondria. To analyze this, we performed real-time 
PCR analysis of single-copy mitochondrial genes COX2 and ND1, but did not 
observe any differences. Also, the quantification of mitochondria from Them5
 mice. The mitochondrial volume was 
increased after fasting in both wildtype and knock-out samples, and there was 
almost a 3-fold difference in volume.  
+/+ and 
Them5-/- hepatocytes in the EM stacks did not show statistically significant 
differences between mutants and wildtype mice (Figure 3.1).   
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We also observed that in Them5-/- hepatocytes there may be an increased 
association between mitochondria and the endoplasmic reticulum (Figure 3.2), but 
this needs further investigation.  
 
 
 
Figure 3.1  
Quantification of mitochondria number in the electron microscope images. (A) Example of 
mitochondria number quantification in the EM stack obtained from SBFSEM of liver tissue. Mitochondria 
number was quantified in the slices through the whole stack of images, which was a complete cell. (B) 
Quantification of mitochondria in the EM stack did not show and statistically significant differences 
between Them5 WT and KO hepatocytes. 
Figure 3.2 
Electron micrographs of hepatocytes from Them5 WT (left) and KO (right), showing that there may be an 
increased association between mitochondria and the endoplasmic reticulum. 
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Analysis of pancreatic β-cells showed a similar phenotype. The increase in 
mitochondrial volume was almost 4-fold (Figure 3.3D,E). We have not observed any 
other abnormalities at the EM level in β-cells. In addition, the histological analysis of 
the pancreas from Them5-/- mice confirmed a typical organization of pancreatic 
islets, with insulin-producing β-cells concentrated in the middle, and glucagon-
Figure 3.3 
(A) Presence of Them5/CTMP2 mRNA in mouse β-cells (MIN6 cell line). Total RNA was extracted, cDNA 
was synthesized and PCR with corresponding primers was performed using 30ng of template. (B) 
Immunofluorescent staining of endogenous Them5/CTMP2 protein in MIN6 cells. (C) Endogenous 
Them5/CTMP2 protein is present in primary β-cells and co-localizes with the mitochondrial marker 
Mitotracker Red. (D) Electron micrographs of pancreatic islets isolated from Them5 WT and KO mice, 
obtained by serial-block face scanning EM (upper panel), and 3D reconstruction of mitochondria showing 
greater volume of mitochondria from Them5 KO mice (lower panel). (E) Quantification of the mitochondrial 
volume in Them5 KO and WT β-cells. A minimum of 15 mitochondria per cell were reconstructed in at least 
three cells per mouse per genotype. Data are presented as mean ± S.E.M. p<0.05.  
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secreting α-cells on the periphery of the islet structure (Figure 3.4A). We performed 
morphometrical analysis of pancreas from Them5-/-
 
 female mice (and littermate 
controls), and found a trend to an increase in islet area in knock-out mice (Figure 
3.4C). Samples from males have been collected and being processed. However, 
hematoxilin-eosin staining of pancreas sections revealed infiltration of the endocrine 
area with lymphocytes, which is usually sign of type I diabetes (Figure 3.4B). This is 
an unexpected observation, which needs further analysis and study. 
 
 
 
 
 
 
 
3.2.2 Enhanced insulin sensitivity in Them5-/-
We examined the effect of Them5 loss on glucose homeostasis and insulin 
sensitivity. Them5
 mice  
-/- males and females were fed with a standard chow diet and 
subjected to insulin and glucose tolerance tests. Glucose tolerance test results 
showed no difference between WT and KO mice (Figure 3.5F). However, we 
observed enhanced insulin sensitivity in Them5 KO male mice compared to WT 
Figure 3.4 
Preserved organization of pancreatic islets in Them5-/- mice, but signs of lymphocytes infiltration and 
increased area of islets. (A) Immunohistochemistry (IHC) analysis of pancreas endocrine area from Them5 
KO and WT mice (males, 6 months old). Them5 WT and KO pancreas was embedded in paraffin and cut 
into serial sections 5μm thick. Slices were stained with antibodies against insulin (upper panel) and glucagon 
(lower panel). IHC analysis shows typical organization of endocrine pancreas. (B) H&E staining of pancreas 
from Them5 WT and KO mice (males, 6 months old). Them5-/- have larger islets and the endocrine part of 
the pancreas has been infiltrated with lymphocytes (indicated with an arrow). (C) Quantification of the islet 
area in Them5 WT and KO pancreas (females, 6 months old). Preliminary quantification shows trend to 
increased area of β-cells. 
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littermates (Figure 3.5D). The window of insulin dose given to mice was very narrow, 
since Them5-/-
 
 mice suffered hypoglycemic shock and subsequently died as a result 
of having received too high a dose of insulin. Interestingly, only knock-out males, not 
females, showed differences in insulin sensitivity (Figure 3.5E). We also performed 
tests on 3-month-old mice, but insulin sensitivity was still unaltered in Them5 KO 
females. 
3.2.3 PI3K/PKB signaling is enhanced in Them5-/-
Our studies indicate that increased insulin sensitivity in Them5 knock-out mice is 
mainly caused by increased responsiveness of adipose tissue (both white and 
brown) and liver (Figure 3.5A-C). To study this, we starved mice for 8 hours and 
injected insulin or saline intra-venously. Increased PKB phosphorylation was 
observed in white and brown adipose tissue and liver. Muscle, heart, and brain did 
not show any difference in phosphorylated PKB levels. However, PKB was not the 
only kinase affected by loss of Them5. We also observed decreased phosphorylation 
of AMPK at Thr172, a major activation site, which is consistent with increased insulin 
sensitivity upon Them5 deficiency (Figure 3.5A). 
 mice 
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Figure 3.5  
Enhanced PKB signaling in Them5-/- mice. (A) Overactivation of PKB signaling in Them5-/- hepatocytes. 
Primary hepatocytes of Them5-/- and control mice were treated with insulin for the indicated time. Protein 
lysates were prepared and analyzed by western blotting with indicated antibodies. (B) Quantification of 
PKB-S473 and Thr-308 phosphorylation relative to total PKB levels (from the experiment described in A). 
(C) Overactivation of PKB signaling in Them5-/- white and brown adipose tissue after insulin stimulation. 
Mice were starved overnight and injected with insulin (1U/kg) or saline, and sacrificed 5min after injection. 
Tissues were collected and snap-frozen in liquid nitrogen. Protein lysates were prepared and analyzed by 
western blotting using the antibodies indicated. (D) Enhanced insulin sensitivity in Them5-/- males. Mice 
were starved overnight and injected with 0.6U/kg of insulin i.p. Blood glucose levels were measured at the 
time indicated. Both representations, absolute values of glucose concentration in the blood (upper panel) and 
percent change from the baseline values (lower panel), show statistically significant differences between 
Them5-/- and control mice (n=8-11). (E) Insulin sensitivity test of Them5-/- females and littermate controls (6 
months old) showed indistinguishable blood glucose levels after insulin injection (n=8-10). (F) Glucose 
tolerance test, performed on Them5-/- and control littermates (males and females, 6 months old) showed no 
difference in glucose clearance after i.p. injection of glucose (2g/kg of body weight). (n=8-11).  
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Figure 3.6 
Overexpression of Them5 in HepG2 cells decreases activation of PKB signaling after insulin 
stimulation. (A) HepG2 cells were transfected with Them5-HA (or vector control), starved overnight, and 
treated with insulin (100nM) for the time indicated. Later, cells were collected and lysed, and protein 
extracts were analyzed by western blotting with the antibodies indicated. (B) Quantification of PKB-S473 
phosphorylation relative to total PKB levels (from the experiment described in A). (C) Overexpression of 
Them5 lowers levels of oxidized PTEN after insulin/H2O2 stimulation. HepG2 cells were transfected with 
Them5-HA (or vector control), starved overnight, and treated with insulin (100nM, 15min) and/or H2O2 (5 
mM, 15min). After treatment, cells were lysed in non-reducing buffer, lysates were purged with argon, and 
50μg of protein extract were loaded onto the gel (reducing and non-reducing conditions) and analyzed with 
the antibodies indicated. (D) Schematic representation of changes in PTEN redox status (taken from (Kwon 
et al., 2004)). (E) ROS staining of primary hepatocytes from Them5 WT and KO males (6 months old), 
showing increased accumulation of ROS-sensitive dye.  
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When overexpressed, Them5 leads to a decrease in PKB phosphorylation (Figure 
3.6A). Due to the mitochondrial localization of CTMP2/Them5, we were interested in 
seeing if the PTEN redox status was affected by the loss of Them5. To assess this, 
we transfected HepG2 cells with hCTMP2-HA, starved the cells overnight, and 
stimulated them with H2O2
In line with this observation, we stained primary hepatocytes with ROS-sensitive dye. 
There was increased positive staining in the KO hepatocytes, indicating higher ROS 
levels (Figure 3.6E). However, more samples should be analyzed and quantified. 
, or with insulin. Preliminary analysis showed that 
overexpression of Them5/CTMP2 led to lower levels of oxidized PTEN. This 
indicates that an absence of Them5 promotes oxidation, i.e. inactivation of PTEN, 
thus positively regulating PI3K/PKB signaling (Figure 3.5C).  
 
3.2.4 OXPHOS complexes are affected upon loss of Them5  
We assessed levels of OXPHOS complexes after loss of Them5. We observed a 
decrease in complexes I, IV, and V in Them5 KO at the protein level, but not at the 
mRNA level (see Figure 4 and Figure S7; ND1 is part of complex I, COX1 is part of 
complex IV), which may be explained by changes in protein stability due to an 
increased MCL/CL ratio (Zhang et al., 2003). CL molecules are known to associate 
specifically with complexes I and IV of the respiratory chain, and are required for 
their functional activity (Zhang et al., 2005). Changes in CL content, upon 
peroxidation for example, affect activity of complexes I and III (Paradies et al., 2001, 
2002). Also, in patients with Barth syndrome, aberrant respiratory complexes are 
detected along with the increase in MCL/CL ratio (McKenzie et al., 2006), Thus, a 
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decrease in protein levels of the OXPHOS complexes can be a consequence of 
increased levels of immature cardiolipin. More in-depth analysis of respiratory 
complexes is required to assess ETC functionality upon Them5 ablation.    
 
 
 
 
 
3.2.5 Mouse embryonic fibroblasts as a model for studying Them5 function 
We generated mouse embryonic fibroblasts from timed matings (E13.5) of Them5 
mice. Embryos were gender- and genotyped, and paired MEFs were used in the 
experiments (cells derived from male embryos of 2-20 passages were used). 
Similarly to the WB analysis of other tissues, Them5 antibodies do not recognize 
endogenous levels of Them5 in MEFs. However, when we use generated antibodies 
in the immunofluorescence analysis, endogenous Them5 protein could be detected 
and was found to co-localize with mitochondrial marker Grp75 (see section 3.1) in 
the manuscript).  
In order to analyze mitochondrial morphology, we stained primary MEFs with anti-
TOM20 antibodies, and performed the analysis using the confocal microscope, with 
Figure 3.7 
Decreased respiratory complexes in Them5 KO and HET mice. Mitochondria were isolated from Them5 
KO, WT and HET mice (males, 9 months of age), and  20 μg of mitochondria were separated by 4-20%  SDS-
PAGE and immunoblotted for respiratory complexes I-V components with MitoProfile® Total OXPHOS 
Rodent WB Antibody Cocktail (MitoSciences, Oregon, USA). 
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subsequent reconstruction of mitochondria. The analysis showed a significant 
increase in the length of mitochondria in Them5-/-
To analyze the response of cells to fatty-acid exposure, we treated MEFs with 
palmitic acid and oleic acid, for 4 and 10 hours. We did not see any significant 
differences in mitochondrial morphology between KO and control cells upon vehicle 
treatment (type of mitochondria was analyzed: fragmented, intermediate, or 
interconnected) (Figure 3.8A, B). After fatty-acid exposure, however, the percentage 
of fragmented mitochondria in Them5 WT cells increased, with no significant 
changes in Them5
 MEFs (see section 3.1). 
-/-
Ricchi et al., 2009
 cells. Changes in mitochondrial morphology were observed in 
both palmitic and oleic acid treatments (Figures 3.8, 3.9). More pronounced 
mitochondrial fragmentation occurred after oleic acid treatment, which is not 
surprising  given the pro-apoptotic effects of oleic acid ( ). In line 
with this, strong upregulation of fission protein Fis1 mRNA was observed in Them5 
WT cells, with no changes in Them5-/-
Our results suggest that Them5
. We considered whether fatty acid 
accumulation differs between Them5 WT and KO cells, which could potentially lead 
to the differences observed. However, lipid-specific BODIPY staining showed similar 
lipid accumulation in both WT and KO MEFs. 
-/-
 
 mitochondria may be more resistant to 
lipoapoptosis, but more experiments are required for complete characterization. To 
analyze whether the observed effects are dependent on the thioesterase activity of 
Them5, we generated MEF lines which overexpress the wild-type and enzyme-dead 
versions of the proteins. The analysis of mitochondrial morphology and functions in 
these cell lines is ongoing. 
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Figure 3.8 
(A) MEFs were treated with palmitic acid (100μM for 16 hours) or vehicle control (ethanol) and 
subsequently stained with anti-TOM20 antibodies to visualize mitochondria. (B) Different types of 
mitochondria (interconnected, fragmented or mixed) were quantified after treatment as decribed in A. 
Quantification shows reduced appearance of fragmented type of mitochondria in Them5-/- MEFs upon 
palmitic acid treatment. (C) Representative pictures of mitochondria from form Them5-/- (left) or 
Them5+/+ (right) cell, treated with palmitic acid, and visualized with anti-TOM20 antibodies (cells were 
treated as in A).  
 118 
 
 
 
 
 
 
 
 
 
Figure 3.9 
Mitochondria from Them5 KO MEFs are do not undergo fragmentation upon fatty acid exposure 
(A) Them5-/- (left) and WT (right) MEFs were treated with oleic acid (10 hours, 200μM), fixed and stained 
with anti-TOM20 antibodies and lipid-sensitive dye BODIPY. Lipid staining showed that both types of cell 
accumulate lipids upon free fatty acid exposure. (B) Mitochondria morphology was analyzed in cells treated as 
in A. Upon oleic acid treatment up to 60% of Them5_WT analyzed cells have predominantly fragmented 
mitochondria morphology, whereas Them5-/- have only 20%. 3 independent experiments were performed with 
minimum 200 cells per experiment analyzed. Images were taken with Zeiss Z1 microscope and 40x 
magnification objective, and analyzed with AxioVision software. (C) Them5+/+ expressing MEFs upregulate 
Fis1 mRNA levels in response to the oleic acid treatment, whereas Them5-/- cells show no changes in genes 
expression. Total RNA was extracted from the cell trated as in A (100 μM oleic acid for 16 hours or vehicle 
control), reversely transcribed and levels of mitochondria fusion/fission genes were assessed by real-time 
PCR. Data from 4 independent experiments were analyzed. 
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4. EXPERIMENTAL PROCEDURES 
 
Isolation of primary hepatocytes 
Briefly, the mouse was anesthetized and a needle (30G) connected to the pump 
system was inserted into the portal vein. The flow of buffers was maintained at a 
constant speed of 3.5 ml/min. The vena cava was cut to permit the outflow of 
perfusion solutions. The mouse was perfused with Hanks solution I for 5 min, then 
with Hanks solution II for 4 min. After perfusion, the liver was cut out, transferred to a 
Petri dish with sterile non-supplemented Williams E medium (WEM), and 
Figure 3.10 
Generation of stable MEFs expressing WT or enzyme-dead Them5 
(A) Western-blot analysis of Them5-/- MEFs, stably expressing hThem5_WT, D167A, or an empty vector 
control, and Them5+/+ MEFs with a vector control (pBabe vector with puromycin resistance cassette was 
used for generation above constructs). Protein lysates were prepared and analyzed with SDS-PAGE, 
transferred to the PVDF membrane and subsequently probed with anti-hThem5 antibodies. Actin was used 
as a loading control. (B) Immunofluorescence analysis of MEFs cells lines (as described in A). Cells were 
grown on cover slips, fixed and probed with anti-hThem5 (anti-mouse Alexa-488 as secondary antibodies), 
and TOM20 (anti-rabbit Alexa-568 as secondary antibodies). 
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disintegrated. The cell suspension was filtered through a 70μm sterile nylon filter and 
washed twice with 30ml of non-supplemented 4°C WEM (centrifuged for 2min at 
80g). Cells were resuspended in WEM (Williams’ E medium) supplemented with 
10% FCS, 100nM dexamethasone, 2mM L-glutamine, and 1% Pen/Strep, and plated 
on collagen pre-coated dishes (750,000 cells per well in 6-well plate format). 4 hours 
later the medium was changed and cells were incubated overnight and until further 
treatment.  
 
Stimulation of primary hepatocytes with insulin 
Cells were starved overnight and stimulated with insulin or H2O2
 
. After treatment, 
cells were lyzed in non-reducing buffer (100mM Tris-HCl, pH 6.8; 150mM NaCl; 
1mM EDTA; 1% Triton X-100; 50mM N-ethylmaleimide, added freshly, stock solution 
prepared in ethanol), lysates were purged with argon, and 50μg of protein extract 
was loaded onto the gel (reducing and non-reducing conditions). 
Immunofluorescence staining 
Primary hepatocytes and pancreatic islets were fixed with methanol/acetone (1:1) for 
5min at −20°C. The cover slips were left to air dry and afterwards were transferred to 
−20°C. The next day, cells were rehydrated with PBS and stained overnight with 
rabbit polyclonal antibodies against mouse Them5 at 4°C (1/100 dilution in 
PBS/1%BSA). Afterwards slides were washed three times with PBS and incubated 
with secondary antibodies of appropriate dilution for 1 hour at room temperature. 
After that, slides were washed and mounted with Prolong Gold Antifade Reagent 
(Invitrogen).  
Primary MEFs were fixed with PFA (3.7%, pH 7.4) for 30min at room temperature, 
washed twice with PBS, and permeabilized with NP-40 0.01% in PBS pH 7.4 for 
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20min at room temperature. Slides were washed with PBS and blocked with 0.5% 
BSA in PBS for 30min at room temperature. Primary antibodies of appropriate 
dilution were applied to the slides and incubated for 1 hour at room temperature 
(rabbit polyclonal anti-mouse Them5 at 1/50 dilution, anti-TOM20 from Santa Cruz 
Biotechnologies at 1/100 dilution). Secondary antibodies of 1/200 dilution were 
incubated for 1 hour at room temperature. Slides were washed in PBS and mounted 
with Prolong Gold Antifade Reagent (Invitrogen). 
 
In vivo insulin stimulation  
Insulin stimulation was performed on 2- and 24-month-old Them5-/-
 
 mice and 
wildtype controls. Mice were fasted for 8 hours, terminally anesthetized with 
Ketamine/Xylazine and 1U/kg of insulin was injected into the vena cava. 5min (or 
15min) later tissues were collected, snap-frozen in liquid nitrogen, and afterwards 
processed for western blot analysis.  
Insulin and glucose tolerance tests 
For glucose and insulin tolerance tests, mice (3 and 6 months old) were fasted for 8 
hours, and insulin (0.6U/kg of body weight) or glucose (2g/kg of body weight) was 
injected intraperitoneally. Blood samples were collected at the indicated times from 
the tail vein, and glucose levels were determined using Glucometer Elite and 
Acsentia Elite test strips (Bayer).  
 
ROS staining 
For ROS staining, cells or tissue slices were fixed with PFA (3.7%, pH 7.4, in PBS) 
for 10min at room temperature, washed twice with PBS, and incubated with 200μl of 
5μM solution of CM-H2DCFDA (Molecular Probes, Invitrogen) at 37°C for 30min. 
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Later, sections were washed with PBS and mounted with Prolong Gold Antifade 
Reagent with Dapi. Fluorescence was detected using 488nm laser illumination with 
an LSM700 confocal microscope. 
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5. GENERAL DISCUSSION 
The aim of this thesis was to characterize the novel mitochondrial protein 
CTMP2/Them5. As previously mentioned, CTMP2/Them5 has been identified as a 
paralogue of CTMP/Them4, whose gene is located just 20kb away from that of 
Them5. A phylogenetic tree analysis shows that Them5 evolved relatively recently, 
in mammals only, whereas Them4 orthologs were already found in yeasts.  
We have shown that Them5 is a novel protein that belongs to the mitochondrial 
proteome. Them5 has an N-terminally located mitochondrial targeting sequence and 
is imported into the mitochondria, where further processing occurs. It is localized in 
the mitochondrial matrix, and is also associated with the inner mitochondrial 
membrane facing the matrix side.  
We determined the structures of Δ36Them4 and Δ34Them5 at high resolution and 
showed that both Them4 and Them5 belong to the hotdog-fold class of proteins. The 
hotdog fold, which is formed by several anti-parallel β-sheets wrapped around an α-
helix, is found in all branches of life. However, up to now the mammalian proteins of 
this group have been widely left unstudied. 
The key feature of such thioesterases is that the hotdog domain does not exist as a 
single entity: It must form at least dimeric structures. The tertiary structures vary and 
can include either dimers, tetramers, or hexamers (Dillon and Bateman, 2004). In our 
experiments we found that both CTMP1/Them4 and CTMP2/Them5 form dimers. 
These are the only characterized mammalian 4HBT thioesterases which have a 
dimeric quaternary structure. Analysis of functionally relevant residues showed a 
conserved catalytic machinery, composed of the HGG motif and Asp/Thr residues.  
Results from both our group and others have shown that CTMP/Them4 plays an 
important role in regulating PKB signaling. Therefore, we were keen to investigate 
whether CTMP2/Them5 also has a similar effect on this pathway. Indeed, our results 
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with insulin tolerance tests and primary hepatocyte culture clearly indicate that 
Them5 KO mice are more insulin-sensitive, although we did not observe any 
difference between WT and KO mice in glucose tolerance tests. Additionally, levels 
of insulin and glucose in the plasma upon fasting seem to be similar in mutants and 
control mice. However, Them5/CTMP2 knock-out females had no signs of insulin 
hypersensitivity compare to males. With age, CTMP2 knock-out mice tend to 
develop fatty liver disease and display decreased hepatic insulin responsiveness. 
Fatty liver disease had a different progression rate in Them5-/-
Perreault 
et al., 2008
 mice depending on 
gender, as females develop signs of liver steatosis earlier than males. We cannot 
explain this observation yet, but clearly it requires further investigation. It is known 
from previous work that males and females have different predispositions to the 
development of certain disorders, such as fatty liver disease and diabetes (
), (Li et al., 2010). It is unclear if the phenotype observed in Them5-/- mice 
involves a hormonal regulatory mechanism. Histological analysis of the pancreas 
has shown a trend for increased islet mass in knock-out samples which, together 
with changes in mitochondrial morphology of β-cells, may be indicative of either (1) 
an independent phenotype that develops in the pancreas; or (2) being a part of a 
liver-pancreas metabolic loop, which requires further characterization. The 
interaction between pancreas and liver at the physiological level is an established 
fact, and interplay between the two organs in Them5-/-
Imai et al., 2008
 mouse model cannot be 
excluded ( ).   
To assess lipid profiles upon Them5 ablation, we employed detailed mass 
spectrometry analysis (MS). The MS results show very specific changes in the lipid 
profile of cardiolipin and its metabolites, namely the accumulation of a major species 
of monolyso-cardiolipin (MCL), which acts as an upstream metabolite in the re-
modeling cycle of cardiolipin. CL is a phospholipid synthesized in the inner 
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mitochondrial membrane and subsequently re-modeled, predominantly within 
mitochondria (Esposti et al, 2003; Schlame, 2008). On the basis of these results, we 
propose that Them5 has a rather specific action in vivo, namely that of regulating the 
initial metabolism of mitochondrial cardiolipin. In particular, Them5 thioesterase 
activity would maintain the pool of acyl groups that serve to re-acetylate one 
metabolic intermediate of cardiolipin, SP2-MCL (stearoyl-di-palmitoyl-
monolysocardiolipin). It is likely that the accumulation of this and other stearoyl- and 
palmitoyl-containing MCL species reflects an early impairment in the re-modeling 
cycle of cardiolipin, which progressively adds long unsaturated fatty acids to the 
saturated precursors, forming the mature forms of cardiolipin enriched in linoleyl 
(Schlame, 2008). Reduced thioesterase activity as a consequence of Them5 
ablation will trap a portion of the mitochondrial pool of CoA into long acyl-CoA 
molecules (as indicated in Figure 6C,D). Those that are not normally used in the 
local metabolism of cardiolipin re-modeling (e.g. stearoyl-CoA) will then exit the 
mitochondria and subsequently be hydrolyzed to free fatty acids by cytosolic or 
peroxisomal thioesterases. The process will produce extra-mitochondrial 
accumulation of free fatty acids, which will progressively remain in hepatocytes once 
their release capacity as cholesterol esters or triglycerides is saturated. In support of 
this theory, we found minimal changes in the MS profile of mitochondrial fatty acids 
and in the acyl groups of phospholipids synthesized outside mitochondria, e.g. PI. Of 
note, a previous study has shown that altering the supply of acyl-CoA modifies 
cardiolipin re-modeling (Rijken et al, 2009).  
We observed a lack of FAS mRNA induction in Them5-/-, which can be explained in 
two ways. First, the cytosolic accumulation of free fatty acids by the above 
mechanism would induce feedback inhibition of fatty acid synthase by its product 
palmitate. Secondly, the finding of impaired β-oxidation in Them5-/- mice implies a 
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reduced production of acetyl-CoA, with consequent reduction in mitochondrial citrate 
and its export into the cytosol, where it is required for FAS initiation. 
We have shown that Them5 KO mice display hypoketosis and have decreased 
levels of β-oxidation (as measured by 14CO2 generated from the oxidation of [1-14C]-
palmitate). Due to the limited availability of CoA in Them5-/- mitochondria, β-oxidation 
(and, finally, the TCA cycle) is impaired. This in turn reduces FAS (see above). 
Ultimately, cytosolic accumulation of fatty acids derives from the alteration in 
cardiolipin remodeling within mitochondria, due to the reduced potential for utilizing 
long acyl-CoA molecules caused by Them5 loss. Additionally, accumulation of fatty 
acids over time leads to the development of fatty liver disease, which is exacerbated 
with a high fat diet. Moreover, Them5 ablation leads to increased UCP2 expression, 
with enhanced basal uncoupling of mitochondria. Potentially, CPT1 expression could 
be elevated in random-fed mice, reflecting increased levels of fatty acids. However, 
Them5-/-
Our data obtained through electron microscopy analysis of primary hepatocytes 
showed a 2-fold increase in mitochondrial volume, most probably resulting from the 
fact that mutant mitochondria are forming a highly interconnected network. However, 
mitochondrial biogenesis was not affected by the loss of the Them5 protein. We 
could show that overexpression of the thioesterase-dead version of the 
CTMP2/Them5 protein leads to the mitochondrial phenotype similar to that observed 
in Them5
 failed to upregulate CPT1 upon fasting, which additionally negatively 
affected β-oxidation.  
-/- mice. In extended studies, we did not observe any measurable change in 
the transcript levels of Mfn1, Mfn2, or Opa1. However, the results of the detailed MS 
analysis of mitochondrial lipids indicated a plausible mechanism for the more tubular 
appearance of the mitochondria. The plasticity and dynamics of mitochondria are 
highly dependent upon the levels of cardiolipin and other lipids. In particular, the 
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balance between CL and MCL is essential to dynamically maintain crista 
homeostasis (Rujiviphat et al., 2009), (Ban et al., 2010), (Acehan et al., 2011). We 
have found that this balance is altered in Them5-/-
Parcellier et al., 
2009b
 mitochondria, which show more 
than a two-fold increase in major MCL species relative to CL species. The 
membrane tubulation propensity of MCL would probably account for the more tubular 
appearance of Them5-deficient mitochondria. In any case, we propose that the 
elongated morphology of mitochondria is primarily derived from the increase in the 
MCL/CL ratio. Previous analysis of Them4-deficient cells had shown changes in the 
mitochondrial morphology without any affect on their biogenesis (
). It was proposed that loss or accumulation of non-processed protein leads to 
the appearance of an interconnected mitochondrial network, suggesting defects in 
mitochondrial fusion processes (Parcellier et al., 2009b). One can speculate that the 
above-mentioned effects of CTMP/Them4 on mitochondrial morphology may involve 
thioesterase activity of Them4, but this should be experimentally confirmed. It cannot 
be excluded that the observed phenotype in Them4-/-
Sequence analysis shows 38% similarity between hThem4 and hThem5 proteins. 
This represents a high structural similarity, also observed in the similar 3D-structure 
of the proteins. However, certain differences exist: mapping these sequence 
differences onto the structures reveals distinct structural features, highlighting the 
potential functional variance between Them4 and Them5. These differences might 
provide a structural explanation for the differential substrate preferences exhibited. 
Additional structural differences are found at the C-terminus and on the solvent-
 is mediated by an interaction 
with the Letm1 protein. However, the new evidence that its paralog, Them5, 
participates in cardiolipin remodeling suggests that the alteration in mitochondrial 
morphology upon Them4 ablation may well derive from alteration in the metabolism 
of mitochondrial lipids.  
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exposed side of the N-terminal α-helix, a finding that might indicate different 
interacting proteins for Them4 and Them5.  
Recent work by Claypool et al. has identified a yeast homolog of Them4, FMP10, as 
an interactor of the ATP/ADP carrier ACC2 in the mitochondria (Claypool et al., 
2008b). The authors studied an ACC2 interactome in the presence of cardiolipin, and 
provided a model where the physical interaction of ACC2 with complexes III and IV 
promotes OXPHOS efficiency in the presence vs. absence of cardiolipin. 
Alterations in phospholipid and fatty acid composition have been previously detected 
in neural tumors (Campanella, 1992). These changes, in turn, can affect the pool of 
available FA used for CL remodeling. A study by Kiebish et al. has shown that 
mouse brain tumors contain CLs with different fatty acid composition, which are 
unique to each tumor type and are associated with deficiencies in electron transport 
chain activities (Kiebish et al., 2008). This is a very interesting finding, given that 
CTMP1/Them4 has been shown to be transcriptionally downregulated in 
glioblastoma (Knobbe et al., 2004). It is unclear whether alterations in CTMP1 levels 
are causative of CL changes in brain tumors, but this possibility cannot be excluded. 
Additionally, CTMP1 has been shown to have protective effects upon ischemia-
induced cell death in neurons (Miyawaki et al., 2009). Thus, our in vitro evidence that 
CTMP1 sensitizes cell to apoptosis are confirmed by in vivo observations and, 
together with the above-mentioned publications, may indicate that CTMP1 has a role 
in cardiolipin-mediated effects on cell survival and apoptosis. 
Enhanced insulin sensitivity in Them5-/- mice may be a consequence of altered 
mitochondrial function due to lipid metabolism and cardiolipin remodeling 
dysregulation. The acyltransferase ALCAT1 promotes pathological remodeling of CL 
by enriching it with PUFA, and promotes oxidative stress. ALCAT KO mice are 
protected from diet-induced obesity. Additionally, they show increased insulin 
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sensitivity and enhanced energy expenditure. Loss of Them5 leads to effects 
somewhat similar to those observed in ALCAT1 KO, namely enhanced insulin 
sensitivity and lower AMPK phosphorylation. However, the phenotype of ALCAT1 
KO mice only partially resembles that of Them5 KO. ALCAT1 KO mice show 
changes in glucose tolerance, and decreased fat content is accompanied by smaller 
size of lipid droplets Them5 KO mice have no such manifestations.  
Another important and exciting finding is that changes in mitochondrial morphology 
were not only observed in hepatocytes, but also in pancreatic β-cells. Them5-/-
Campello and Scorrano, 2010
 β-
cells are characterized by similar interconnected mitochondria to those observed in 
hepatocytes. Changes in the mitochondrial morphology are known to be linked to the 
bioenergetic state of the cell ( ). This is especially 
important for β-cells, which are particularly sensitive to changes in ATP and Ca2+
Krauss et al., 2003
 
levels ( ). Considering that Them5 affects cardiolipin remodeling, 
the question of energy status, insulin-secreting capabilities, etc. of β-cells should be 
further investigated. Analysis of the effect of Them5 loss on other tissues, such as 
the heart, given its exquisite sensitivity to cardiolipin alterations (Acehan et al., 2011; 
Ostrander et al., 2001), will undoubtedly result in many new discoveries. 
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Introduction
PKB/Akt is a ubiquitous and evolutionarily con-
served serine/threonine kinase that is recognized as 
a major coordinator of various intracellular signals. 
It controls cell responses to extrinsic stimuli and reg-
ulates cell metabolism, proliferation, and survival. 
Proper tuning of PKB activity via direct or indirect 
mechanisms is of utmost importance for stringent 
regulation of PKB-dependent cellular activities. 
Many diseases, such as cancer or metabolic disor-
ders, are the result of, or are associated with, aber-
rant activity of the PI3K/PTEN/PKB pathway. In 
many tumors, the PI3K/PTEN/PKB pathway is acti-
vated by upstream mutations in PI3K or PTEN or by 
the amplification/overexpression/mutation of PKB iso-
forms themselves. Liver tumors are not the only 
pathological condition associated with disorders of 
this pathway. PKB has also been implicated in the 
development of hepatic insulin resistance, type 2 dia-
betes mellitus and, as has become evident over the 
past few years, in ischemia/reperfusion processes. 
In this chapter, the role of PKB in major physiologi-
cal processes of cells is summarized and different 
liver disease conditions are considered by analyzing 
their pathophysiology from the perspective of PKB 
involvement.
Description of the PKB Family
The first publication identifying PKB as a serine/threo-
nine kinase came from Jones et al. in 1991 [1]. The 
authors initially termed the kinase Rac, for related to 
the A and C kinases, but was then renamed PKB/Akt [2, 
3]. Since the publication of these landmark studies more 
than 17 years ago, it became clear that PKB/Akt is one 
of the major targets of phosphatidylinositol 3-kinase 
(PI3K)-generated signals and is involved in the regula-
tion of cell growth, proliferation, apoptosis, glucose 
metabolism, angiogenesis, and migration. Readers are 
referred to other excellent reviews covering the history 
of PKB discovery and in-depth analysis of its involve-
ment in all these diverse cellular processes [4–7].
The mammalian genome encodes three isoforms of 
Akt/PKB: Akt1/PKBa, Akt2/PKBb, and Akt3/PKBg, 
which are highly conserved despite being the products 
of three different genes located on different chromo-
somes. Interestingly, worms and flies have a single 
Akt/PKB protein. PKB family members share a simi-
lar domain structure containing an N-terminal pleck-
strin homology (PH) domain [8], a catalytic domain 
and a C-terminal regulatory domain with a regulatory 
phosphorylation hydrophobic motif (HM) [4]. PKB 
that fully activated and exerts its biological functions is 
phosphorylated at two sites, one located within the 
activation loop of the kinase domain (Thr308 in PKBa) 
and the other within the HM (Ser473).
Although PKB isoforms are highly conserved (approx-
imately 80% amino acid identity), they apparently per-
form distinct biological functions, which could reflect 
tissue specific expression. For instance, PKBa mRNA is 
present in the majority of organs with low levels in pan-
creas and skeletal muscle [9–11]; PKBb mRNA is highly 
abundant in insulin-responsive tissues such as skeletal 
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muscle, liver, and adipose tissue, and PKBg mRNA levels 
are high in brain, testis, lung, mammary gland, and adi-
pose. Interestingly, in tissues and organs with the highest 
levels of PKBb, PKBg levels are the lowest [11].
Taking into account the complex cellular compo-
sition of the liver, it should be noted that hepatocytes 
are not the only cell types expressing PKB. Kupffer 
cells, hepatic stellate cells (HSC), and sinusoidal 
endothelial cells (SEC) also express this kinase and 
PKB is involved in their functions in normal physi-
ological conditions as well as in pathological states. 
For example, Kupffer cells stimulated by lipote-
ichoic acid and lipopolysaccharide reduce the inflam-
matory response via activation of the PI3K/PKB 
pathway [12]. It has also been suggested that PKB 
plays a key role in early liver regeneration and in the 
induction of cytokines secretion and the prolifera-
tion of SECs [13, 14].
Activation and Regulation of PKB/Akt
Activating Stimuli and Upstream Kinases
Growth factor (Table 16.1) binding promotes the recruit-
ment and activation of class I PI3K after autophos-
phorylation of the receptor on tyrosine residues. At the 
Table 16.1 List of selected PKB activators (top row) and PKB substrates assigned to two major groups: growth/survival/cell cycle-
related and metabolism-related (middle and bottom rows)
A
ct
iv
at
o
rs
Growth factors 
and cytokines
Interactors
and other molecules
Chemical compounds 
and other stimuli
Insulin
Insulin like growth factor (IGF)
Epidermal growth factor (EGF)
Hepatic growth factor (HGF)
Basic fibroblast growth factor (FGFb)
Nerve growth factor (NGF)
Platelet derived growth factor (PDGF)
Vascular endothelial growth factor  
(VEGF)
Leukemia inhibitory factor (LIF)
Interleukins 2,3,4,5,8 (IL2,3,4,5,8)
RANTES
Stem cell factor
Tumor necrosis factor alpha (TNFα)
Heat shock protein 90 kDa (Hsp90)
BTB (POZ) domain containing 10
(BTBD10)
Fused toes protein 1 Ft1
T-cell leukemia antigen 1 (Tcl1)
Adaptor protein containing PH          
domain, PTB domain, and Leucine    
zipper motif (APPL)
Akt phosphorylation enhancer (APE)
Orthovanadate (phosphatase inhibitor)
Okadaic acid (phosphatase inhibitor)
DNA damage
Hydrogen peroxide/reactive oxygen
species
Hypoxia
Heat shock
Zinc, cadmium
Exercise  
Becomes a target for 14-3-3-proteins, is released from anti-apoptotic Bcl-2 proteins BAD
Caspase 9
Nuclear exclusion, prevents transcription of pro-apoptotic genesFoxOs
Inactivation, translocates to the cytosol from the nucleusYAP
Stabilization, leads to increase of p53 levelsMdm2
IKKα Inhibition, induces NF-κB transcriptional activity
Cytoplasmic retention, blocks cell-cycle progressionp21
Cytoplasmic retention, attenuates cell-cycle inhibitionp27
  Inhibition, is released from Rheb, which leads to mTOR phosphorylation/activation2CST
Inhibition (when non-phosphorylated, binds to mTORC1 and inhibits its activity) PRAS40
Hexokinases
GSK3α/β Inhibition, leads to stabilization of proteins involved in G1/S phase transition
S
u
b
st
ra
te
s
Growth, survival, and cell cycle related
Metabolism related
Inhibition, leads to release of GLUT4 and increase of glucose transportAS160
Activation, increases fatty acid synthesis ACL
PGC-1α Inactivation of co-activating transcriptional activity for FoxOs, HNF4α, and other genes
GSK3α/β Inactivation, increase in glycogen synthesis
Inactivation (when active, decreases glycolysis and fatty acids synthesis, increases
   gluconeogenesis)
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membrane the PI3K phosphorylates PtdIns(4,5)P2 to 
form PtdIns(3,4,5)P3, which then serves as docking site 
for a subgroup of proteins with PH domains. The PI3K 
family comprises of three classes, I, II, and III. Class I 
PI3Ks are heterodimers of distinct regulatory (p50-55/p85) 
and catalytic (p110a, p110b or p110d) subunits; their 
activity is directed mainly to the phosphorylation of 
PIP2 to PIP3. Class II and class III differ from class I in 
structure and function (for more comprehensive reviews 
see [15, 16]). PI3K is involved in the regulation of a 
wide range of cellular processes, such as cell growth, 
proliferation, differentiation, motility, survival, and intra-
cellular trafficking; many of these PI3K effects are medi-
ated by downstream PKB. The constitutive activation of 
PI3K class I due to a gain-of-function mutation (in the 
p110a subunit, for example) or the downregulation of its 
negative regulator PTEN (lipid phosphatase and tensin 
homolog deleted on chromosome ten) are striking fea-
tures of many human cancers [17].
Thus, inactive PKB/Akt that is translocated to the 
plasma membrane (PM), undergoes a conformational 
change, attaches to phospholipid through a PH domain 
and becomes phosphorylated (schematic representation 
of PKB activation is shown on the Fig. 16.1). Once 
recruited to the PM, PKB is activated in a two-step pro-
cess that requires phosphorylation on both Thr308 in 
the activation loop of the kinase domain and Ser473 
within the HM of the regulatory domain. Thr308 is sub-
jected to phosphorylation by PDK1 kinase, which is 
recruited to the PM through its PH domain; precom-
plexed PDK1 in cytoplasm [18, 19]. Notably, mutation 
of the PH domain of PDK1 in mice diminishes PKB 
Fig. 16.1 Schematic representation of PKB activation and regulation (adapted from [6])
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 activation, leading to small size and insulin resistance 
[20].
PKB, monophosphorylated on Thr308 has ca. 10% 
of the activity of the fully phosphorylated enzyme. 
Additional Ser473 phosphorylation stabilizes the active 
conformation, allowing most PKB molecules to adopt a 
fully active state [21]. The identity of the kinase phos-
phorylating PKB on Ser473 remained controversial for 
many years; today it is accepted that the PI3K-related 
protein kinase family the TORC2 complex, DNA-PK, 
and ATM are responsible for this phosphorylation. The 
fact that mTORC2 is a Ser473 kinase for PKB is widely 
recognized [22, 23]. Work done on knock-out mice and 
Drosophila cells has provided genetic evidence favor-
ing the hypothesis that components of the rapamycin-
insensitive Rictor-mTOR complex have a shared posi tive 
role in the phosphorylation of the HM site of PKB [22]. 
DNA-PK has also been identified as an upstream Ser473 
kinase of PKB [24, 25]. However, DNA-PK does not 
play a role in insulin-promoted activation of PKB in 
serum-sufficient cells. It has been shown that DNA-
PKcs specifically phosphorylates PKB on Ser473 after 
DNA damage, thus promoting survival in response to 
genotoxic stress in vivo [25].
Activation of growth factor receptors (GFR) by a 
ligand (insulin, growth factors (GF)) induces their 
autophosphorylation and recruits the p85 regulatory 
subunit of phosphatidylinositol 3-kinase (PI3K). Subse-
quent activation of the p110 catalytic subunit leads to 
phosphorylation of phosphoinositol-(4,5)-bis phos-
phate (PIP2) and formation of the phosphoinositol-
(3,4,5)-tris phosphate (PIP3). PIP3 is a substrate for 
lipid phosphatase, the tensin homolog PTEN, and the 
SH2-domain-containing inositol polyphosphate 5-phos-
phatase SHIP, which act as endogenous inhibitors of 
the PI3K-dependent pathway, indirectly inhibiting 
PKB activity. Wortmannin and LY294002 also inhibit 
PI3K. Once formed, PIP3 serve as docking sites for 
the PH domains of PDK1 and PKB, which translo-
cate to the plasma membrane from the cytoplasm. As 
a result of this translocation, inactive PKB is phos-
phorylated by PDK1 on Thr308 in a regulatory kinase 
domain. The second phosphorylation event on Ser473 
in the HM by upstream kinases such as TORC2, 
DNA-PKc, and ATM are cell-type and stimuli spe-
cific. It leads to conformational changes in the PKB 
molecule and full activation of the kinase. Activated 
PKB then trans locates to different subcellular com-
partments, such as the nucleus, ER, Golgi, and 
mitochondria, where it exerts its biological activity. 
Protein phosphatase 2A (PP2A) and a PH domain 
leucine-rich repeat protein phosphatase (PHLPP) 
dephosphorylate and inactivate PKB. Other negative 
regulators of PKB are Grb10, carboxyl-terminal 
modulator protein (CTMP), tribbles homolog 3 
(Trb3), casein kinase 2-interacting protein-1 (CKIP-
1), and keratin 10. Positive regulation of PKB activity 
may be achieved through interaction with BTBD10 
and the heat shock proteins Hsp90 and Hsp27, which 
protect the PKB molecule from dephosphorylation. 
T-cell leukemia antigen-1 (Tcl-1) and fused toes pro-
tein-1 (Ft1) may also function as positive regulators 
of PKB. For more details on the activation and regu-
lation of PKB please refer to the corresponding sec-
tion of this chapter.
Positive Regulation of PKB via Interaction 
with Other Proteins
Positive regulation of PKB activity may be mediated 
through interaction with Hsp90, Tcl1, and Ft1 (see 
Table 16.1). Protein chaperone Hsp90, a prominent 
target for anticancer therapy, protects many kinases 
bearing activated mutations [26, 27]. It is known that 
activated PKB requires Hsp90 to maintain the phos-
phorylation state, which allows cancer cells to prolifer-
ate and circumvent apoptosis [28, 29]. T-cell leukemia 
antigen (Tcl1) interacts with PKB and enhances its 
kinase activity [30, 31]. It is highly activated in multi-
ple neoplastic conditions, mainly T- and B-cell malig-
nancies. Fused toes protein 1 (Ft1) was identified as a 
direct PKB interactor, leading to the enhanced phos-
phorylation of both Thr308 and Ser473 by promoting 
its interaction with the PDK1 [32].
Negative Regulation of PKB 
by Phosphatases
Certain cellular mechanisms counteract the activation 
of PKB. Negative regulation of PKB could be mediated 
either by a direct mechanism, such as intramolecular 
interactions, or indirectly by modulation of factors impor-
tant for PKB activation.
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The best-studied negative regulator of the PI3K/PKB 
pathway is PTEN, a tumor suppressor protein that is 
often inactivated in many disorders characterized by 
PKB hyperactivation, such as cancers and some meta-
bolic diseases (described in detail below). This mole-
cule acts as a lipid phosphatase by dephosphorylating 
PIP3 at the D3 position converting it to PIP2. This leads 
to inhibition of the PI3K pathway and reduces recruit-
ment of PDK1 and PKB to the PM and thus, subse-
quently decreases PKB activity. At the transcription 
level, PTEN is positively regulated by p53, Myc, Egr-1, 
and PPARg, whereas Ras, JNK, Notch, and miR-21 are 
negative regulators of PTEN transcription (reviewed in 
[33]). Downregulation due to the loss of promoter activ-
ity or loss-of-function mutations of PTEN are distinct 
characteristics of many neoplastic diseases, including 
hepatocellular carcinoma (HCC) [34, 35].
Given that PKB activation is achieved by increased 
phosphorylation, protein phosphatases are direct nega-
tive regulators acting on phosphorylated PKB. Protein 
phosphatase 2A (PP2A) acts as a negative regulator by 
dephosphorylation of PKB at both sites [36, 37], but par-
ticularly at Thr308 [38]. Heat shock protein 90 (Hsp90), 
a general chaperone to numerous targets may inhibit 
PP2A-mediated dephosphorylation, offering PKB pro-
tection from inactivation. BTB (POZ) domain contain-
ing 10 (BTBD10) has also been reported to interact with 
PKB and protect it from PP2A-mediated dephosphory-
lation [39]. There is no structural similarity between 
BTBD10 and Hsp90 and, unlike Hsp90, BTBD10 does 
not affect PDK1 activity [40]. BTBD10 probably acts by 
binding to PP2A and its target. It remains to be estab-
lished whether BTBD10 is a PKB-specific activator or 
whether it protects other PP2A targets.
A further phosphatase directly dephosphorylating 
Ser473 is the PHLPP, which has a PP2C-like catalytic 
core, is not sensitive to okadaic acid, and binds directly 
to PKB via a C-terminal PDZ motif [38]. This phos-
phatase is markedly reduced in several colon cancer and 
glioblastoma cell lines with elevated PKB phosphoryla-
tion. Recently, a second PHLPP isoform, PHLPP2, has 
been cloned [41]. In parallel to the different tissue expres-
sion patterns and substrate specificities of the different 
PKB isoforms, the PHLPP isoforms have been reported 
to show specificity for distinct PKB isoforms. PHLPP1 
was shown to affect PKBb/g while PHLPP2 influences 
the activity of PKBa/g, with marked differences in the 
affected PKB substrates. These data led to the specula-
tion that PHLPP1 may regulate PKBb and affect glucose 
metabolism, while PHLPP2 is involved mostly in the 
regulation of PKBa and cell survival [41].
Further PKB/Akt Interactors
Molecules other than phosphatases also negatively reg-
ulate PKB activity. Grb10, a growth factor receptor-
bound protein 10, interacts with numerous receptor 
tyrosine kinases and has been implicated in the regula-
tion of the PI3K pathway downstream of the insulin 
receptor. Whether Grb10 has positive or negative effects 
on insulin- or IGF-receptor signaling remains contro-
versial [42–44]. In 2005, it was shown that Grb10 and 
PKB form a constitutive complex that promotes kinase 
translocation to the PM; thus, it has been proposed that 
Grb10 functions as a PKB coactivator [45]. However, 
these studies were performed mainly in vitro and the in 
vivo role of Grb10 was unknown until recently. First, it 
was shown that overexpression of Grb10 in mice leads 
to insulin resistance [46] and the Liu group reported 
later that disruption of this gene enhances insulin sig-
naling and sensitivity [43]. CTMP, shown to interact 
with PKB, delays Ser473 phosphorylation and thus 
inhibits kinase activation [47]. Keratin K10 is also a 
negative regulator of PKB, to which it binds and inhib-
its its intracellular translocation, leads to downregula-
tion of PKB activity [48]. Casein kinase 2-interacting 
protein-1 (CKIP-1) has been shown recently to interact 
with the PH domain of PKB and inhibit kinase active, 
thus suppressing tumor growth [49]. Tribbles homolog 
3 (Trb3) is a pseudokinase that binds preferentially to 
nonphosphorylated PKB, thereby blocking Thr308 
phosphorylation induced by insulin and other GF [50]. 
Trb3, the abundance of which increases during fasting, 
may be especially relevant for liver tissue. It was sug-
gested that Trb3 activation is beneficial under fasting 
conditions, but that pathological overexpression after 
food intake may contribute to insulin resistance and 
hyperglycemia. However, genetic deletion of Trb3 in 
mice had a minimal effect on insulin-induced PKB 
activation in hepatic tissues, arguing that Trb3 has a 
minor effect on glucose and energy homeostasis [51]. 
Further studies are clearly needed to evaluate the 
importance of Trb3 in other contexts such as hypoxia 
and other stresses, and after tissue-specific deletions of 
Trb3. Overall, it may be concluded that fine tuning of 
PKB signaling occurs at different levels, beginning 
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with activation by a variety of exogenous signals, which 
is then contra-regulated via either direct dephosphory-
lation or interaction of numerous proteins with differ-
ent domains of the kinase.
PKB Substrates and Their Functions
Regulation of PKB has been studied extensively ever 
since its discovery and all the results obtained have 
made clear that PKB, being so stringently regulated, is 
one of the most versatile proteins in the cell. The long 
list of PKB substrates can be divided into several sub-
groups corresponding to the processes in which PKB is 
involved. These include regulation of cell size, tran-
scription, survival, antiapoptotic activity, and metabo-
lism (for a recent review see [7]).
Regulation of Cell Size and Survival
Once activated following GF/insulin treatment 
(Table 16.1), PKB translocates from the cell membrane 
to its targets and phosphorylates them at the consensus 
site RXRXXS/T. Constitutive activation of PKB con-
tributes greatly to aberrant cell cycle regulation, result-
ing in uncontrolled cell proliferation and suppressed 
apoptotic pathways. This prosurvival and antiapoptotic 
activity is exerted through phosphorylation of target pro-
teins, leading to either activation or inhibition of their 
activities. The predominant mechanism by which PKB 
regulates cell size (cell mass) is activation of the mTOR 
complex 1 (mTORC1). This is exerted via phosphoryla-
tion of TSC2 within the complex TSC1/2 and abroga-
tion of TSC2 activity. When nonphosphorylated, TSC2 
prevents formation of Rheb-GTP. Upon TSC2 phospho-
rylation, Rheb-GTP accumulates and activates mTORC1, 
which in turn activates S6K1 and 4E-BP1, stimulating 
translation initiation and ribosome biogenesis [52–56]. 
Like TSC2, PKB also phosphorylates PRAS40 (proline-
rich Akt substrate of 40 kDa) [57–59]. Overexpression 
of a mutant, which cannot be phosphorylated by PKB, 
blocks PKB-mediated activation of S6K1. Recently, 
PRAS40 has been found to associate with and be phos-
phorylated by mTORC1 and is thought to negatively 
regulate its signaling [59–62].
DNA double strand breaks and promotes PKB acti-
vation. Recently published work by Bozulic et al. has 
implemented the role of PKBa isoform in promotion 
of cell survival and antiapoptotic processes upon geno-
toxic stress [25]. DNA-PK recruitment to double-
stranded, damaged DNA results in activation of PKBa; 
DNA-PK serves as an upstream kinase for PKBa and 
Ser473 PKBa phosphorylation occurs in the nucleus, 
presumably leading to the activation of transcription 
factors with prosurvival activity.
The importance of PKB for cell proliferation and 
survival is further illustrated by overexpression experi-
ments in which myristoylated or constitutively active 
variants of PKB were introduced into either cells or 
mice in a tissue/organ-specific manner. For example, 
overactive PKB alone contributes to tumorigenesis; the 
overexpression of PKB in the prostate gives rise to neo-
plasia. Increase in PKB activity enhances the number 
and size of thymocytes, cardiomyocytes [63], pancre-
atic b-cells [64, 65] prostate epithelial cells [66], and 
hepatocytes [67]. In contrast, PKBa knock-out mice are 
small, suffer increased neonatal lethality and increased 
spontaneous apoptosis in the thymus [11, 68, 69]. This 
isoform was shown to be important for trophoblast dif-
ferentiation and it was concluded that PKBa regulates 
placental development and differentiation. These mul-
tiple in vivo studies emphasize a role for PKB at differ-
ent stages of development and point to an indispensable 
role of the PKBa isoform in guiding cell size and sur-
vival processes.
Regulation of Apoptosis
The first identified PKB target involved in apoptosis 
was the BH3-only protein Bad, which is a negative 
regulator of prosurvival Bcl-2 family members [70]. 
Phosphorylated on Ser136 by PKB, Bad becomes a 
 target for 14-3-3 proteins, which triggers release of Bad 
from Bcl-2 proteins. Caspase 9, which is another 
PKB substrate with proapoptotic activity, participates 
in the formation of the apoptosome. Phosphorylation 
on Ser 196 inhibits protein activity and blocks caspase 
9 induced cell death [71]. PKB substrates from the 
FoxO family (FoxO1-4) are inactivated upon phospho-
rylation via their exclusion from the nucleus, where 
they normally act as transcription factors. FoxOs target 
genes promote apoptosis, cell-cycle arrest, and various 
metabolic processes (see below); among these are Bim, 
Bad, and the proapoptotic protein FasL [72, 73]. Similar 
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to FoxO proteins, the proapoptotic protein YAP translo-
cates to the cytosol after being phosphorylated, whereas 
when active in the nucleus, it activates transcription of 
proapoptotic genes such as p73 [73]. Overall, activation 
of the PKB pathway provides cells with survival signals 
that allow them to withstand apoptotic stimuli.
Cell Cycle Control
PKB-mediated control of cell-cycle progression has been 
shown to be crucial for the G1/S transition. This activity 
is mediated mainly by regulation of FoxO localization 
and p53 intracellular concentration (via Mdm2 stabiliza-
tion). PKB also phosphorylates p21, which act as cell-
cycle inhibitor. When phosphorylated it accu mulates in 
the cytoplasm and cannot bind and inhibit CDK2, which 
allows cell-cycle transition. p21 can be regulated also at 
the transcriptional level by FoxO proteins, promoting 
antiproliferative effect. The Mdm2/p53 signaling path-
way plays an extremely important role in the regulation 
of cell cycle progression [74]. Mdm2, which is an E3 
ubiquitin-ligase targeting p53 to its degradation, is phos-
phorylated and consequently stabilized by active PKB 
[75]. Mdm2 stabilization consequently leads to p53 
ubiquitination and degradation. Notably, the p53 path-
way is the most mutated in cancer cells, including HCC. 
Its deregulation, i.e., loss-of-function, promotes cell 
cycle transition and blocks apoptosis, leading in many 
cases to cancer progression. Cell cycle transition, medi-
ated by PKB, is closely associated with proliferation and 
apoptosis, greatly contributing to the events of transfor-
mation and regeneration.
Metabolism
The role of PKB in the regulation of metabolic path-
ways is tightly interconnected with its positive effects 
on cell growth and proliferation. The main PKB iso-
form important for executing these effects in insulin-
sensitive tissues is PKBb (and to some extent PKBa). 
As already discussed, the principal sites of expression 
of the b isoform are liver, muscle, and adipose tissue. 
Analysis of PKBb KO mice revealed the importance of 
this particular isoform in mediating metabolic effects 
of PKB. Notably, PKBb KO mice exhibit impaired 
 insulin-mediated glucose uptake in muscle and in 
 adipocytes and an inability to lower hepatic glucose 
production [76–78]. As a result, these mice are insulin 
resistant and glucose intolerant and exhibit subse-
quent b cell failure. All these phenomena are typical of 
type 2 diabetes mellitus (T2D), which is characterized 
by an increased insulin requirement compounded by 
decreased insulin secretion.
Role of PKB in Glucose Metabolism
PKB exerts its biological activity by actively stimulat-
ing glucose uptake. Here, the important substrate is 
AS160 (Akt substrate of 160 kDa, or TBC1D4), a mol-
ecule with Rab-GAP activity that has up to nine poten-
tial PKB phosphorylation sites. Upon phosphorylation, 
AS160 loses its GAP activity, which leads to the accu-
mulation of Rab-GTP and, consequently, to the translo-
cation of the glucose transporter molecule Glut4 to 
the PM and glucose uptake. In line with this, insulin- 
stimulated AS160 phosphorylation is substantially 
reduced in muscles of T2D patients. Thus, after uptake, 
glucose is exploited either in the pentose-phosphate 
pathway (PPP), is oxidized via glycolysis, or is stored 
in the form of glycogen. PKB can be viewed as an 
important signaling node that coordinates signals of 
metabolic and antiapoptotic pathways. This effect is 
mediated by hexokinases (HKs), which phosphorylate 
glucose to glucose-6-phosphate; it is used later in PPP 
or glycolysis. HKs are bound to the outer membrane of 
mitochondria and PKB activation maintains or enhances 
this association. This leads, in turn, to antiapoptotic 
effects of PKB/HKs on the cell via mitochondrial mem-
brane stabilization [79]. Such effects require glucose 
and may be considered as a system linking cell survival 
and metabolism.
To a large extent PKB signaling affects both glyco-
lysis and glycogenesis. Glycogen synthase, the enzyme 
catalyzing the last step in glycogen synthesis, is phos-
phorylated by glycogen synthase kinase 3 (GSK3) [80]; 
this phosphorylation leads to inactivation of glycogen 
synthase. Both the a and b isoforms of glycogen syn-
thase kinase are PKB substrates. Phosphorylation on 
Ser21 and Ser9 of GSK3a and b, respectively, leads to 
inactivation of the kinase, which in turn stimulates gly-
cogenesis. The subsequent activity is of utmost impor-
tance in liver and muscle. Most of the research has 
been focused on the GSK3b isoform, implicating it in 
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muscle glucose metabolism [81]; Woodgett’s group 
has reported recently that the GSK3a isoform is a 
major regulator of glucose turnover in the liver [82]. 
PKB activation also increases rates of glycolysis, 
which has been shown in numerous cancer lines [83]. 
Its overexpression correlates with increased glucose 
consumption and the accumulation of NADH and lac-
tate without increase in oxygen usage, which suggests 
that it does not affect mitochondrial respiration. The 
fact that many tumors are characterized by increased 
PKBa activity raises the interesting possibility that 
PKBa regulates Glut1 membrane localization. Tumors 
often display overexpression of Glut1 on the cell sur-
face as well as elevated glucose transport, which would 
identify PKBa as a cause of increased Glut1 expres-
sion and glycolysis.
Regulation of Lipid Metabolism
Insulin is a potent anabolic hormone and, in addition to 
glucose metabolism, it also regulates lipid homeostasis 
by increasing lipogenesis in the case of nutrient excess. 
PKB was shown to mediate insulin/PI3K effects through 
GSK3 inactivation, which when actively promotes deg-
radation of sterol regulatory element binding proteins 
(SREBPs). It should be mentioned that a further PI3K-
dependent kinase, atypical PKC, mediates the insulin 
effect on increased lipogenesis via increasing SREBP 
expression [84]. Three isoforms of SREBPs, -1a, -1c, and 
-1b, trigger expression of more than 30 genes involved in 
cholesterol metabolism, fatty acid, triglyceride, and 
phospholipid biosynthesis. In liver, as well as in adipose 
tissue, the predominant isoform is SREBP-1c, which 
upregulates transcription and expression of lipogenic 
enzymes such as fatty acid synthase (FAS) and ATP cit-
rate lyase (ACL).
ACL is also a PKB substrate important for fatty 
acid synthesis. ACL links glucose metabolism to lipid 
synthesis by cleaving citrate to acetyl-CoA and oxalo-
acetate in the cytosol, thus supporting the synthesis of 
fatty acids, cholesterol, etc. [85]. ACL has been pro-
posed as a target for anticancer therapy, since it is 
positively regulated in PKB-overexpressing tumors it 
mediates metabolic switches characteristic of cancer 
cells [86]. HCC, a neoplastic disease of liver, is asso-
ciated with a marked increase in lipogenic enzymes 
and it was suggested that SREBP-1c is involved in this 
process [87].
FoxOs at the Crossroads of Metabolism 
and  Survival: The Role of PGC-1a
FoxO is a further target of PKB, belonging to a fam-
ily of proteins associated with cell cycle regulation 
by PKB. FoxO also contributes to glucose homeosta-
sis and is an important target of insulin action. FoxO1 
promotes hepatic glucose production and regulates 
the differentiation of cells involved in metabolic 
 control (reviewed in [88]). In the liver, FoxOs have 
been shown to increase gluconeogenesis and triglyc-
erides (TG) metabolism via transcriptional upregula-
tion of phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (G6Pase), and PPAR-g 
coactivator 1a (PGC-1a). FoxOs decrease glycolysis 
and fatty acid/TG synthesis [89]. The results of liver-
 specific KO of FoxO1 illustrate the pivotal role of this 
transcription factor in promoting hepatic glucose pro-
duction and provide details of the interconnection of 
the cAMP and insulin pathways in the regulation of 
glucose production [90].
Coactivator PGC-1a is a well-recognized global 
regulator of liver metabolism in the fasting state that 
interacts with and recruits transcription factors to gene 
promoter regions [91]. It is involved in the control of 
gluconeogenic gene expression by coactivating FoxO1 
and HNF-4 and was also shown to be associated with 
the promoter of the glucose G6Pase gene. It was found 
recently that PKBb directly phosphorylates and inhib-
its PGC-1a activity, which suggests a further role for 
insulin and PKB in controlling lipid catabolism in the 
liver [92].
FoxOs also protect cells from oxidative stress via 
upregulation of MnSOD2, catalase, and other enzymes 
involved in detoxifying reactive oxygen species (ROS). 
This activity is highly conserved among mammals, in 
worms, and flies. Overexpression of constitutively active 
PKB results in increased susceptibility to oxidative 
stress [93]. In addition, it may also regulate amino acid 
uptake through the activity of the TSC2/mTORC2 
pathway, but the complex network of the PKB/mTOR 
pathway is still not sufficiently defined.
Role of PKB in Liver Regeneration
The liver has an enormous capacity to regenerate 
after traumatic tissue loss or exposure to hepatotoxic 
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substances. It compensates efficiently for large tissue 
loss as experienced after surgical removal of intrahe-
patic tumors [94]. The mechanisms of this regenera-
tion are still the subject of intense research and new 
players like serotonin have been discovered recently 
[95]. Liver regeneration in response to tissue damage 
is a complex and well-orchestrated process and many 
excellent studies cover this topic [96, 97]. After major 
tissue loss many cytokines and GF (e.g., HGF, EGF, 
VEGF, or PDGF) are released leading to proliferation 
of hepatocytes. Within 48 h, the majority of hepato-
cytes re-enter the cell cycle moving from G0 to S 
phase. After cessation of proliferation, hepatocytes 
regain cellular volume and the original liver volume is 
almost completely restored within 1 week in rodents. 
PKB is strongly activated by many GF shown to be 
crucial in hepatic regeneration, e.g., HGF, EGF, or 
PDGF [96]. During liver regeneration in a partial 
 hepatectomy model, a robust and sustained activation 
of total PKB was observed [98]. Hepatic expression of 
constitutively active PKBa was associated with a three-
fold increase in liver mass due to the increase in hepa-
tocyte size without change in cell number [99]. 
Additionally, PKB-dependent hypertrophy of hepato-
cytes was sufficient for compensatory recovery of liver 
mass in liver-specific STAT3 mutant mice and in a 
thrombocytotic model of liver regeneration [100, 101]. 
In contrast, total PI3K inhibition with wortmannin, or 
selective inhibition with siRNA, resulted in a signifi-
cant decrease in hepatocyte proliferation, especially at 
the earliest time points [102]. Liver regeneration appears 
to be dependent on the presence of PKB. However, the 
expected reduction in regenerative capacity in PKBa or 
PKBb mutant mice has not yet been demonstrated.
Involvement of the PI3K/PTEN/PKB 
Pathway in Liver Diseases
Liver diseases contribute significantly to human mor-
tality and rising health-care expenditure. Although the 
liver can compensate for significant injury, there may 
be a significant decrease in function leading to organ 
failure. Proper functioning of the PKB network may be 
needed to maintain organ function and its deregulation 
is a significant factor in the development of certain 
hepatic diseases and liver-associated syndromes.
Insulin Resistance, Nonalcoholic Fatty 
Liver Disease, and Hepatosteatosis
Among liver diseases, nonalcoholic fatty liver disease 
(NAFLD) is becoming increasingly common; every 
third adult and tenth child/adolescent in the USA is 
affected by this condition [103]. NAFLD is considered 
to be a hepatic manifestation of a metabolic syndrome. 
The prerequisite feature of NAFLD is increased accu-
mulation of lipids in hepatocytes, which can originate 
either from increased levels of nonesterified fatty acids 
(NEFA) circulating in the blood or from enhanced de 
novo synthesis of lipids in the cells. Whereas, simple 
steatosis seems to have a relatively benign clinical 
course, a subgroup of patients develops inflammatory 
changes, known as nonalcoholic steatohepatitis (NASH) 
and potentially liver cirrhosis with increased risk for 
HCC [104]. Increase in intracellular lipid metabolites 
may lead to activation of the PI3K/PKB pathway. Initial 
overactivation of the signaling cascade then results in 
inhibition of IRS-1, which mediates a negative feed-
back effect on PI3K activation, leading finally to the 
inhibition of insulin signaling. Patients with NAFLD 
display lower levels of phosphorylated PKB and an 
increase in Bax/Bcl-2 ratio [105]. A similar situation 
has been described for activated PKCe, which led to the 
decrease in insulin-stimulated IRS-2 phosphorylation 
and hepatic insulin resistance [106]. Later, insulin resis-
tance involves other peripheral organs, such as skeletal 
muscle and adipose tissue, eventually becoming sys-
temic. Under physiological conditions, insulin released 
from the pancreas decreases glucose output from the 
liver but stimulates glucose uptake by muscle and adi-
pose tissue. In patients with insulin resistance, a syn-
drome associated with impaired metabolic clearance of 
glucose, the concentration of NEFA in the bloodstream 
increases due to the high lipogenic effect of insulin. 
NEFA act by reducing adipocyte and muscle glucose 
uptake and promoting hepatic glucose output, which 
leads to increased blood glucose concentration. Obesity 
worsens the situation and leads to increased levels of 
NEFA released directly into the portal vein from vis-
ceral adipose. This adds to the vicious cycle leading to 
even higher insulin resistance.
Hepatocellular lipid accumulation concerns about 
40% of the population and renders the liver partic-
ularly susceptible to inflammatory cytokines, endo-
toxins, iron accumulation, and oxidative stress [107]. 
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The latter is caused to a large extent by increased intra-
cellular lipids. Most studied are the effects of lipotox-
icity on beta cells [108, 109] and cardiomyocytes 
[110], but hepatocytes are also affected significantly, 
via a direct or an indirect mechanism, often displaying 
mitochondrial dysfunction [111]. Key characteristics 
of mitochondrial dysfunction are respiratory chain 
defects that lead to an increase in ROS production. In 
addition to damaging mtDNA and respiratory chain 
enzymes, increase in ROS leads to the oxidation of 
many cytoplasmic enzymes, including PTEN. Thus, it 
is now clear that ROS are not only deleterious for the 
cell but are very important with respect to signaling 
molecules [112]. Their presence at low concentrations 
helps maintain certain basal levels of kinase activity, 
namely PI3K/PKB in cells not supplemented with GF. 
However, when cells are overloaded with ROS, this 
may lead to hyperactivation of the PI3K/PTEN/PKB 
pathway, to inhibition of FoxO1 and PGC-1a and the 
transcription of adipogenic- and lipogenic- as well as 
beta-oxidation-related genes. This leads to liver steato-
sis and potentially to hepatic tumorigenesis.
The role of cell types other than hepatocytes in insu-
lin resistance should not be neglected. Sinusoidal liver 
cells are often ignored but they are an important factor 
in the maintenance of the pathological situation of 
insulin resistance, exacerbating the oxidative damage 
of hepatocytes, as well as secreting the proinflamma-
tory cytokines, TNF-a and IL6 [113]. It has been sug-
gested that the degree of insulin sensitivity depends on 
the state of activation of stellate cells, which have 
phosphorylated IR and IRS1 when activated and do 
not respond further to insulin, thus failing in glucose 
uptake. Their activation brings hepatic tissue one step 
closer to the development of fibrosis and, ultimately, 
cirrhosis [113, 114].
Involvement of Phosphatases 
in Insulin Sensitivity
Beneficial for the restoration of insulin sensitivity may 
be the target of the PI3K/PKB pathway via a decrease 
in phosphatase activity and the negative regulation of 
PKB activity. This is indeed the case is shown by the 
protein tyrosine phosphatase 1 B (PTP1B), which neg-
atively regulates insulin receptor and IRS-1 signaling 
knock-out mice. Disruption of the PTP1B gene in mice 
leads to enhanced insulin sensitivity and decrease in 
adipose mass. In mice with polygenic insulin resis-
tance, deficiency in PTP1B results in improved glucose 
tolerance and a decrease in the occurrence of diabetes 
[115]. Similarly, muscle-specific KO of PTP1B also 
has a beneficial effect on insulin sensitivity [114].
Another example of increased insulin sensitivity due 
to loss of lipid phosphatase activity are PTEN knock-
out mice. Quite unexpectedly, in addition to the insulin 
hypersensitive phenotype, liver-specific PTEN knock-
outs suffer from hepatomegaly and fatty liver, being at 
the same time overall leaner than their wild type litter-
mates [116]. These mice have low levels of NEFA in 
the plasma and relative hypoinsulinemia concomitant 
with the higher PKB activity. They display an increased 
liver glycogen content and enhanced FA synthesis and 
secretion. PTEN null mice are in principle a further 
model of NAFLD that does not involve overnutrition 
and is not polygenic in nature. These mice are valuable 
for the absence of obesity/T2D, which is speculated not 
to be mandatory for insulin resistance but be only an 
associated complication. PTEN null mice provide a 
new insight into the in vivo role of PTEN, underly-
ing the importance of negative regulators of PKB in 
 insulin-signaling pathway in liver. HCC, recognized as 
a complication of NAFLD, is often accompanied by 
downregulation of PTEN, leading to the poor prognosis 
in HCC patients [29]. Deregulation of PTEN activity 
may be due to hypermethylation of its promoter [14], 
microRNA-21 induced degradation of PTEN mRNA 
[117], or loss-of-function mutations [118]. Alternatively, 
PTEN may be the target of increased ROS in cells, 
leading to its oxidation and blockage of the catalytic 
cystein residues, important for proper function [119]. In 
this context, PTEN heterozygous and liver-specific 
KOs are invaluable models for studying the pathogen-
esis of NAFLD, that later develops into steatohepatitis 
and progresses to liver carcinoma without any addi-
tional exogenous treatment.
The PI3K/PTEN/PKB Pathway 
in the Development of HCC
Alterations in PI3K/PKB signaling components are 
generally frequent in many tumors and HCC is not an 
exception. Various pathway components that provide a 
balance between cell survival and apoptosis are often 
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deregulated. A mutation in the PIK3CA gene, which 
encodes a p110a subunit of PI3K class IA, is found in 
35% of HCC cases, although it may depend on the pop-
ulation [120–122]. This is a gain-of-function mutation 
that results in enhanced oncogenic activity of PI3K. 
Other recent data have shown that the phosphorylation 
status of PKB may serve as a prognostic factor for early 
disease recurrence and poor prognosis [123]. In addition 
to altered metabolic regulation upon hyperactivation of 
PKB, many prosurvival and antiapoptotic activities start 
to prevail over cell death/apoptosis processes. Among 
the proapoptotic molecules downregulated in HCC are 
many PKB targets, including Bid, Bax, and p53. Proapop-
totic molecule Bad was recently shown to be activated 
upon knock-down of hepatoma-derived growth factor 
(HDGF) in human HCC cell line HepG2. Tsang et al. 
reported that downregulation of HDGF leads to inacti-
vation of PKB and ERK and induces Bad expression, 
leading to activation of the apoptotic pathway followed 
by the release of cytochrome c and the caspase 3 and 9 
cleavage [124].
mTORC1, a further downstream target of PKB that 
is extremely important in HCC for growth and prolif-
eration, angiogenesis, and resistance to apoptosis, is 
also affected as a result of PI3K/PKB hyperactivation 
[125]. Phosphorylation of the mTOR target p70S6 is 
associated with elevated cyclinD1 levels and decreased 
overall survival of patients with HCC, indicating the 
aggressive nature of HCC (p53, apoptosis, and mTOR 
are described more extensively in corresponding chap-
ters of this book) [125, 126]. Several studies have shown 
that downregulation of PKB signaling promotes apop-
tosis and enhances susceptibility of HCC patients to 
anticancer drugs [127].
Another aspect of PKB involvement in liver carci-
noma development and progression is an impact on 
tumor metabolism. It is known that PKB stimulates the 
biosynthesis of fatty acids via activation of SREBP, 
which leads to an increase in the concentrations of cel-
lular fatty acids and PM components [128]. In addition 
to SREBP activation, PKB also has an impact on FAS 
expression. FAS has been shown to be significantly 
upregulated in various types of cancers whereas, except 
for liver and adipose tissues, FAS levels are usually 
quite low in normal tissues [129–131]. Many tumors 
switch their metabolism and start de novo synthesis of 
fatty acids as an energy component; FAS as one the 
major enzymes of lipogenesis is consequently upregu-
lated. FAS overexpression is often accompanied by the 
induction of antiapoptotic mechanisms, leading to a 
selective advantage for tumor cells in survival and cell 
cycle progression. Indeed, this is the case in HCC, 
where key lipogenic enzymes such as FAS and ACL 
are markedly induced [69]. Until recently, the mecha-
nism responsible for this upregulation was unclear. In 
2008, the group of Watabe reported that upregulation of 
the FAS gene occurs under hypoxia conditions via PKB 
and SREBP-1 activation, and that inhibition of FAS 
overcomes hypoxia-induced chemoresistance, which is 
a major clinical problem in many cancer patients [132]. 
It is worth noting that changes in the metabolism of 
cancer cells, known as the Warburg effect, or glycolysis 
under normoxic conditions, lead to changes in redox 
balance. This, in turn, causes PTEN inactivation and 
subsequently PKB hyperactivation, all of which later 
contribute to the induction of FAS and enhancement of 
lipogenesis.
Viruses, PKB, and Liver Diseases
What makes patients with chronic liver diseases more 
prone to develop HCC? One important feature defining 
the outcome is PTEN status, which may serve as an 
independent prognostic marker of HCC associated with 
HCV patient survival and the presence of viral infec-
tions, such as combined hepatitis B and C (HBV/HCV) 
(for further details, see the corresponding chapters about 
HBV/HCV in this volume) [118, 133]. Hepatitis viruses 
are known to cause PKB activation. Thus, HCV protein 
NS5A may either activate PI3K via binding to its regu-
latory subunit or inhibit apoptosis by acting on the Bax 
protein [134, 135]. Furthermore, approximately 50% of 
patients with a chronic HCV infection develop liver 
 steatosis and insulin resistance, mediated by increased 
 oxidative stress, the activation of PI3K/PKB and the 
transactivation of PPARg and SREBP-1/2 [136–138]. 
On the other hand, insulin resistance may be linked to 
inhibition of PKB signaling, either through impairment 
of upstream IRS-1 and PI3K [139], or, as shown recently, 
through overexpression of protein phosphatase PP2A 
[140]. Recent analysis of HCC samples revealed that 
activation and overexpression of PKB and phosphoryla-
tion of its target GSK3b are among the most consistent 
features in HBV-associated HCC [141]. Activation of 
the PKB pathway as a consequence of viral infection 
leads to antiapoptotic effects on infected cells. This is 
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the case with HBV protein HBx, which activates the 
PI3K/PKB/Bad prosurvival pathway. HBx was shown 
to affect PTEN expression by inhibiting the function of 
p53, an established transcriptional regulator of PTEN 
[142], and overexpression of PTEN in these cells may 
reverse signaling modulated by HBx and have a positive 
effect on apoptosis [143].
Conclusions
The serine/threonine protein kinase PKB is major down-
stream mediator of PI3K.
PKB coordinates a constellation of intracellular sig-
nals and controls cellular responses to a variety of extrin-
sic stimuli.
PKB regulates cell proliferation, survival, growth, 
glucose and lipid metabolism, and malignant transfor-
mation.
Insulin and other GF are potent PKB activators.
In many pathological conditions such as NAFLD or 
HCC the PI3K/PKB pathway is often overactivated 
due to aberration in the upstream regulation of the 
kinase.
PKB isoforms were shown to be amplified, overex-
pressed, or mutated in various types of cancer.
The importance of fine tuning of PKB activity can 
be displayed in one frame that incorporates PI3K/PKB 
signaling to pathophysiology of insulin resistance asso-
ciated with other factors like viral infections and subse-
quent transition to NAFLD/NASH and later to the 
development and progression of fibrosis, cirrhosis, and 
finally HCC.
Targeting the PI3K/PTEN/PKB/mTOR pathway in 
order to alleviate burden of associated diseases seems 
to be an attractive, and, in some cases, successful 
approach, that could be exploited in targeted therapy.
Multiple Choice Questions
1. Protein kinase B/Akt phosphorylates its substrates, 
which leads to
(a) Activation of their function only
(b) Inhibition of their function only
(c) Activation/inhibition of their function and trans-
location to a different cellular compartment
2. Protein kinase B/Akt has three isoforms, PKBa, b, 
g, which
(a) Are found in all species, from worms to 
humans
(b) Have low conservation of amino acid sequence, 
but similar domain organization
(c) Have distinct tissue distribution patterns
3. Full activation of PKB requires
(a) Phosphorylation on Ser473 within the hydro-
phobic motif
(b) Phosphorylation on Thr308 in the kinase domain, 
which changes the conformation of kinase, and 
is followed by Ser473 phosphorylation
(c) Dual phosphorylation on Thr308 and Ser473; it 
is still arguable whether it happens in parallel or 
consequently
4. Which of the following statements is wrong?
(a) PTEN is a lipid phosphatase that regulates the 
PI3K/PKB pathway. It is overexpressed in many 
cancer cell lines and its gain-of-function muta-
tions are the hallmark of different cancers
(b) PTP1B and PTEN are negative regulators of the 
PI3K/PKB pathway; mouse models show that 
decrease in the levels of PTP1B and PTEN may 
restore insulin sensitivity
(c) PKB activity might be regulated via direct 
dephosphorylation, via interaction with protein 
other than phosphatases, via upstream modula-
tion of PI3K activity
5. The PKBb isoform is
(a) The major isoform that regulates cell growth 
and proliferation; PKBb KO mice are smaller 
and have increased neonatal lethality
(b) Expressed ubiquitously at similar levels in all 
tissues
(c) Expressed at the highest levels in insulin- 
responsive tissues, and its ablation leads to 
development of insulin resistance and T2D in 
mice
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CTMP led to accumulation of swollen and interconnected mitochondria, without affecting the mitochondrial fusion process.
Importantly, in vivo results support the relevance of these findings, as mitochondria from livers of adult CTMP knockout
mice had a similar phenotype to cells depleted of CTMP.
Conclusions/Significance: Together, these results lead us to propose that CTMP has a major function in mitochondrial
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Introduction
Mitochondria are the site of metabolic and survival functions
important in organism development, immunity, aging and
pathogenesis [1–3]. It is becoming clear that these crucial
functions within the cell rely on the integrity of the complex
double-membrane mitochondria structure that compartmentalizes
vastly different enzymatic activities, mainly involved in oxidative
phosphorylation [4], the TCA cycle, gluconeogenesis [5], death
signal integration [6,7] and the amplification and transmission of
mitochondrial DNA (mtDNA) [8]. Mitochondria within healthy
cells are often organized into a dynamic tubular and branched
network that undergoes intensive remodeling in response to
various stimuli related to cell death [9–11] as well as metabolic and
developmental processes [12]. The anti-apoptotic Bcl-2 family
member Bcl-xL and the antagonist BH3 only proteins Bak/Bax
were shown to regulate mitochondrial shape in healthy cells as well
as in cells undergoing apoptosis [13,14]. Thus, the increasing
reports of the involvement of signaling proteins in the modulation
of mitochondria expose a link between mitochondrial function and
dynamics in the regulation of metabolism, cell death, neurotrans-
mission, cell cycle control and development [15].
Studies with yeast led to the identification of the conserved
mammalian ‘‘mitochondria-shaping’’ proteins. Profusion proteins,
such as the dynamin-related protein mitofusins 1 and 2 (Mfn1 and
Mfn2), are integral components of the outer mitochondrial
membrane (OMM), essential to mitochondria tethering and fusion
[16,17]. These proteins act together with the optic atrophy protein
1 (OPA1), and an inner mitochondrial membrane (IMM) located
dynamin-like GTPase mutated in heritable optical atrophy [18].
Conversely, the dynamin-related protein 1 (Drp1/DNM1) is a
cytosolic protein, recruitment of which to the OMM by the
anchored fission 1 protein (Fis1p/FIS1) adaptor initiates and
controls the fission and distribution of mitochondria in cells [19].
Previously, we identified the Carboxy-Terminal Modulator
Protein (CTMP) in a two-hybrid search for PKB/Akt binding
partners [20]. CTMP has been shown to inhibit PKB/Akt
activation at the plasma membrane in response to various stimuli
and also to have tumor suppressor-like functions. This notion was
strengthened by the observation that primary glioblastomas exhibit
downregulation of CTMP mRNA levels due to promoter
hypermethylation [21]. We recently reported the mitochondrial
localization of endogenous and exogenous CTMP [22]. CTMP
exhibits a dual sub-mitochondrial localization as a membrane-
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bound pool and a free pool of mature CTMP in the inter-
membrane space; it was released from the mitochondria into the
cytosol early during apoptosis. CTMP overexpression was associ-
ated with an increase in mitochondrial membrane depolarization,
caspase-3 and polyADP-ribose polymerase (PARP) cleavage. In
contrast, CTMP knockdown resulted in a marked reduction in the
loss of mitochondrial membrane potential as well as a decrease in
caspase-3 and PARP activation. Mutant CTMP retained in the
mitochondria lost its capacity to sensitize cells to apoptosis. Thus,
proper maturation of CTMP appears essential for its pro-apoptotic
function. Finally, we demonstrated that CTMP delayed PKB/Akt
phosphorylation following cell death induction, suggesting that
CTMP regulates apoptosis via inhibition of PKB/Akt.
Here we show that compromising Carboxy-Terminal Modula-
tor Protein (CTMP) integrity by preventing its N-terminal
cleavage by point mutation or by a knockdown approach affected
mitochondrial network organization in cells. CTMP depletion did
not affect mitochondria intercomplementation but enhanced the
interconnected network, suggesting that CTMP positively influ-
ences the mitochondrial fission process, arguing for a potential role
of CTMP in regulating mitochondrial functions.
Results
A defect in N terminal cleavage of CTMP expression leads
to swollen mitochondria
HeLa cells transfected with full-length CTMP GFP-tagged
expressed CTMP in the mitochondria (Fig. 1A). Cells expressing
high levels of CTMP induced a change in mitochondrial
phenotype in some cells, with more rounded shaped mitochondria
evident in these cells (Fig. 1A, lower panels). CTMP contains a
conserved N-terminal cleavable mitochondrial localization signal
(MLS) and is located almost exclusively in mammalian cell
mitochondria. CTMP has been found to be strongly associated
with the inner mitochondrial membrane or free in the inter-
membrane space [22]. Most MLS are cleaved by a mitochondrial
processing peptidase (MPP) that recognizes a special sequence
comprising a positive arginine residue at position 22 and/or 210
from the cleavage site [23,24]. The CTMP sequence displays a
highly probable R-2 site at serine 35, surrounded by a
hydrophobic residue at +1 and a serine at +2. A CTMP mutant
(m5) in which R34, F36 and S37/38 have been mutated to alanine
(Fig. 1B) leads to the expression of a non-mature CTMP that still
bears the MLS and that cannot be released to the cytosol after
apoptosis induction [22]. Similar to full-length CTMP, we
observed that over-expression of a CTMP mutant m5 refractory
to N-terminal cleavage promoted the formation of rounded, ball-
shaped mitochondria, compared with the tubular structures
observed in cells transfected with the wild-type protein (Fig. 1C),
or untransfected cells (Fig. S1). It should be noted that CTMP
subcellular distribution was not affected by its over-expression.
These data led us to hypothesize that CTMP may regulate
mitochondrial biogenesis.
Loss of CTMP affects mitochondria morphology
Mitochondrial dynamics is regulated by continuous fusion and
fission events. Previous reports indicate that cellular depletion of
pro-fission proteins, such as Drp1 or the pro-fusion proteins Mfn-1
and -2, leads to the formation of an interconnected or a
fragmented mitochondrial network, respectively [16,17,25]. In
contrast, overexpression of Mfn-1 or Mfn-2 produces an
imbalance in mitochondrial dynamics in a dose-dependent
manner and subsequently the perinuclear clustering of the entire
mitochondrial network. The putative involvement of CTMP in
mitochondrial network rearrangement was further investigated by
siRNA-mediated depletion of CTMP in HeLa cells. Efficient and
reproducible knockdown of CTMP protein was achieved in cells
transfected with two independent CTMP siRNAs (Si#1 and
Si#2) compared with the mock siRNA (Si-cont) (Fig. 2A).
Cells expressing RFP-labeled mitochondria (mt-RFP) were used
to monitor the impact of CTMP depletion on mitochondrial
network organization. In these cells, loss of CTMP protein led to a
twofold decrease in tubular mitochondrial subpopulation (type II)
compared with control cells (Fig. 2B). Although most CTMP-
negative cells displayed filamentous mitochondria, detailed
confocal examination showed the accumulation of a mixed
network of interconnected swollen and thick mitochondria
(Fig. 2C; type I Si-CTMP#1 and #2) compared with the Si-
cont transfected cells (Fig. 2C; type I Si-cont). To further explore
the correlation between CTMP protein depletion and mitochon-
dria remodeling at the single-cell level, tetracycline repressor-
expressing HeLa cells were stably transfected with sh-RNA
specifically targeting CTMP (CTMP-Sh; targeting a sequence
distinct from the previously described Si#1 and Si#2) or control
sh-RNA (Fig. 3A). We confirmed that organization of the
mitochondria network in CTMP-depleted cells was similar to
the previously observed network (Fig. 3B). The population of cells
exhibiting a swollen interconnected mitochondrial network was
evident 3 days after tetracycline treatment (Fig. 3C). Combined,
these results strongly suggest that the modulation of CTMP
protein levels and maturation affect mitochondrial shape.
CTMP depletion does not impair mitochondrial fusion
To determine whether loss of CTMP function affected
mitochondrial fusion or fission, an intermitochondrial comple-
mentation assay was carried out using CTMP-depleted cells
[26,27]. Forty-eight hours after transfection with CTMP siRNA
(Si#1, Si#2) or the siRNA control (Si-cont), HeLa cells carrying
labeled mitochondria (mt-GFP and mt-RFP) were mixed in equal
proportions and fused by addition of PEG 1500. Heterokaryons
were fixed at the indicated times and mitochondrial fusion kinetics
assessed by examination using confocal microscopy of the yellow
fluorescence resulting from the mixing of matrix-targeted GFP and
RFP mitochondria (Fig. 4A). CTMP-depleted cells completed
mitochondria fusion with kinetics comparable to those of control
cells (Fig. 4B). These data suggested that CTMP is not critical for
the mitochondrial fusion process and further supports the
conclusion that the effects of CTMP depletion result from an
altered fission process.
CTMP deletion reveals an extensively interconnected
mitochondrial network in mouse liver
We next examined the effect of CTMP deletion on mitochon-
drial shape at the whole organism level. CTMP knockout mice
generated in our lab were viable and fertile and showed no obvious
phenotype. A summary of the knockout strategy is given in Fig. 5A,
B. We further validated the mitochondrial localization of CTMP
in mouse tissue. Immunodetection of CTMP protein in wild-type
(WT), heterozygous and homozygous knockout mice showed a
correlation between loss of CTMP protein and CTMP allele
disruption (data not shown). Mitochondria from WT and CTMP
knockout (2/2) mouse livers were purified by differential and
density gradient centrifugation (Fig. 5C, left panel). Immunoblot
analysis of the collected fractions demonstrated the purity of the
mitochondria (cytochrome c and mHsp70) and the absence of
cytosolic contaminants (actin). As expected, CTMP immunodetec-
tion showed that mouse CTMP protein co-purified with the
mitochondrial fraction, as confirmed by the loss of a signal in
CTMP and Mitochondria Dynamic
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Figure 1. Interfering with CTMP maturation leads to swollen mitochondria. (A) Full length human CTMP tagged with GFP was transfected
into HeLa cells at low (upper panels) or high (lower panels) levels of expression. Mitochondria were visualized with Mitotracker Red. Merged
fluorescence indicates CTMP-GFP expression in mitochondria. The round appearance of mitochondria is visible in cells with high levels of CTMP
CTMP and Mitochondria Dynamic
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samples from CTMP knockout mice (Fig. 5C). Electron micros-
copy of thin liver sections from WT and CTMP knockout mice
revealed a correlation between the ablation of CTMP and the
appearance of elongated mitochondria (Fig. 5D lower panels),
compared with the round and compact mitochondria in the liver
of wild-type animals (Fig. 5D upper panels). Accordingly,
mitochondria were found to be elongated in hepatocytes isolated
from CTMP knockout mice (2/2), compared with round and
compact mitochondria observed in hepatocytes of wild-type
animals (Fig. S2). Interestingly, loss of CTMP did not interfere
with mitochondria biogenesis, since the number of mitochondrial
DNA copies measured by real time PCR was the same in brown
adipose tissue (Fig. S3A) and in hepatocytes (Fig. S3B) from both
WT and knockout animals (2/2). Taken together, these results
demonstrate that depletion of CTMP protein impairs mitochon-
dria shape and structure both in vitro and in vivo.
Discussion
We provide here the first evidence that CTMP, previously
reported to be an inhibitor of PKB/Akt [20], is involved in the
modulation of mitochondria homeostasis. We have shown that
interference with CTMP expression and/or protein maturation
critically affected mitochondria morphology. Loss of cellular
CTMP expression led to the establishment of an interconnected
mitochondrial network in 40% of cells without affecting cell
viability (data not shown). Furthermore, CTMP knockdown
appeared to have a second long-term effect leading to the
accumulation of swollen mitochondria, either interconnected or
tubular. Importantly, such a phenotype has been reported
previously in cells depleted for proteins involved in the regulation
of the mitochondrial fission process, such as Drp1 or the recently
identified Drp1-binding protein MARCH-5 [14,28]. Mitochon-
dria from CTMP knockdown cells efficiently fuse in vitro,
suggesting that the observed phenotype, presumably caused by
imbalanced fusion/fission, does not result from a dysfunction in
mitochondrial fusion. Indeed, we provide evidence that CTMP
function in mitochondria is tightly linked to its submitochondrial
distribution, where it is found in both soluble and membrane-
bound mitochondrial fractions [22]. Expression of a non-cleavable
mutant of CTMP (refractory to mitochondrial membrane
peptidase cleavage) in HeLa cells promoted dissociation of the
mitochondrial network into individual round-shaped, dilated
mitochondria.
We recently reported that CTMP is released early from
mitochondria into the cytosol upon apoptosis and we demonstrat-
Figure 2. Loss of CTMP affects mitochondria morphology. (A) Immunoblot detection of CTMP using 75 mg of protein lysates extracted from
Hela cells 48 h after transfection with control SiRNA (cont) or CTMP SiRNA#1 or #2. (B) Representative confocal picture of mitochondria shape in
HeLa cells expressing mt-RFP and treated as in (A). (C) Morphological analysis of mitochondria shape in HeLa cells treated as in (A). For each
experiment, at least 200 cells were counted in three distinct fields. Data are means6SEM, n= 2. The differences in mean values are statistically
significant (Si cont compared to Si-CTMP#1 and Si-CTMP#2) as determined by 1-way ANOVA; * P#0.05, ** P#0.001.
doi:10.1371/journal.pone.0005471.g002
expression (lower panels). (B) Amino acid sequence of the R-2 predicted MPP cleavage site (indicated by the arrow) in human CTMP and a CTMP
mutant (m5) in which R34, F36 and S37/38 have been mutated to alanine. (C) Twenty-four hours after transfection with CTMP-IRES-GFP or the m5
point mutant, HeLa cells were fixed and stained for CTMP and mitochondria as indicated. A detail of the squared area is shown in the right panel.
Representative confocal pictures of three independent experiments are shown.
doi:10.1371/journal.pone.0005471.g001
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ed that CTMP overexpression is associated with an increase in
mitochondrial membrane depolarization and the activation of
apoptotic markers such as caspase-3 and PARP. Furthermore, we
observed that CTMP depletion or a defect in CTMP maturation
leads to inhibition of apoptosis. We suggested that CTMP
regulates apoptosis via PKB/Akt inhibition since we detected a
delay in PKB/Akt phosphorylation in cells overexpressing CTMP
in which apoptosis was induced [22]. Similarly, other recent
reports suggest that the regulation of OPA1 relies on the activity of
a presenilin-associated rhomboid-like protein (PARL), a protease
that regulates OPA1 release into the inner mitochondrial space
[29]. Furthermore, Cipolat et al. [30] suggested that the loss of this
soluble OPA1 species in PARL2/2 cells is responsible for their
extreme sensitivity to apoptotic stimuli. They further proposed a
complex mechanism by which both soluble and inner mitochon-
drial membrane-anchored OPA1 regulates the tight closure of the
mitochondria cristae, preventing massive release of cytochrome c
into the inter-mitochondrial space.
Taken together, these observations lead us to hypothesize that
accumulation of a premature form of CTMP in the inner
mitochondrial membrane (due to inhibition of mitochondrial
membrane peptidase cleavage) may be responsible for the
observed mitochondrial phenotype. Moreover, in vitro character-
ization of the molecular mechanisms regulating inner mitochon-
drial membrane dynamics are as yet poorly understood.
Surprisingly, a subtle abnormal mitochondrial phenotype in the
Figure 3. CTMP expression affects mitochondrial network organization. (A) Confocal microscopy of CTMP expression in tetracycline
inducible HeLa clones stably expressing pTer plasmid coding for a control short hairpin (Sh-cont) or a short hairpin directed against CTMP (Sh#1 and
Sh#2). Cells were visualized by immunofluorescence after 5 days culture in the presence or absence of tetracycline (2 mg/mL), together with the
MitoTracker Red. (B) Representative confocal pictures of mitochondrial shape in tetracycline-inducible HeLa clones cultured 5 days in the presence of
tetracycline. Mitochondria were visualized with MitoTracker Red. (C) Morphological analysis of mitochondria shape in HeLa Tet-on clones treated as in
(A) for 3, 4 or 5 days. For each experiment, at least 200 cells were counted in three distinct fields. Data are means6SEM, n=2. The differences in mean
values are statistically significant (Sh#2 minus tetracycline compared to Sh#2 plus tetracycline) as determined by 1-way ANOVA; ** P#0.001.
doi:10.1371/journal.pone.0005471.g003
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Figure 4. CTMP is not required for mitochondrial fusion. (A) Hela cells expressing mt-RFP and mt-GFP transfected with either siRNA#1 and
#2 against CTMP or the siRNA control were fused in 50% PEG1500 for 60 s, washed and fixed at different times (4, 6 and 8 h). (B) Time-course of
mitochondrial fusion in HeLa cells treated as in (A). Mitochondrial fusion was measured from 30 randomly selected polykaryons and classified as
described in (A), n= 2.
doi:10.1371/journal.pone.0005471.g004
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brain tissue of PKB/Akt knockout mice has been reported recently
[31]. These animals display fewer and larger mitochondrial
structures, and the authors suggest that PKB/Akt plays a
significant role in mitochondrial biogenesis. In addition, PKB/
Akt has been shown to translocate to the outer mitochondrial
membrane, following plasma membrane activation [32–34].
Although the biological significance of the translocation of active
PKB/Akt to the mitochondria is not yet clear, it has been reported
to be cell-type and stimulus-specific [35,36]. Thus, CTMP may
modulate PKB/Akt activity in a specific subcellular compartment,
e.g. the mitochondria or the cytosol, depending on the nature of
the stimulus (survival or apoptosis). Further investigation is needed
to integrate the direct and/or indirect modulation of PKB/Akt
activity in this model and more experiments will be required to
address the biological activity of CTMP.
Striking similarities exist between the mitochondria network
rearrangement observed in CTMP knockdown cells and those
already reported in cells knocked down for the Drp1 fission protein
or cells missing a functional OPA1 protein [14,29]. Nonetheless,
the loss of electron absorbance observed in CTMP knockout mice
liver mitochondria further supports the involvement of CTMP in
the maintenance of inner mitochondrial membrane integrity.
Thus, the phenotype observed following CTMP depletion with
respect to mitochondrial network rearrangements is less penetrant
than those already reported for the key mitochondria-shaping
proteins. Moreover, CTMP protein depletion did not affect HeLa
cell growth or mitochondrial transmembrane potential measured
in vitro (data not shown). Most interestingly, it has been shown that
CTMP interacts with LETM1, another mitochondrial protein
involved in mitochondrial morphology [37]. LETM1 is located in
the inner membrane of mitochondria and oligomerized in higher
molecular weight complexes [38]. LETM1 has been found to be
deleted in Wolf-Hirschorn syndrome (WHS), a complex congenital
syndrome characterized by microcephaly, growth and mental
retardation, seizures, epilepsy and other associated symptoms
[39,40]. LETM1 is considered as playing a major role in the
pathogenesis of seizures. The function of LETM1 in apoptosis,
mitochondrial homeostasis and mitochondrial dynamics is well
documented, although the different reports drew different
conclusions [37,38,41]. Thus, it will be very exciting to further
investigate the interplay between CTMP and LETM1 in
regulating mitochondrial dynamics and functions in future studies.
In particular, it would be of interest to explore the phenotype of
CTMP knockout mice in the context of Wolf-Hirschorn
syndrome.
It is plausible that CTMP mediates its effect by modulating the
activity of the key regulators of mitochondrial dynamics and
further experiments should address the biological mechanism by
which CTMP regulates mitochondrial functions. We have
demonstrated already that CTMP exhibits a dual submitochon-
drial localization. Therefore, the tight association between CTMP
protein integrity and maintenance of mitochondria shape observed
in this study provides a novel opportunity to investigate the
mitochondrial function of CTMP in metabolic regulation.
Materials and Methods
Cloning and plasmids construction
All CTMP untagged plasmids used in this study were constructed
following PCR amplification of hCTMP cDNA [20] and inserted
into the BamHI and EcoRI sites of the pcDNA4-IRES-GFP plasmid
[42]. CTMP point mutant (m5) was generated by site-directed
mutagenesis. To C-terminally tag the CTMP protein, the
pcDNA3.1-Myc-RFP plasmid was constructed by subcloning the
mRFP1 (monomeric Red Fluorescent Protein 1) cDNA [43] into the
KpnI and EcorV sites of the hygromycin resistant vector pcDNA3.1-
Myc. The following sequences encoded the CTMP-SiRNA#1 59-
UCGUCAUGACUGCCAAUCU-39 59- AGAUUGGCAGUCA-
UGACGA-39 and CTMP Si-RNA#2 59-CCCAUUUUCUUGA-
CCCAAA-39, 59- UUUGGGUCAAG AAAAUGGG-39 used in this
study. The control SiRNAs were directed against the fluorescein
protein 59-UUCUCCGAACGUGUCACGU-39 and 59-ACGUGA-
CACGUUCGGAGAA-39 (Quiagen). To stably induce expression of
short hairpins in cells, the CTMP-specific tandem sequences 59-
GATCCCAAGACCCTATACTCAGA GGCGTTCAAGAGAC-
GCCTCTGAGTAGGGTCTTTTTGGAAA-39 and 59- AGCT-
TTT CCAAAAAGACCCTACTCAGAGGCGTCTCTTGAAC-
GCCTCTGAGT ATGGG TCGG-39 were cloned in the BglII/
HindIII sites of pTer vector [44]. The pTer control construct (cont-
Sh) used was directed against luciferase as previously described [45]
or a scramble sequence 59GATCCCA GAGACAGCTACCAAG-
GACTTCAAGAGAGTCCTTGGTAGCTGTCTCTTTTTTG-
GAAA 39and 59-AGCTTTTCCAAAAAAGAGACAGCTAC-
CAAGGACTCTCTTGAAGTCCTTGGTAG CTG TCT
CTGG39. All construct sequences were confirmed using an ABI
PRISM 3700 DNA Analyzer (Applied Biosystems).
Antibodies
CTMP monoclonal antibodies were generated by repeated
immunization of BALB/c mice with 50–100 mg of purified full-
length His-CTMP protein (produced in E. coli), using Stimune
(Prionics AG, Schlieren Switzerland) as an adjuvant. Two months
after the priming injection, spleenic lymphocytes cells were fused
with P3AG8.653 myelanoma cell line (ATCC) and cultured
according to standard procedures. After ELISA screening of
hybridomas clone supernatants, epitope mapping was carried out
for the clone used in this study (52F11) using the GST-CTMP
deletion mutant and synthetic polypeptides. The monoclonal anti-
CTMP antibody characterized is IgG1. Anti-a-tubulin (YL 1/2)
antibody was used as hybridoma supernatants. The commercial
mouse anti-mHsp70 (JG1) was from Affinity BioReagents, mouse
anti-cytochrome c was from R&D System and rat a-actin was
from Santa Cruz Biotechnology.
Transient and stable transfections
HeLa cells were grown in Dulbecco’s Medium (Gibco)
supplemented with 10% fetal calf serum. HeLa cell lines stably
expressing the tetraycline repressor (HeLa Tet-on) and/or
mitochondria-labeled cells (mt-GFP, mt-RFP) were cultured in
Figure 5. The mitochondrial network is extensively interconnected in CTMP knockout mice liver. (A) Summary of the knockout strategy
used to generate CTMP knockout mice. (B) Genotyping of CTMP +/+ (wild-type), +/2 (heterozygous) and 2/2 (knockout) mice. Genomic DNA was
digested using Spe1 and probed using a CTMP cDNA fragment. A wild-type band (9 kb, lower band) and a CTMP knockout band (14 kb, upper band)
are indicated. (C) Summary of the mitochondria purification strategy outlined in Materials and Methods (left panel). Percoll gradient-isolated liver
mitochondria from wild-type (WT) or CTMP knockout (2/2) mice were separated by SDS-PAGE and immunoblotted for a-actin, mHsp70, cytochrome
c and CTMP (right panel). (D) Representative electron micrographs of liver mitochondria ultrastructure in (top) wild-type and (bottom) CTMP
knockout mice. Arrows indicate normal liver mitochondria (top) and elongated mitochondria (bottom). Representative images of mitochondria shape
from different experiments (blind) are shown at different magnifications (611,000,614,000,628,000).
doi:10.1371/journal.pone.0005471.g005
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medium supplemented with 100 ng/mL and 0.4 mg/mL G418
(Sigma), respectively. For transfection, cells were plated in 6-well
plates or 10-cm dishes and transfected the following day at 60%
confluence using Lipofectamine 2000 following the manufacturer’s
instruction (Invitrogen). Small inhibitory RNA delivery was
achieved with Oligofectamine (Invitrogen). Stable clones express-
ing CTMP short hairpins or negative controls were selected 48 h
after transfection by addition of 0.8 mg/mL Zeocin and positive
clones were further maintained in 0.4 mg/mL Zeocin.
Protein extraction and mitochondria isolation
For whole cell extracts, cells were washed in 16 PBS and
resuspended in lysis buffer (50 mM Tris [pH 7.4], 150 mM
NaCl, 10% glycerol, 0.5% NP40, 0.5 mM Na-orthovanadate,
50 mM NaF, 80 mM b-glycerophosphate, 10 mM Na-pyro-
phosphate, 1 mM dithiothreitol, 1 mM EGTA, 10 mg leupep-
tin/ml and 10 mg aprotinin/ml). Mitochondria isolation was
carried out as previously described [41]. Briefly, cells were
washed twice in 100 mM sucrose, 1 mM ethylene glycol-bis(b-
aminoethyl ether)-tetraacetic acid (EGTA), 20 mM 3-(N-mor-
pholino) propanesulfonic acid (MOPS), pH 7.4 and 1 mg/mL
BSA. The pellet was resuspended in the same buffer solution
supplemented with 10 mM triethanolamine, 5% (v/v) Percoll,
0.1 mg/mL digitonin for 3 min at 4uC and homogenized with a
Potter homogenizer (10 strokes, 1’000 rpm) before being diluted
1/5 in 300 mM sucrose, 1 mM EGTA, 20 mM MOPS, pH 7.4
and 1 mg/mL BSA, and centrifuged at 2’500 g for 5 min at
4uC. The supernatant containing mitochondria was collected
and centrifuged at 10’000 g for 10 min at 4uC to collect
mitochondria as a pellet. Isolated mitochondria were washed
twice in the same conditions before being resuspended and
further processed.
Western-blotting
For Western blot analysis, protein lysates were prepared by
homogenization of various organs in lysis buffer (50 mM Tris-
HCl, pH 8.0, 120 mM NaCl, 1% NP-40, 40 mM b-glycerophos-
phate, 10% glycerol, 4 mM leupeptin, 0.05 mM phenylmethylsul-
fonyl fluoride, 1 mM benzamidine, 50 mM NaF, 1 mM Na3VO4,
5 mM EDTA, 1 mM Microcystin LR). Homogenates were
centrifuged twice (13’000 rpm for 10 min at 4uC) to remove cell
debris. Protein concentrations were determined using the Bradford
assay. Proteins were separated by 12% or 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and then transferred to
Immobilon-P polyvinylidene difluoride membranes (Millipore).
Immunostaining
For immunostaining, cells were grown on coverslips for 24 h
following transfection with different plasmids or siRNAs. Where
mitochondria were visualized by MitoTracker Red, cells were
treated with 300 nM MitoTracker Red CMXRos for 15 min
before being washed in PBS and fixed in 3% paraformaldehyde/
2% sucrose. Cells were further permeabilized using 0.2% Triton
6100 (3 min at room temperature) before being washed in PBS
and incubated together with an appropriate dilution of the
primary antibody for 1 h at room temperature in 1% BSA/1%
goat serum. This was followed by incubation with secondary
antibodies at 1:100 for 45 min at room temperature. After a final
washing, coverslips were mounted in Vectashield medium (Vector
lab) and visualized on a laser scanning microscope (Olympus
FV500). Confocal images were processed using the Imaris
program (Bitplane AG, Zu¨rich, Switzerland) and Photoshop 6.0
(Adobe System Inc).
Mitochondria intercomplementation
HeLa cells carrying different fluorescent mitochondria (mt-RFP
or mt-GFP) were mixed 1/1 and plated on coverslips 24 h after
transfection. Mt-GFP HeLa cells were pre-treated for 20 h with
1 mM trichostatin to increase GFP expression levels. After washes
in FCS-free DMEM, droplets of 50% PEG 1500 were added
directly to cells and aspirated after 45–60 s. After several washes,
cells were collected and fixed at the indicated times and processed
for immunofluorescence. Heterokaryons were visualized by DNA
staining of the nucleus (To-Pro-3 iodide) and/or a-tubulin
staining.
Generation of CTMP knockout mice
For the generation of CTMP mutant mice, a mouse genomic
DNA fragment containing exons 2 and 3 was cloned into the
pBluescript vector and a Not1 site was generated in exon 2. A
,5-kb IRES-lacZ-Neo cassette was inserted into the NotI site,
which introduced a translational frame shift. The targeting
vector was linearized and electroporated into 129/Ola ES cells.
ES cell clones were screened by Southern blotting. DNA was
digested with SpeI and probed with an external probe. An
internal probe was then used on KpnI-digested DNA for further
characterization of ES cell clones that were positive for
homologous recombination. Correctly targeted ES cells were
used to generate chimeras. Male chimeras were mated with
wild-type C57BL/6 females to obtain CTMP+/2 mice, which
were intercrossed to produce CTMP homozygous mutants.
Progeny were genotyped for the presence of a targeted allele by
multiplex PCR.
Liver mitochondria isolation
All steps were carried out at 4uC. Mice were housed and
terminated according to Swiss legislation. Following termination,
freshly dissected liver tissues were immersed and extracted in MSH
buffer (pH 7,3) (5 mM HEPES, 70 mM sucrose, 210 mM manni-
tol, supplemented with 1 mM EDTA), before homogenization in a
glass homogenizer (at 500 rpm) in MSH Buffer (supplemented with
anti-proteases inhibitors) and centrifugation for 10 min at 800 g.
The fat coat was removed after centrifugation (10,000 g for 10 min
at 4uC) and the pellet was manually resuspended in 80 ml of
mitochondrial isolation buffer (MSH buffer: 36 ml/ml aprotinin,
5 ml/ml PMSF, 1 ml/ml leupeptin). A crude mitochondrial pellet
was isolated by differential centrifugation (3,000 g, 10,000 g and
9,000 g) before being layered on top of a 20-mL Percoll solution
(39.3 ml of Percoll, 73.5 ml of 10 mM HEPES, and 13.2 ml of
2.5 M sucrose) and centrifuged at 26,000 rpm for 45 min at 4uC. A
pure mitochondria layer was collected below the peroxisome layer
and washed twice in mitochondrial isolation buffer before being
submitted to protein quantification.
Transmission electron microscopy
Samples were collected from the same regions of liver (left lobe and
median lobe neighboring the gallbladder) for both wild-type [2
females (27,5 and 42 weeks old) and 1 male (42 weeks old)] and
CTMP knockout mice [2 females (27,5 and 42 weeks old) and 1 male
(42 weeks old)] and immediately fixed for 1 h in 3% paraformalde-
hyde and 0.5% glutaraldehyde in PBS puffer (pH 7.4), washed twice
in PBS and post-fixed for 1 h in 1% osmium tetroxide (OSO4). After
dehydration with a graded ethanol series (50–100%) and infiltration
in 100% acetone, samples were embedded using an Epoxy-
Embedding kit (Epon, FLUKA) for 24 h at 60uC. Thin sections
(60–70nm) were obtained on Ultracut (Reichert-Jung) and analyzed
on a TEM Moragni 268D (Philips) at 80 kV.
CTMP and Mitochondria Dynamic
PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5471
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0005471.s001 (2.26 MB TIF)
Figure S2
Found at: doi:10.1371/journal.pone.0005471.s002 (3.10 MB TIF)
Figure S3
Found at: doi:10.1371/journal.pone.0005471.s003 (1.17 MB TIF)
Supplementary Text S1
Found at: doi:10.1371/journal.pone.0005471.s004 (0.03 MB
DOC)
Acknowledgments
We acknowledge our FMI colleagues and core facilities for contributions to
this study. We thank Dr. M. Rojo (INSERM, Universite´ Pierre et Marie
Curie, Paris, France) and Dr. DR. Green (St. Jude Children’s Research
Hospital, Memphis, USA) for plasmids. We also acknowledge Dr. P. King,
Dr. L. Bozulic and R. Kohler for editing the manuscript.
Author Contributions
Conceived and designed the experiments: AP LAT. Performed the
experiments: AP LAT EZ DH VO. Analyzed the data: AP LAT EZ
BAH. Contributed reagents/materials/analysis tools: LAT EZ BD DPB
PC SS. Wrote the paper: AP LAT.
References
1. Balaban RS, Nemoto S, Finkel T (2005) Mitochondria, oxidants, and aging. Cell
120: 483–495.
2. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death.
Science 305: 626–629.
3. McWhirter SM, Tenoever BR, Maniatis T (2005) Connecting mitochondria and
innate immunity. Cell 122: 645–647.
4. Smeitink JA, Zeviani M, Turnbull DM, Jacobs HT (2006) Mitochondrial
medicine: a metabolic perspective on the pathology of oxidative phosphorylation
disorders. Cell Metab 3: 9–13.
5. McBride HM, Neuspiel M, Wasiak S (2006) Mitochondria: more than just a
powerhouse. Curr Biol 16: R551–560.
6. Green DR (2005) Apoptotic pathways: ten minutes to dead. Cell 121: 671–674.
7. Parcellier A, Tintignac LA, Zhuravleva E, Hemmings BA (2008) PKB and the
mitochondria: AKTing on apoptosis. Cell Signal 20: 21–30.
8. Brandon M, Baldi P, Wallace DC (2006) Mitochondrial mutations in cancer.
Oncogene 25: 4647–4662.
9. Cereghetti GM, Scorrano L (2006) The many shapes of mitochondrial death.
Oncogene 25: 4717–4724.
10. Youle RJ (2005) Morphology of mitochondria during apoptosis: worms-to-
beetles in worms. Dev Cell 8: 298–299.
11. Youle RJ, Karbowski M (2005) Mitochondrial fission in apoptosis. Nat Rev Mol
Cell Biol 6: 657–663.
12. Detmer SA, Chan DC (2007) Functions and dysfunctions of mitochondrial
dynamics. Nat Rev Mol Cell Biol 8: 870–879.
13. Delivani P, Adrain C, Taylor RC, Duriez PJ, Martin SJ (2006) Role for CED-9
and Egl-1 as regulators of mitochondrial fission and fusion dynamics. Mol Cell
21: 761–773.
14. Jagasia R, Grote P, Westermann B, Conradt B (2005) DRP-1-mediated
mitochondrial fragmentation during EGL-1-induced cell death in C. elegans.
Nature 433: 754–760.
15. Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and
development. Cell 125: 1241–1252.
16. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, et al. (2003) Mitofusins
Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for
embryonic development. J Cell Biol 160: 189–200.
17. Rojo M, Legros F, Chateau D, Lombes A (2002) Membrane topology and
mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the
transmembrane GTPase Fzo. J Cell Sci 115: 1663–1674.
18. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, et al. (2000) Nuclear
gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in
dominant optic atrophy. Nat Genet 26: 207–210.
19. Smirnova E, Shurland DL, Ryazantsev SN, van der Bliek AM (1998) A human
dynamin-related protein controls the distribution of mitochondria. J Cell Biol
143: 351–358.
20. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, et al. (2001) Carboxyl-
terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-
Akt at the plasma membrane. Science 294: 374–380.
21. Knobbe CB, Reifenberger J, Blaschke B, Reifenberger G (2004) Hypermethyla-
tion and transcriptional downregulation of the carboxyl-terminal modulator
protein gene in glioblastomas. J Natl Cancer Inst 96: 483–486.
22. Parcellier A, Tintignac LA, Zhuravleva E, Cron P, Schenk S, et al. (2009)
Carboxy-Terminal Modulator Protein (CTMP) is a mitochondrial protein that
sensitizes cells to apoptosis. Cell Signal.
23. Gakh O, Cavadini P, Isaya G (2002) Mitochondrial processing peptidases.
Biochim Biophys Acta 1592: 63–77.
24. Taylor AB, Smith BS, Kitada S, Kojima K, Miyaura H, et al. (2001) Crystal
structures of mitochondrial processing peptidase reveal the mode for specific
cleavage of import signal sequences. Structure 9: 615–625.
25. Ishihara N, Jofuku A, Eura Y, Mihara K (2003) Regulation of mitochondrial
morphology by membrane potential, and DRP1-dependent division and FZO1-
dependent fusion reaction in mammalian cells. Biochem Biophys Res Commun
301: 891–898.
26. Legros F, Lombes A, Frachon P, Rojo M (2002) Mitochondrial fusion in human
cells is efficient, requires the inner membrane potential, and is mediated by
mitofusins. Mol Biol Cell 13: 4343–4354.
27. Mattenberger Y, James DI, Martinou JC (2003) Fusion of mitochondria in
mammalian cells is dependent on the mitochondrial inner membrane potential
and independent of microtubules or actin. FEBS Lett 538: 53–59.
28. Nakamura N, Kimura Y, Tokuda M, Honda S, Hirose S (2006) MARCH-V is a
novel mitofusin 2- and Drp1-binding protein able to change mitochondrial
morphology. EMBO Rep 7: 1019–1022.
29. Frezza C, Cipolat S, Martins de Brito O, Micaroni M, Beznoussenko GV, et al.
(2006) OPA1 controls apoptotic cristae remodeling independently from
mitochondrial fusion. Cell 126: 177–189.
30. Cipolat S, Rudka T, Hartmann D, Costa V, Serneels L, et al. (2006)
Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis
via OPA1-dependent cristae remodeling. Cell 126: 163–175.
31. Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, et al. (2008)
VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase.
Faseb J 22: 3264–3275.
32. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, et al. (1997) Role
of translocation in the activation and function of protein kinase B. J Biol Chem
272: 31515–31524.
33. Kunkel MT, Ni Q, Tsien RY, Zhang J, Newton AC (2005) Spatio-temporal
dynamics of protein kinase B/Akt signaling revealed by a genetically encoded
fluorescent reporter. J Biol Chem 280: 5581–5587.
34. Sasaki K, Sato M, Umezawa Y (2003) Fluorescent indicators for Akt/protein
kinase B and dynamics of Akt activity visualized in living cells. J Biol Chem 278:
30945–30951.
35. Ahmad N, Wang Y, Haider KH, Wang B, Pasha Z, et al. (2006) Cardiac
protection by mitoKATP channels is dependent on Akt translocation from
cytosol to mitochondria during late preconditioning. Am J Physiol Heart Circ
Physiol 290: H2402–2408.
36. Bijur GN, Jope RS (2003) Rapid accumulation of Akt in mitochondria following
phosphatidylinositol 3-kinase activation. J Neurochem 87: 1427–1435.
37. Piao L, Li Y, Kim SJ, Sohn KC, Yang KJ, et al. (2009) Regulation of OPA1-
mediated mitochondrial fusion by leucine zipper/EF-hand-containing trans-
membrane protein-1 plays a role in apoptosis. Cell Signal.
38. Dimmer KS, Navoni F, Casarin A, Trevisson E, Endele S, et al. (2008) LETM1,
deleted in Wolf-Hirschhorn syndrome is required for normal mitochondrial
morphology and cellular viability. Hum Mol Genet 17: 201–214.
39. Bergemann AD, Cole F, Hirschhorn K (2005) The etiology of Wolf-Hirschhorn
syndrome. Trends Genet 21: 188–195.
40. Zollino M, Lecce R, Fischetto R, Murdolo M, Faravelli F, et al. (2003) Mapping
the Wolf-Hirschhorn syndrome phenotype outside the currently accepted WHS
critical region and defining a new critical region, WHSCR-2. Am J Hum Genet
72: 590–597.
41. Tamai S, Iida H, Yokota S, Sayano T, Kiguchiya S, et al. (2008)
Characterization of the mitochondrial protein LETM1, which maintains the
mitochondrial tubular shapes and interacts with the AAA-ATPase BCS1L. J Cell
Sci 121: 2588–2600.
42. Tintignac LA, Sirri V, Leibovitch MP, Lecluse Y, Castedo M, et al. (2004)
Mutant MyoD lacking Cdc2 phosphorylation sites delays M-phase entry. Mol
Cell Biol 24: 1809–1821.
43. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, et al.
(2004) Improved monomeric red, orange and yellow fluorescent proteins derived
from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567–1572.
44. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, et al.
(2003) Specific inhibition of gene expression using a stably integrated, inducible
small-interfering-RNA vector. EMBO Rep 4: 609–615.
45. Hergovich A, Lamla S, Nigg EA, Hemmings BA (2007) Centrosome-associated
NDR kinase regulates centrosome duplication. Mol Cell 25: 625–634.
CTMP and Mitochondria Dynamic
PLoS ONE | www.plosone.org 10 May 2009 | Volume 4 | Issue 5 | e5471
171 
 
7.3 Carboxy-Terminal Modulator Protein (CTMP) is a mitochondrial protein that 
sensitizes cells to apoptosis   
Parcellier A., Tintignac L.A., Zhuravleva E., Cron P., Schenk S., Bozulic L., Hemmings 
B.A. Cell Signal, 2009; 21(4):639-50 
 
Cellular Signalling 21 (2009) 639–650
Contents lists available at ScienceDirect
Cellular Signalling
j ourna l homepage: www.e lsev ie r.com/ locate /ce l l s igCarboxy-Terminal Modulator Protein (CTMP) is a mitochondrial protein that
sensitizes cells to apoptosis
Arnaud Parcellier 1, Lionel A. Tintignac 1, Elena Zhuravleva, Peter Cron, Susanne Schenk,
Lana Bozulic, Brian A. Hemmings ⁎
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland⁎ Corresponding author. Tel.: +41 61 6974872, +41 61
E-mail address: brian.hemmings@fmi.ch (B.A. Hemm
1 Authors contributed equally to the work.
0898-6568/$ – see front matter © 2009 Elsevier Inc. Al
doi:10.1016/j.cellsig.2009.01.016a b s t r a c ta r t i c l e i n f oArticle history: The Carboxy-Terminal Mod
Received 27 October 2008
Received in revised form 15 December 2008
Accepted 2 January 2009
Available online 8 January 2009
Keywords:
CTMP
PKB
Mitochondria
Apoptosisulator Protein (CTMP) protein was identified as a PKB inhibitor that binds to its
hydrophobic motif. Here, we report mitochondrial localization of endogenous and exogenous CTMP. CTMP
exhibits a dual sub-mitochondrial localization as a membrane-bound pool and a free pool of mature CTMP in
the inter-membrane space. CTMP is released from the mitochondria into the cytosol early upon apoptosis.
CTMP overexpression is associated with an increase in mitochondrial membrane depolarization and caspase-
3 and polyADP-ribose polymerase (PARP) cleavage. In contrast, CTMP knock-down results in a marked
reduction in the loss of mitochondrial membrane potential as well as a decrease in caspase-3 and PARP
activation. Mutant CTMP retained in the mitochondria loses its capacity to sensitize cells to apoptosis. Thus,
proper maturation of CTMP is essential for its pro-apoptotic function. Finally, we demonstrate that CTMP
delays PKB phosphorylation following cell death induction, suggesting that CTMP regulates apoptosis via
inhibition of PKB.
© 2009 Elsevier Inc. All rights reserved.1. IntroductionThemitochondria areoneof themajor sites in the regulationof cellular
metabolism and survival that are crucial for organism development,
immunity, agingandpathogenesis [1–3]. Thesecomplexcellular functions
rely on both the proteomic and the structural integrity of mitochondria,
which together contribute to facilitate specific enzymatic activities
involved in a variety of functions including oxidative phosphorylation
[4], theTCAcycle, gluconeogenesis [5], death signal integration [6] and the
amplification and transmission of mitochondrial DNA (mtDNA) [7].
Recently almost 1100 genes encoding mitochondrial proteins in the
mouse was reported [8]. Whilst a small number of these mitochondrial
proteins are encoded by mtDNA, the vast majority are encoded in the
nucleus. Studies into themechanismbywhichnuclear transcribedgenes
that are then translated and located in the cytosol are transported into
the mitochondria, have shown that many of these proteins possess a
Mitochondrial Localization Signal (MLS) which targets the protein into
themitochondria. Once correctly located in themitochondria this signal
is often cleaved, resulting in a functional protein that can act inside the
mitochondria, or via retrogrademovementbe released back to cytosol to
perform cytoplasmic functions [9].
The serine/threoninekinasePKB/Akt is a keyeffectorof the evolutionary
conserved PI3K signalingmodule that transduces crucial extracellular cues,6974046; fax: +41 61 6973976.
ings).
l rights reserved.such as growth factors and death signals [10–12]. Chronic activation of the
PI3 K-PKB pathway, results in tumorigenesis and metastasis [13–18], and
can protect tumor cells from apoptosis via inhibition of many proapoptotic
proteins, such as Bax, Bid, YAP, mdm2/p53 and others.
CTMP was initially identified as a cytosolic interactor of PKB, which
prevents its activation at the plasma membrane in response to various
stimuli [19,20], and exhibit tumor suppressor-like functions [19]. This
notion was strengthened by the observation that primary glioblastomas
exhibit downregulation of CTMP mRNA levels due to promoter
hypermethylation [21]. Despite this the physiological localization and
function of CTMP is still poorly understood [22].
Here we identify CTMP as a mitochondrial protein, capable of
sensitizing cells to apoptosis. Once CTMP is synthesized, it translocates
to the mitochondria via a MLS and undergoes maturation through
cleavageof thisMLSbymitochondrial peptidases.Uponapoptotic stimuli,
CTMP is then released into the cytosol and promotes apoptosis with a
concomitant delay/inhibition of PKB activation. Our overexpression and
loss-of-function studies reportedherein, reveal CTMPas a regulatorof the
apoptotic process, which must be processed in the mitochondrion and
then released into the cytosol in order to fulfil these functions.
2. Materials and methods
2.1. Cloning and plasmids construction
All untagged CTMP plasmids used in this study were constructed
following PCR amplification of hCTMP cDNA [19] and inserted into the
BamHI and EcoRI sites of the pcDNA4-IRES-GFP plasmid [23]. CTMP
640 A. Parcellier et al. / Cellular Signalling 21 (2009) 639–650point mutants (m1-3) were generated by site-directed mutagenesis. To
C-terminally tag the CTMP protein, the pcDNA3.1-Myc-RFP plasmidwas
constructed by subcloning the mRFP1 (monomeric Red Fluorescent
Protein 1) cDNA [24] into the KpnI and EcorV sites of the hygromycin
resistant vector pcDNA3.1-Myc. Wild-type CTMP and deletion mutants
were further generated by subcloning of CTMP PCR fragments in the
NheI and KpnI sites upstream of the Myc-RFP tag. pcDNA3-Flag-hBcl2
was a gift from Dr. Christoph Borner.
2.2. Short hairpins targeting CTMP
To stably induce expression of short hairpins in cells, the CTMP-
specific tandem sequences 5′GATCCCAAGACCCTATACTCAGAGGCGTT-
CAAGAGACGCCTCT GAGTAGGGTCTTTTTGGAAA-3′ and 5′-AGCTTTTC-
CAAAAAGACCCTACTCA GAGGCGTCTCTTGAACGCCTCTGAG-
TATGGGTCGG-3′ were cloned in the BglII/ HindIII sites of pTer vector
[25]. The pTER control construct (cont-Sh) used was directed against
luciferase as previously described [26] or a scramble sequence 5′
GAGTCCTT GGTAGCTGTCTCTTTTTTGGAAA3′ and 5′AGCTTTTC-
CAAAAAAGAGACAGCTACCAAGGACTCTCTTGAAGTCCTTGG-
TAGCTGTCTCTGG3′. All construct sequences were confirmed using an
ABI PRISM 3700 DNA Analyzer (Applied Biosystems).
2.3. Cell lines, transient and stable transfection, reagents
HEK293, HeLa, and LN229 cells were grown in Dulbecco's Medium
(Gibco) supplemented with 10% foetal calf serum. HeLa cell lines stably
expressing the tetracycline repressor (HeLa Tet-on) were cultured in
medium supplemented with 100 ng/mL G418 (Sigma). For transfection,
cell lines (HeLa, HeLa Tet-on cells) were plated in 6-well plates or 10-cm
dishes and transfected the following day at 60% confluence using
Lipofectamine 2000 following the manufacturer’s instruction (Invitro-
gen). Stable clones expressing CTMP, short hairpins or negative controls
were selected 48 h after transfection by addition of 0.8 mg/mL Zeocin
and positive clones were further maintained in 0.4 mg/mL Zeocin.
Actinomycin D and etoposide were from Sigma; zVAD-fmk was from
R&D System.
2.4. Antibodies
CTMP monoclonal antibodies were generated by repeated immu-
nization of BALB/c mice with 50–100 μg of purified full-length His-
CTMP protein (produced in E coli), using Stimune (Prionics AG,
Schlieren, Switzerland) as an adjuvant. Two months after the priming
injection, spleenic lymphocytes cells were fused with P3AG8.653
myelanoma cell line (ATCC) and cultured according to standard
procedures. After ELISA screening of hybridoma clone supernatants,
epitope mapping was carried out for the four clones used in this study
(52F11, 4B13 and 41G21) using the GST-CTMP deletion mutant and
synthetic polypeptides. All monoclonal anti-CTMP antibodies char-
acterized are IgG1.
The antibodies anti-Myc (9E10), anti-HA (12CA5), anti-α-tubulin
(YL 1/2), anti-PKB (AB10) were used as hybridoma supernatants and
rabbit anti-hLetm1 (epitope amino acids 349 to 740) [27] was kindly
provided by Dr. R. J. O'Brien (Caritas St. Elizabeth's Medical Center,
Boston, USA). The commercial mouse anti-mHsp70 (JG1) was from
Affinity BioReagents, mouse anti-cytochrome c and rabbit anti-Htr2a/
Omi were from R&D System, anti-cleaved PARP and rabbit monoclonal
anti-caspase-3 from Cell Signaling Technology. The commercial anti-
phospho Ser473 PKB/AKTantibodywas fromAlexis and anti-Bcl2 from
Santa Cruz Biotechnology.
2.5. Protein extraction and mitochondria fractionation
Forwhole cell extracts, cellswerewashed inPBS1Xand resuspended
in lysis buffer (50mMTris pH 7.4,150mMNaCl,10% glycerol, 0.5%NP40,0.5 mM Na-orthovanadate, 50 mM NaF, 80 mM ß-glycerophosphate,
10 mM Na-pyrophosphate, 1 mM dithiothreitol, 1 mM EGTA, 10 µg
leupeptin/ml and 10 µg aprotinin/ml).
Mitochondria isolation was carried out as described [28]. Briefly,
cells were washed twice in 100 mM sucrose, 1 mM ethylene glycol-bis
(β-aminoethyl ether)-tetraacetic acid (EGTA), 20 mM 3-(N-morpho-
lino)propanesulfonic acid (MOPS) pH 7.4 and 1 mg/mL BSA. The pellet
was resuspended in the same buffer solution supplemented with
10 mM triethanolamine, 5% (v/v) Percoll, 0.1 mg/mL digitonin for
3 min at 4 °C and homogenized in a Potter homogenizer (10 strokes,
1000 rpm) before being diluted 1/5 in 300 mM sucrose, 1 mM EGTA,
20 mM MOPS pH 7.4 and 1 mg/mL BSA, and centrifuged at 2500 g for
5 min at 4 °C. The supernatant containing mitochondria was collected
and centrifuged at 10,000 g for 10 min at 4 °C to collect mitochondria
as a pellet. Isolated mitochondria were washed twice in the same
conditions before being resuspended and further processed.
2.6. Western blotting
For Western blot analysis, protein lysates were prepared by using
lysis buffer (50 mM Tris–HCl pH 8.0, 120 mM NaCl, 1% NP-40, 40 mM
β-glycerophosphate, 10% glycerol, 4 μM leupeptin, 0.05 mM phenyl-
methylsulfonyl fluoride, 1 mM benzamidine, 50 mM NaF, 1 mM
Na3VO4, 5 mM EDTA, 1 μM Microcystin LR). Homogenates were
centrifuged twice (13,000 rpm for 10 min at 4 °C) to remove cell
debris. Protein concentrations were determined using the Bradford
assay and proteins separated by 12% or 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and before transfer to Immobilon-
P polyvinylidene difluoride membranes (Millipore).
2.7. Immunostaining
For immunostaining, cells were grown on coverslips for 24 h
following treatment. To visualize mitochondria, cells were treated
with 300 nM Mito Tracker Red CMXRos for 15 min before being
washed in PBS and fixed in 3% paraformaldehyde/2% sucrose. Cells
were further permeabilized using 0.2% Triton X100 (3 min at room
temperature) before beingwashed in PBS and incubated together with
the appropriate dilution of the primary antibody for 1 h at room
temperature in 1% BSA/1% goat serum. This was followed by
incubation with secondary antibodies including donkey anti-mouse-
fluorescein isothiocyanate (FITC) (Jackson Immunoresearch Inc.) at
1:100 together with 1 μMTo-Pro-3 iodide (DNA, Molecular Probes Inc)
for 45 min at room temperature. After final washing, coverslips were
mounted in Vectashield medium (Vector lab) and visualized with a
laser scanning microscope (Olympus FV500). Confocal images were
processed using the Imaris program (Bitplane AG, Zurich, Switzerland)
and Photoshop 6.0 (Adobe System Inc).
2.8. Measurement of mitochondrial membrane potential
Mitochondrial membrane potential (Δψm) was measured with the
MitoProbe™ 1,1′,3,3,3′,3′-hexamethylindodicarbocyanine iodide
(DiIC1(5)) assay kit (Molecular Probes) as instructed by the manu-
facturer. Briefly, cells (including floating cells) grown in 6-well plates
were collected following mild trypsinization. Trypsinized cells were
washed once with PBS, and the cells were resuspended in 500 µl PBS.
Resuspended cells were labelled with 50 nM DiIC1(5) (excitation/
emission, 638/658 nm) at 37 °C in the dark for 30 min. Labelled cells
were washed once in PBS and analysed by fluorescence-activated cell
sorting using a FACSCalibur (Becton Dickinson) flow cytometer.
2.9. Hoechst staining
Cells (including floating cells) were collected following mild
trypsinization. Trypsinized cells were washed once with PBS and the
Fig.1. CTMP contains a functional N-terminal mitochondrial localization signal (MLS). (A) Alignment of CTMP proteins fromhuman (hsCTMP, Uniprot: Q5T1C6), dog (doCTMP, Refseq:
XP_851465), mouse (mmCTMP, Uniprot: Q3UUI3), rat (raCTMP, Uniprot: Q566R0) and Xenopus (xeCTMP, Uniprot: Q6GLK2). The sequences were collected using PSI-BLAST against
the Uniprot and Refseq sequence collections at the myHits server of the SIB (myhits.isb-sib.ch). The alignment is based on ClustalW at the same server, with some manual refinement.
The arrow between positions 36 and 37 of the human protein shows the candidate cleavage site for the N-terminal mitochondrial targeting sequence predicted by TargetP (www.cbs.
dtu.dk/services/TargetP/) in the human andmouse sequences. (B) HeLa cells were transfected with a C-terminusMyc-RFP tagged CTMP, CTMP deletion mutant, or empty vector. Cells
were visualized by immunofluorescence 24 h after transfection; mitochondria were immunostained with anti-mHsp70 (mitochondrial Hsp70) mAbs visualized by a FITC coupled
anti-mouse Abs. Yellow in the third panel depicts co-localization. (C) Whole cell extract (WCE) (20 μg) of transfected HeLa cells (treated as in B), differential centrifugation-purified
mitochondria and the cytosolic compartment were analysed by SDS-PAGE and immunoblotted for myc (RFP fusion proteins) and mHsp70 (mitochondria). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
641A. Parcellier et al. / Cellular Signalling 21 (2009) 639–650cells resuspended in PBS. The nuclear chromatin was stained with
Hoechst 33342 for 30 min at 37 °C. After staining, nuclear morphology
was studied under UV light by fluorescence microscopy (Nikon E800).
Apoptotic cells were characterized by condensed and/or fragmented
nuclei. For each sample, 300 cells were examined.
3. Results
3.1. CTMP is a mitochondrial protein targeted by an N-terminal signal
sequence
Bioinformatics analysis of the CTMP amino acid sequence with
subcellular localization prediction tools [TargetP (www.cbs.dtu.dk/
services/TargetP/) iPSORT, MitoProt] identified an N-terminal mito-
chondrial localization signal (MLS) conserved in CTMP orthologues
(Fig. 1A) [29,30]. To assess the function of the human CTMP
mitochondria targeting sequence, full-length protein and deletion
mutants were C-terminally fused to the monomeric red fluorescent
protein 1 (mRFP1) and the subcellular localization of the chimeric
protein was assessed by immunocytochemistry. The staining pattern
of the full-length fusion protein overlapped with the mitochondrial
marker anti-mHsp70 (mitochondrial Hsp70) (Fig. 1B, a-f). In contrast,
a CTMP deletion mutant lacking the first 36 amino acids (36–240)
was excluded from the mitochondria and accumulated in the cytosol
and to a lower extent in the nucleus (Fig. 1B, g-i), supporting the
concept that the CTMP N-terminus is responsible for mitochondrial
targeting. Conclusive evidence was obtained by assessing the ability of
C-terminal deletion mutants of CTMP to efficiently relocate the
cytoplasmic/nuclear mRFP1 protein to the mitochondria. Both
immunocytochemistry and biochemical fractionation experiments
demonstrated that the first 20 amino acids of CTMP are sufficient to
relocate mRFP1 to the mitochondria, as measured by co-localizationwith mHsp70 staining (Fig. 1B, l-o). Moreover, Western blotting of
mitochondrial and cytosolic extracts of HeLa cells confirmed that
CTMP is a mitochondrial protein bearing a conserved and functional
MLS in the 20 first amino acids (Fig. 1C). To test whether the
subcellular localization was an artefact due to CTMP overexpression,
the presence of endogenous human CTMP in mitochondria was
assessed by immunocytochemistry and subcellular fractionation. To
this end, anti-CTMP monoclonal antibodies were generated against
the recombinant human CTMP protein. Anti-CTMP antibody 52F11
specificity was tested on different cell lines transfected with CTMP, the
deletion mutant or an empty vector (Fig. 2A) in the presence or
absence of peptide epitope (Fig. 2B). Immunocytochemistry per-
formed with the mouse monoclonal antibody 52F11 showed mito-
chondrial staining in both HeLa cells and LN229 (a glioblastoma cell
line known to express a high level of CTMP [19]) (Fig. 2C). Specificity of
the signal was confirmed by peptide competition with the 52F11
antigenic epitope peptide containing amino acids 100–118 of hCTMP
(Fig. 2C). Mitochondria from HeLa and LN229 were isolated biochemi-
cally and immunoblot analysis confirmed the integrity (cytochrome c
and mHSP70 positive) and the purity (α-tubulin negative) of the
mitochondrial fractions. Anti-CTMP immunoblotting showed that
endogenous CTMP essentially co-purified with the mitochondrial
protein marker (Fig. 2D).
Altogether, these results demonstrate that the nuclear CTMP gene
encodes a conserved mitochondrial protein targeted to the mitochon-
dria via an N-terminal signal peptide.
3.2. Mitochondria contain both membrane-bound and soluble CTMP
species
To determine the exact sub-mitochondrial localization of CTMP,
mitochondrial membranes were selectively permeabilized by
Fig. 2. CTMP is a mitochondrial protein. (A) Whole cell extracts of HEK293 cells transfected with N-terminus GFP-HA tagged hCTMP, CTMP deletion mutant, or empty vector (40 μg)
were analysed by SDS/PAGE gel and immunoblotted with monoclonal 52F11 anti-CTMP antibody or anti-HA. (B) Proteins extracted fromHeLa cells transfected with untagged hCTMP
or empty vector, and LN229 cells (50 μg) were analysed by SDS/PAGE gel and immunoblotted with monoclonal 52F11 anti-CTMP antibody in the presence or absence of peptide
epitope (0.5 mg/mL). (C) HeLa and LN229 cells were immunostained with anti-CTMP 52F11 antibody in the presence or absence of peptide epitope (0.5 mg/mL) and visualized by a
FITC-coupled secondary antibody. Mitochondria were stained with the MitoTracker Red. Yellow in the third panel depicts co-localization. (D) HeLa and LN229 whole cell extract
(WCE) (20 μg), differential centrifugation-purified mitochondria and cytosolic fractions were analysed by SDS-PAGE and immunoblotted for CTMP, Htr2A and mHsp70
(mitochondria) and α-tubulin (cytosol). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
642 A. Parcellier et al. / Cellular Signalling 21 (2009) 639–650incubating cells with increasing concentrations of digitonin [31,32].
Mitochondrial outer membrane disruption was achieved by incuba-
tion of cells in digitonin at 0.1 mg/mL, as assessed by immunodetec-
tion of cytochrome-c protein (Fig. S1). Digitonin at 0.9 mg/mL
disrupted the inner membrane (mHsp70 staining) (Fig. 3A). Myc
immunodetection of C-terminal-tagged CTMP-myc-RFP protein
fusion showed positive staining that overlapped with RFP fluores-
cence at a low digitonin concentration (0.3 mg/mL), suggesting that
the C-terminal of CTMP is accessible from the inner mitochondrial
space. To gain further insights into CTMP sub-mitochondrial
localization, mitochondria isolated from HeLa cells were fractionated
by carbonate treatment into a membrane pellet (P) and a soluble
fraction (S). Immunoblotting for CTMP showed that the endogenous
protein co-purified with both membrane-associated protein Letm1
[33] and soluble proteins of the supernatant fraction (cytochrome c
and mHsp70) (Fig. 3B). Moreover, exogenous untagged CTMP
showed the same co-purification pattern from HeLa cells (Fig. 3C).
The combined results from these experiments suggest that CTMP is
strongly associated with the mitochondrial inner membrane. Thus,
we propose the existence of two sub-mitochondrial CTMP popula-
tions: an inner mitochondrial membrane-associated pool and a free
soluble form in the inner mitochondrial space. Interestingly,
immunodetection of the overexpressed untagged CTMP revealed a
dual electrophoresis mobility pattern characterized by a slow-(27 kDa) and a fast-migrating form (25 kDa) (Fig. 3C). Only the
smaller species was detected in the mitochondrial soluble fraction,
suggesting that posttranslational modification regulates CTMP sub-
mitochondrial sorting.
3.3. Mitochondrial processing of the CTMP N-terminus
The vast majority of N-terminal MLS are matrix-targeting signals
cleaved by the mitochondrial processing peptidase [34,35]. Despite
the fact that the MPP amino acid cleavage sequence is highly
degenerate, the requirement for a positive arginine residue at
positions −2 and/or −10 from the cleavage site has been established
by several authors [36,37]. CTMP sequence analysis showed a highly
probable R-2 site at serine 35, surrounded by a hydrophobic residue
at +1 and a serine at +2 (Fig. 4A). The functionality of this putative
cleavage site was assessed by the generation of various CTMP point
mutants and determination of their electrophoretic mobilities
(Fig. 4A). Immunodetection of the CTMP m1, -m2 and -m3 mutants
showed accumulation of a single larger form (premature, 27 kDa). In
contrast, WT-CTMP and the m1 mutant were mostly detectable as
fast-migrating bands (mature, 25 kDa) (Fig. 4B). A monoclonal
antibody specific for the first 25 amino acids of the human CTMP
protein was used to further test this hypothesis. Only the m3 mutant
was detected by the 4B13 antibody, whereas the 52F11 antibody
Fig. 3. Soluble and membrane-bound CTMP species reside in the mitochondria. (A) HeLa cells transfected or not with wild-type CTMP-myc harbouring a C-Terminal RFP tag were
fixed and treated with the indicated concentrations of digitonin (0, 0.1, 0.3, 0.9 mg/mL). The overexpressed protein was detected by RFP fluorescence (red) and anti-myc antibody
(green) by confocal microscopy. The digitonin-dependent mitochondrial permeabilization was estimated by sequential immunodetection of the mitochondrial protein cytochrome-c
(inner mitochondrial space and cristae), Letm1 (inner membrane) andmHsp70 (matrix). (B) Mitochondria were extracted from HeLa cells and 20 μg of proteinwas separated by SDS/
PAGE after Triton X-100 extraction or carbonate-dependent isolation of membrane-bound protein (P) and soluble/weakly bound protein (S) and immunoblotted with the
correspondent antibodies. (C) Mitochondria extracted from HeLa cells transiently transfected with the full-length untagged CTMP were treated as in (B). (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
643A. Parcellier et al. / Cellular Signalling 21 (2009) 639–650directed against the central region of CTMP detected both the 25-kDa
and 27-kDa forms (Fig. 4C). These results suggest that most CTMP is
processed in cells by cleavage of its N-terminal region. To test
whether mutation of the CTMP cleavage site affects sorting to the
mitochondria, CTMP mutants were transfected into HeLa cells and
their subcellular localizations assessed. The m3 mutant co-purified
with the mitochondrial marker and co-localized with mitochondria
in cells (Fig. 4D, E). Together, these data demonstrate that the N
terminal portion of CTMP is cleaved in the mitochondria by theFig. 4. CTMP is N-terminally processed in the mitochondria. (A) Amino acid sequence of the
mutation series. (B) Hela cells were transfected with empty vector, untagged wild-type CTMP
immunoblotted for CTMP protein together with mHsp70 as a loading control; (p) and (m) arr
were separated by SDS/PAGE and the immunoblotted using 52F11 anti-CTMP antibody (epito
lysate, detergent-purified mitochondria (10 μg) and cytosolic compartment of HeLa cells tran
immunoblotted for CTMP and the CTMP m3 mutant. (E) HeLa cells were fixed and stained f
from three different experiments are shown. Yellow in the third panel depicts co-localization.
to the web version of this article.)mitochondrial protein peptidase to generate a mature CTMP protein
(amino acids 36–240).
3.4. CTMP is released from mitochondria into the cytosol upon apoptosis
As described above, CTMP is amitochondrial protein localized both
at the inner membrane and in the inter-membrane space of the
mitochondria (IMS). Many pro-apoptotic proteins, e.g. cytochrome c,
AIF, and Smac/Diablo, reside within the IMS and can be released intoR-2 predicted MPP cleavage site (indicated by an arrow) in human CTMP, and a point-
, or CTMP point mutants described in (A). WCE (20 μg) was separated on SDS/PAGE and
ows correspond to pre- and mature CTMP protein, respectively. (C) The extracts as in (B)
pe amino acids 100–118) or 4B13 anti-CTMP antibody (amino acids 1–25). (D)Whole cell
sfected with untagged CTMP, or CTMP point mutant m3were analysed by SDS-PAGE and
or CTMP (green) and mitochondria (red) as indicated. Representative confocal pictures
(For interpretation of the references to colour in this figure legend, the reader is referred
Fig. 5. CTMP is released into the cytosol upon apoptosis. (A) HeLa cells were treated with 2 μM actinomycin D for the indicated times and then fractionated into cytosolic (C) and
mitochondrial (M) fractions. Apoptosis was monitored by measuring PARP cleavage and decrease in pro-caspase-3. Mitochondrial HSP70 was used as a control for mitochondria
purification. (B) HeLa cells were treated with 2 μM actinomycin D for 4 and 8 h then immunostained with anti-CTMP 41G21 antibody and a FITC-coupled secondary antibody.
Mitochondria were stained with Mitotracker and cytosolic CTMP was monitored by counting at least 200 cells per time point.
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membrane [38–40]. Therefore, we investigated whether CTMP is
present in the cytoplasm after induction of apoptosis. HeLa cells were
treated with actinomycin D for 8 h and fractionated into mitochon-
drial and cytosolic samples. As assessed by PARP and caspase-3
cleavage, apoptosis occurred 4 h into the treatment. At the same time,
CTMP appeared in the cytosolic fraction and the amount of CTMP in
the mitochondrial fraction declined (Fig. 5A, B). A similar result was
obtained using etoposide as the apoptosis inducer and treatment for
24 and 48 h (Fig. S2). CTMP and cytochrome c were released with the
same kinetics, which suggests that cytosolic CTMP after cell death
induction corresponds to the free pool of CTMP from the IMS.
Moreover, after 8 h treatment with actinomycin D, approximately 50%
of CTMP remained in the mitochondria (Fig. 5B).
3.5. CTMP overexpression sensitizes cells to apoptosis
To determine whether CTMP has an effect on cell death, we first
transfected HeLa cells with a construct allowing CTMP overexpression
and induced apoptosis using actinomycin D (0.25 μM for 12 h). As
monitored by counting cells positive for Hoechst staining, CTMP
overexpression significantly increased the degree of cell death
occurring after actinomycin D treatment (Fig. 6A). Similar results
were obtained in HEK293 cells (Fig. S3A). In a stable HeLa cell linewith
a high and constant expression of CTMP (Fig. S3B), chemical-induced
cell death was assessed by monitoring mitochondrial membrane
depolarization. Apoptosis induced by actinomycin D or etoposide was
significantly higher in cells overexpressing CTMP than in control cells
transfected with the empty vector (Fig. 6B, D, E and S3C). Caspase-3
and PARP cleavage were much more efficient in cells with a high level
of CTMPwhen apoptosis was induced by actinomycin D (Fig. 6C). Thus,CTMP protein sensitizes cells to apoptosis mediated by cytotoxic
agents such as actinomycin D and etoposide.
3.6. CTMP depletion and a defect in CTMP maturation lead to apoptosis
resistance
To validate the apparent function of CTMP in apoptosis sensitiza-
tion, we generated a cell line in which CTMP was stably down-
regulated and measured apoptosis following actinomycin D treat-
ment. Tetracycline repressor-expressing HeLa cells were stably
transfected with shRNA specifically targeting CTMP (CTMP Sh) or
control shRNA (Scramble) and knock-down efficiency determined by
immunoblotting (Fig. 7B). Neither CTMP depletion nor CTMP over-
expression had any effect on cell proliferation (Fig. S4A). CTMP
depletion not only decreased actinomycin D-mediated apoptosis
twofold after 15 h treatment but also delayed apoptosis. This was
initiated after 7 h treatment in CTMP Sh cells and after 4 h in the
control cells (Fig. 7A). Moreover, non-cleaved caspase-3 was still
detectable 7 h after apoptosis induction in cells lacking CTMP butwas
depleted after only 4 h in cells transfected with scramble RNA
(Fig. 7B). This was also true for a second clone of CTMP Sh (data not
shown).
The IMS localization of CTMP could be regulated by posttranslational
modification and theN terminus of CTMP is cleaved in themitochondria
by the mitochondrial protein peptidase to generate a mature CTMP
protein (amino acids 36–240) (Fig. 4). Therefore, we investigated
whether a mutant immature CTMP protein (CTMP m3) also sensi-
tizes cells to apoptosis. Whereas maximum release of CTMP oc-
curred after 12 h actinomycin-D treatment, the mutant protein
refractory to N-terminal cleavage was only found in the mitochondrial
fraction; in contrast, cytochrome c was efficiently relocated to the
Fig. 6. CTMP sensitizes cells to apoptosis. (A) HeLa cells were transiently transfected with pcDNA3-IRES-GFP (Ctrl) or pcDNA3-GFP-IRES-CTMP (CTMP) and treated 24 h later with
0.25 μM actinomycin D for 12 h. Apoptosis was measured by Hoechst staining (3×100 cells were counted). HeLa inducible cell lines expressing CTMP (CTMP) or not (Ctrl) were
induced by tetracycline (2 μg/mL) for 5 days and then treated with 2 μM actinomycin D (B) or 100 μM etoposide (D) for the indicated times. Apoptosis was determined by measuring
the loss of mitochondrial membrane potential (Δψm) using MitoProbe™ DiIC1(5). Data are the means and standard deviations from three independent experiments. (C) α-Tubulin,
CTMP, caspase-3 and PARP cleavage were detected by immunoblotting. Caspase-3 and PARP cleavage were quantified using ImageQuant software™ (GE Healthcare). One
representative experiment of three is shown. (E) Etoposide-induced apoptosis (100 μM) was examined by phase contrast microscopy in control (Ctrl) and CTMP-overexpressing cells
(CTMP) for the indicated times.
645A. Parcellier et al. / Cellular Signalling 21 (2009) 639–650cytoplasm (Fig. 7C). Induction of apoptosis in cells stably overexpressing
CTMP m3 was delayed compared with control cells. After 4 h
actinomycin D treatment, apoptosis was twofold lower in cells over-
expressing the CTMP mutant (Fig. 7D). Caspase-3 was still present in
cells expressing the mutant CTMP but was completely lacking in the
control cells (Fig. 7E). However, the decrease in cell death mediated by
CTMP m3 was not maintained over time. Surprisingly, apoptosisincreased in these cells after 15 h (Fig. 7D) and after 24 h treatment
(data not shown). It is possible that prolonged induction of cell death
results in the complete dismantling of the mitochondria, leading to
release of the CTMPmutant protein into the cytosol, where it sensitizes
cells to apoptosis. Altogether, these results confirm that CTMP behaves
as a pro-apoptotic protein and strongly suggest that CTMP maturation
and release into the cytosol is required for its effect on cell death.
Fig. 7. CTMP depletion and a defect in CTMP maturation lead to apoptosis resistance. (A) HeLa inducible cell lines expressing scramble RNA or short-hairpin RNA targeting CTMP
(CTMP Sh) were induced by tetracycline (2 μg/mL) for 5 days and then treated with 2 μM actinomycin D for the indicated times. Apoptosis was determined by measuring loss of
mitochondrial membrane potential (Δψm) using MitoProbe™ DiIC1(5). (C) Hela cells were transfected with untagged wild-type CTMP or CTMP m3. Cells were treated with DMSO or
2 μM actinomycin D for 12 h and then fractionated into mitochondrial (M) and cytosolic fractions (C). CTMP, mHSP70 and cytochrome c were detected by immunoblotting. (D) HeLa
inducible cell lines expressing CTMP m3 or not (Ctrl) were induced by tetracycline (2 μg/mL) for 5 days and then treated with 2 μM actinomycin D for the indicated times. Apoptosis
was measured as described previously. (B and E) α-Tubulin, CTMP and caspase-3 cleavage were detected by immunoblotting. Caspase-3 cleavage was quantified using ImageQuant
software™ (GE Healthcare). One representative experiment of three is shown.
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mediated by CTMP
To investigate whether the pro-apoptotic effect of CTMP is inhibited
by blocking caspases, themain effectors of apoptosis in cells, we treated
control cells or cells overexpressing CTMP with actinomycin D in the
presence or not of the broad-spectrum caspase-inhibitor zVAD-fmk.
Control cells treated with zVAD-fmk showed negligible apoptosis
compared with cells overexpressing CTMP. In the latter, there was
no significant decrease in cell death (Fig. 8A). Moreover, caspase
inhibition did not prevent CTMP release into the cytosol after
actinomycin D-mediated apoptosis in HeLa cells (Fig. 8B, S5A). CTMP
was released with kinetics very similar to that of cytochrome c, as
observed previously (Fig. 5A). The caspase inhibitor zVAD-fmk does not
affect cytochrome c release [41–44]. Thus, caspase activation appears
not to be required for CTMP release from the mitochondria. CTMP-
mediated sensitization of apoptosis is apparently caspase independent,
although we showed that CTMP overexpression results in a marked
decrease in pro-caspase-3 in actinomycin D- or etoposide-treated cells.
We, therefore, propose a feedback mechanism inwhich cytosolic CTMP
activates further pro-apoptotic molecules that finally induce caspase
cleavage. Bcl-2 is an anti-apoptotic protein localized at the mitochon-drial membrane and able to interfere with programmed cell death by
inhibiting the release of many pro-apoptotic proteins into the cytosol
[40,45–47]. We expressed Bcl-2 transiently in control cells and in cells
overexpressingCTMPandmonitored apoptosis following actinomycinD
treatment. The Bcl-2 transfection efficiency was assessed by immuno-
blotting (Fig. S5B). The level of cell death in control cultures was higher
than in our previous experiments (Fig. 8C, left panel), most probably
because of a deleterious effect of the transfection, which conditioned
cells to death mediated by actinomycin D. With this in mind, we
measured apoptosis up to 8 h instead of 15 h. Whilst CTMP sensitized
cells to apoptosis, Bcl-2 expression almost completely inhibited
actinomycin D-induced cell death in control and CTMP-overexpressing
cultures (Fig. 8C, rightpanel).Most important, Bcl-2 transfectionblocked
CTMP release into the cytosol to the same extent as cytochrome c (Fig.
8D). This finding supports the conclusion that cell death sensitization
mediated by CTMP results from its release into the cytosol.
3.8. CTMP delays PKB phosphorylation on Ser473 occurring upon
apoptosis
CTMPwas described previously as a negative regulator of PKB [19].
However, these results were obtained using a CTMP construct flag-
Fig. 8. CTMP release and CTMP-mediated apoptosis are blocked by Bcl-2 but not by the inhibition of caspases. (A) HeLa inducible cell lines expressing CTMP (CTMP) or not (Ctrl) were
induced by tetracycline (2 μg/mL) for 5 days and then treated with 2 μM actinomycin D with or without zVAD-fmk (100 μM) for the indicated times. Apoptosis was measured using
MitoProbe™ DiIC1(5). (B) HeLa cells were treated with 2 μM actinomycin D with and without zVAD-fmk (100 μM) for the indicated times. Cytosolic extracts were analyzed by SDS-
PAGE and caspase-3, CTMP, mHSP70 and cytochrome c detected by immunoblotting. (C) HeLa inducible cell lines expressing CTMP (CTMP) or not (Ctrl) were induced by tetracycline
(2 μg/mL) for 4 days and then transfected with an empty vector or a flag-hBcl2 for 24 h in a tetracycline medium (2 μg/mL). Cells were treated with 2 μM actinomycin D for the
indicated times and apoptosis monitored as described in (A). (D) HeLa cells were transiently transfected with Flag-hBcl2 for 24 h and then treated with 2 μM actinomycin D for the
indicated times. CTMP release from mitochondria (M) into the cytosol (C) was monitored by immunoblotting. mHSP70, cytochrome c and Bcl-2 were used as controls. Data are the
means and standard deviations from three independent experiments.
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localization. The presence of such positively charged amino acids in
the N terminal region apparently facilitates protein insertion at the
plasma membrane and, therefore, its interaction with PKB. We
proposed that mitochondria-localized CTMP is released into the
cytosol, where it negatively regulates PKB activation. To test this, we
investigated whether CTMP interferes with PKB signalling during
apoptosis. PKB is considered to be an anti-apoptotic protein [48,49],
and has been reported recently to be phosphorylated and activated in
response to genotoxic stress [50]. We demonstrated that PKB is
phosphorylated transiently on Ser473 following actinomycin D (Fig. 9)
or etoposide-treatment (Fig. S7) of cells transfected with an empty
vector. Maximal phosphorylation was observed after 4 h of Actino-
mycin D treatment, with a slight decrease at 7 h. In contrast, Ser473
phosphorylation was delayed in cells overexpressing CTMP, being
barely detectable after 4 h of treatment and only strongly visible after
7 h of apoptosis induction (Fig. 9A). We also observed that PKB Thr308
was phosphorylated after actinomycin D-treatment. Overexpression
of CTMP could delay PKB Thr308 phosphorylation (Fig. S6). Impor-
tantly, there was no delay of phosphorylation in cells treated with
actinomycin-D after CTMP knock-down (Fig. 9B). In these conditions,
Ser473 phosphorylation occurred 4 h after apoptosis induction and
was slightly higher after 7 h. Thus, CTMP is able to counteract PKB
phosphorylation, as already described [19]. In cells overexpressing theCTMP mutant CTMP m3, which cannot be released into the cytosol,
Ser473 was also phosphorylated without delay after 4 h and 7 h
actinomycin D treatment (Fig. 9C), suggesting that CTMP sequestered
in the mitochondria cannot affect PKB phosphorylation on Ser473.
However, the general level of PKB phosphorylation in CTMP m3 cells
was lower than in control cells. For a reason not yet determined, cells
overexpressing the mutant CTMP did not respond to the apoptotic
stimulus with the intensity observed in the control cells. Taken
together, these results show that CTMP delays PKB phosphorylation
occurring at the onset of apoptosis. Thus, CTMP apparently sensitizes
cells to apoptosis at least in part by inhibiting PKB activity.
4. Discussion
Approximately 10–15% of nuclear-encoded genes are mitochon-
drial pre-proteins synthesized on cytosolic ribosomes and directed to
the surface of the mitochondria via their mitochondrial localization
sequences. We report here that CTMP, a previously reported inhibitor
of PKB/Akt [19], possesses themain characteristics of nuclear-encoded
mitochondrial proteins, andwe provide the first evidence that CTMP is
able to modulate apoptosis. We have shown in different cell lines that
both exogenous and endogenous CTMP reside in the mitochondria. In
silico and in vitro approaches both revealed a critical requirement for
the conserved N-terminal extension of CTMP in the proper sorting and
Fig. 9. CTMP delays PKB phosphorylation on Ser473 occurring upon induction of apoptosis. HeLa inducible cell lines expressing (A) CTMP, (B) shCTMP or (C) CTMP m3 were induced
by tetracycline (2 μg/mL) for 5 days and then treated with 2 μM actinomycin D for the indicated times. Ctrl in (A) and (C) represents cells transfected with an empty vector whereas
scramble RNA was transfected in (B). α-Tub, PKB, and Ser473 were detected by immunoblotting. Phospho-Ser473 was quantified using ImageQuant software™ (GE Healthcare).
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CTMP mutant refractory to mitochondrial membrane peptidase
cleavage appeared to be sequestered in the mitochondrial inner
membrane, suggesting that CTMP processing is similar to that
previously described for mitochondrial class 1 proteins [34]. In the
present study, we also found that CTMP is released from the
mitochondria into the cytosol following cytotoxic stimulation.
CTMP overexpression sensitizes cells to apoptosis, whereas CTMP
depletion or a defect in the CTMP maturation process lead to reduced
or delayed cell death. Cells overexpressing CTMP, when not treated
with a cytotoxic agent, do not suffer more apoptosis than control cells
(Figs. 6B, D, and 8A), i.e. CTMP has no pro-apoptotic effects per se, but
rather potentiates cell death occurring after apoptosis stimulation.
Indeed, we observed that expression of a CTMP mutant lacking the
first 36 amino acids that only resides in the cytosol does not induce
apoptosis (data not shown). Thus the CTMP effect on apoptosis is
dependent on the death stimulus applied to cells and is not only
related to CTMP subcellular localization. Therefore, CTMP is not to be
considered an inducer of apoptosis but rather as a protein able to
sensitize cells to the process. CTMP knock-out mice recently generated
in our laboratory are viable, fertile and, so far, exhibit only very subtle
changes in phenotype. Preliminary data have shown that preputial
glands from knock-out animals are significantly larger than in thewild
type (unpublished data). Furthermore, caspase-3 was cleaved less in
CTMP knock-out preputial glands. These observations confirm our
results showing that lack of CTMP decreases apoptosis and may
explain the increased size of preputial glands in knock-out animals.
These mice will be characterized in detail and CTMP apoptotic
functions studied in vivo.
The delay in PKB phosphorylation on Ser473 brought about by
CTMP after induction of apoptosis suggests that pro-apoptotic effects
of CTMP are mediated partially by PKB inhibition. CTMP was
previously reported to be a negative regulator of PKB. These data
were obtained using the Flag-CTMP construct, in which the tag wasattached to the N terminus of CTMP [19]. The epitope tag apparently
interfered with CTMP localization and prevented CTMP import into
the mitochondria. Instead, due to the presence of positively charged
amino acids in the N terminal region, the protein apparently inserted
into the plasma membrane and facilitated an interaction of CTMP
with PKB. We now propose that CTMP localized in mitochondria
under certain circumstances participates in the regulation of PKB
signalling. Upon apoptosis, CTMP is released into the cytosol, where it
appears to regulate PKB activation negatively. Further, PKB has been
shown to translocate to different subcellular compartments, includ-
ing themitochondrial outer membrane, following plasmamembrane
activation [51–53]. Although the biological significance of the
translocation of active PKB to the mitochondria is not yet clear, it
has been reported to be cell type and stimulus specific [54,55]. These
observations, combined with our results, lead us to propose a
dynamic model by which CTMP modulates PKB activity in a specific
subcellular compartment, the mitochondria or the cytosol, depend-
ing on the nature of the stimulus (survival or apoptosis). So far, we
have not recorded any interaction between PKB and CTMP under
apoptotic conditions (data not shown), which argues for an indirect
mechanism bywhich CTMP delays PKB phosphorylation and, thus, its
activation. PKB is at the crossroads of several mitochondria-mediated
cell death pathways and is considered to be a strong anti-apoptotic
protein [40,56,57]. Thus, plotting the apoptotic pathway inwhich PKB
is involved, and that may be modulated by CTMP, is worthy of future
study. Three PKB isoforms (PKBα, PKBβ and PKBγ) have been
identified in mammals that share a high degree of structural
similarity and sequence homology. It is well established that each
isoform plays a unique as well as a common role in cells [58]. Indeed,
PKB proteins have crucial functions preventing cells entering
apoptosis and there is evidence that the pro-survival effect of the
isoforms is redundant [59–61]. Whether the effect of CTMP on
apoptosis is specific or not for particular PKB isoforms needs to be
investigated further.
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signalling by CTMP. The authors claim that CTMP overexpression
induces PKB phosphorylation, leading to increased phosphorylation of
downstream substrates, promoting survival and glucose metabolism
[62].Why theyare not able to reproduce the inhibitoryeffect of CTMPon
PKB activation is not yet clear. However, similarly to what Maira and
colleagues did, they used a Flag-CTMP construct, in which the tag was
attached to the N terminus of CTMP. As already described above, the
epitope tag interferes with CTMP localization and does not allow CTMP
to be imported into themitochondria. Thus, CTMP function as a positive
regulator of PKB signaling has to be considered as an artifact and cannot
reflect the physiological role of CTMP in cells. In addition, another recent
article favoringourobservations thatCTMP is a negative regulator of PKB
showed that lentivirus-based CTMP delivery inhibits PKB activity
through selective suppression of Ser473 phosphorylation, and prevent-
ing activation of PKB substrates involved in cell cycle [63].
PKB phosphorylation on the Thr308 residue of the activation loop
and on the Ser473 residue of the hydrophobic motif are necessary
for its full activation. Phosphoinositide-dependent kinase 1 (PDK1)
phosphorylates Thr308 in the catalytic domain of PKB [64]. Recently,
PKB and PDK1 were found in a preactivation complex, which is
maintained in an inactive state through a PKB intramolecular
interaction [65]. Regulation of Ser473 phosphorylation appears to
be more complex. Several candidates were proposed to be the kinase
responsible for phosphorylation of PKB Ser473 residue including PKB
itself [66], PDK1 [67], integrin-linked kinase-1 (ILK1) [68], mitogen
activated protein kinase activated protein kinase 2 (MAPKAP-K2) [69],
protein kinase C βII (PKCβII) [70], and themembers of the PI3 K–related
protein kinase family including DNA dependent protein kinase
(DNA-PK) [71,72], Ataxia telangiectasia mutated (ATM) [73], and
mTOR complex 2 (mTORC2) [74]. Recently, interesting studies
indicate that Ser473 phosphorylation is regulated in a stimulus
specific manner. Thus, Ser473 is phosphorylated by mTORC2 under
conditions of growth and mitogen stimulation [75] and in a situation
of stress, as following DNA damage or presence of CpG DNA, we and
others have established DNA-PK as the major PKB Ser473 kinase
[50,76]. Our findings place PKB downstream of DNA-PK in the DNA
damage response signaling cascade, where it provides a pro-survival
signal, in particular by affecting transcriptional p21 regulation.
Furthermore, this function is apparently restricted to the PKBα
isoform. Moreover, in a recent study using genetically mouse models
we reported that DNA-PK phosphorylated PKB on Ser473 upon DNA
damage induced by gamma irradiation in vivo. In contrast, DNA-PK
was dispensable for insulin and growth factor-induced PKB activa-
tion. [77]. Whether the PKB phosphorylation observed in apoptotic
cells is dependent or not on DNA-PK will be further investigated.
DNA-PK distribution will be also examined in our system since it has
recently been shown that it can shuttle from the nucleus to the
cytosol upon specific treatment [78]. As well, delineating the
interplay between CTMP and Ser473 kinases would be of interest.
We have seen that Bcl2 was able to block CTMP release to the
cytosol occurring upon induction of apoptosis (Fig. 8C and D). Bcl2 is
known to be a potent anti-apoptotic protein, localized at the
mitochondrial membrane. It is the founding member of the Bcl2
family of more than 30 proteins, including both pro- and anti-
apoptotic molecules, and it has been well described that it can block
apoptosis induced by various stimuli [79]. Interestingly, PKB has been
reported to directly modulate Bcl2 pro-apoptotic members and
therefore, PKB has been considered to be at the intersection of
mitochondria-mediated cell death pathways [80–84]. The mechanism
by which Bcl2 prevents CTMP to be release to the cytosol has not been
yet investigated. It might be similar to the one inhibiting cytochrome c
to get out of the mitochondria. Cytochrome c is retained in the cristae
of the mitochondrial matrix and is considered to be a key molecule in
programmed cell death [85]. Its release into the cytosol has been
shown to be controlled by the pro-fusion protein OPA1 (optic atrophyprotein 1), which ensures that cytochrome c is sequestered into the
mitochondria by maintaining the integrity of the cristae junctions
[86,87]. We have observed that cytochrome c release into the cytosol
occurs slightly earlier in cells overexpressing CTMP and treated with
actinomycin D (unpublished data).
Since CTMP and cytochrome c release are almost concomitant, a
positive feedback loop in which CTMP would indirectly target the
mitochondria to liberate cytochrome c in the cytosol is very unlikely.
However, we can speculate a role of CTMP in regulating mitochondrial
dynamics. It has been shown that initiation of cell death triggered by
cytochrome c release could be coordinated by “mitochondrial-
shaping” proteins [88–90]. Among them, both pro-fission dynamin-
related protein 1 (Drp1) and OPA1 have been described frequently as
proteins involved in apoptosis [86,87]. Indeed, upon the induction of
cell death the tubular and branched mitochondrial network under-
goes remodelling, leading to its complete fragmentation [91,92]. Drp1
overexpression modulates mitochondrial dynamics and increases
susceptibility to various apoptotic stimuli, whereas its cellular
depletion shows protective effects [93]. Therefore, an imbalanced
fusion/fission process is believed to disrupt the submitochondrial
compartmentalization of many proteins needed to maintain mito-
chondria homeostasis, thus leading to apoptosis [40]. It is possible that
CTMPmediates its effect bymodulating the activity of some regulators
of mitochondrial dynamics. Further experiments addressing the
biological activity of CTMP are required [94].
To conclude, we have shown here for the first time that CTMP is a
mitochondrial protein, localized both at the inner membrane and in
the inner membrane space. CTMP is processed to get mature and
released to the cytosol upon cell death stimulation. Cytosolic CTMP
sensitizes cells to apoptosis, presumably by delaying PKB phosphor-
ylation on Ser473 occurring in response to death signals. Delineating
the mechanisms by which CTMP gets out of the mitochondria and
positively modulates apoptosis needs further efforts, and these
mechanisms are still under investigation.
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Cellular homeostasis depends upon the strict regulation of responses to external stimuli, such as signalling cascades triggered by nutrients and
growth factors, and upon cellular metabolism. One of the major molecules coordinating complex signalling pathways is protein kinase B (PKB), a
serine/threonine kinase also known as Akt. The number of substrates known to be phosphorylated by PKB and its interacting partners, as well as
our broad understanding of how PKB is implicated in responses to growth factors, metabolic pathways, proliferation, and cell death via apoptosis
is constantly increasing. Activated by the insulin/growth factor-phosphatidylinositol 3-kinase (PI3K) cascade, PKB triggers events that promote
cell survival and prevent apoptosis. It is also now widely accepted that mitochondria are not just suppliers of ATP, but that they participate in
regulatory and signalling events, responding to multiple physiological inputs and genetic stresses, and regulate both cell proliferation and death.
Thus, mitochondria are recognized as important players in apoptotic events and it is logical to predict some form of interplay with PKB. In this
review, we will summarize mechanisms by which PKB mediates its anti-apoptotic activities in cells and survey recent developments in
understanding mitochondrial dynamics and their role during apoptosis.
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After the p53 pathway, the PI3K–PTEN–PKB/Akt signal-
ling pathway is one of the most mutated pathways associated
with cancer [1,2]. Together they may be seen as a network
regulating cell responses to external stimuli and metabolic
processes. Once activated, PI3K mediates conversion of PIP2
(phosphatidylinositol (4,5)-bisphosphate) into PIP3 (phospha-
tidylinositol (3,4,5)-trisphosphate), leading to the recruitment of
downstream targets to the cell membrane and their subsequent
activation [3]. PKB, a serine/threonine kinase also known as
Akt, is recognized to be a primary mediator of the downstream
effects of PI3K, coordinating a variety of intracellular signals
and, thus, controlling cell responses to extrinsic stimuli and
regulating cell proliferation and survival [4,5]. Under normal
physiological conditions, PKB is activated by growth factors,
insulin, and DNA damage, and is translocated from the cell
membrane to its target genes, supporting the complex regulatory
network [6,7].
Activated PKB is localized to various subcellular compart-
ments, including the Golgi, endoplasmic reticulum, mitochon-
dria and nucleus [8], where it phosphorylates substrates or
interacts with other molecules. PKB effects on the regulation of
cell proliferation are mediated by multiple effectors. For
example, anti-apoptotic activity is resolved through the
inactivation of many pro-apoptotic factors. In contrast to the
p53 pathway, which is silenced in cancer cells, the PI3K–
PTEN–PKB/Akt pathway is activated in many tumours as a
result of upstream mutations in PI3K [9–12] or PTEN
(phosphatase and tensin homologue mutated in multiple
advanced cancer) [1,13], or of the amplification/overexpres-
sion/mutation of PKB isoforms themselves [10,14–19]. Con-
sequently, the constitutive activation of PKB contributes greatly
to aberrant cell cycle regulation, a hallmark of many cancers,
resulting in uncontrolled cell proliferation and suppressed
apoptotic pathways [20–24].
Mitochondria are now recognized as important players in
apoptotic events. About two billion years ago, after the
incorporation of purple eubacteria and the formation of a
symbiotic relationship, cells acquired the ability to survive in a
new environment, utilizing aerobic metabolism [25,26]. As a
key node in oxidative metabolism in eukaryotes, mitochondria
supply the majority of cellular energy, sustaining viability and
normal cell functions. It is now widely accepted that
mitochondria are not solely ATP suppliers but participate in
regulatory and signalling events, responding to multiple
physiological inputs and genetic stresses and regulating cell
proliferation and death. They sense and integrate signals fromtranslocated proteins and Ca2+ fluxes, and transmit them to
oxidative stress and other metabolic pathways [27]. Mitochon-
dria have been shown to be dynamic tubular networks that
constantly undergo fusion and fission in response to local
environmental changes, with associated changes in morphology.
Following pro-apoptotic stimulation leading to permeabilization
of the outer mitochondrial membrane (OMM), numerous
proteins are released from the mitochondria to the cytosol,
where they act either by activating caspases in the cytosol or by
stimulating endonuclease activity in the nucleus. In addition to
OMM permeabilization, it has also been reported that the
remodelling of cristae occurs early in the apoptotic process,
favouring the release of cytochrome c. It was suggested recently
that proteins known to regulate mitochondrial fusion in yeast
[28] are regulators of cristae remodelling [29,30]. This
connection between mitochondrial morphology, cristae remo-
delling and apoptotic events still remains to be clarified, but a
place for mitochondria in the constellation of intracellular
pathways cannot be excluded.
Several excellent reviews have discussed the role of PKB in
the development of a variety of metabolic diseases and cancer
[11,31] or the substrate specificity of PKB [32]. Many reviews
have also described the role of mitochondria in metabolic
disorders and apoptotic processes. Here we focus on the role of
PKB in apoptosis, accentuating its networking with the
mitochondria in the regulation and inter-connection of meta-
bolic pathways and cell survival.
2. PKB and mitochondria: inter-connection in cell survival
Of its various cellular functions, there is extensive evidence
that PKB plays a central role in regulating growth factor-
mediated cell survival and blocking cell death [22]. For
example, transgenic mice that constitutively express active
PKBα in mammary glands show a delay in mammary gland
involution due to the inhibition of cell death [33]. PKB has also
been shown to exert a neuroprotective effect against brain
damage in genetically modified mice expressing an active form
of PKB in neuronal cells [34]. Cell death is critical for the
organization of cells and tissues in the body. In animals, the
physiological mechanism of cell death is an active and gene-
regulated process [35]. Apoptosis deregulation is involved in
the pathogenesis of various diseases and, thus, strict control of
the apoptotic machinery is required [36]. Moreover, apoptosis is
one of the principal cell death mechanisms triggered by
cytotoxic drugs in tumour cells [37] and novel apoptosis-
targeted therapies are now advancing from pre-clinical and
clinical trials to clinical application [38,39].
Fig. 1. Direct modulation of apoptosis by PKB. Mitochondria play a pivotal role in apoptosis regulation, acting as a central cell executioner by releasing various pro-
apoptotic molecules (cytochrome c, Htra2/Omi, AIF) from their intermembrane space into the cytosol. At the pre-mitochondrial level, the anti-apoptotic HSP27 and
HSP90 proteins stimulate and protect PKB activation, reinforcing PKB effects on cell death, for example by inhibiting the SAPK pathway. The Bcl-2 family of proteins
may represent a critical checkpoint in the mitochondrial intrinsic pathway of apoptosis and its members control cytochrome c release to the cytosol. By
phosphorylating the pro-apoptotic molecule Bad, PKB induces its association with 14-3-3 proteins in the cytosol and thus contributes to the inhibition of Bad cell death
functions. PKB also phosphorylates another pro-apoptotic member of the Bcl-2 family, Bax. Phosphorylated Bax promotes heterodimerization with Mcl-1 and Bcl-XL,
leading to abrogation of Bax activity. Moreover, PKB has been found to phosphorylate and negatively regulate the Mcl-1 inhibitor, GSK-3. PKB is also inhibits Bax
functions by directly interfering with the interaction of Bax with Bid or Bif-1. Cytochrome c release can also be blocked by binding of PKB to hexokinases, thus
inhibiting apoptosis-associated hexokinase detachment from mitochondria. Htra2/Omi and AIF, two further mitochondrial proteins released into the cytosol upon
apoptosis, can be inhibited by PKB phosphorylation or PKB interaction, respectively. At the post-mitochondrial level, PKB may phosphorylate and inactivate caspase-
9, resulting in the abolition of the caspase cascade. PKB can also move to the nucleus, where it inhibits DNA fragmentation and condensation by effects on CAD and
acinus, respectively.
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are the extrinsic and the intrinsic pathways. The extrinsic or death
receptor-mediated pathway plays a major role in, for example, the
immune system (for more information, see reviews [40,41]). The
intrinsic pathway, also called the mitochondrial-dependent path-
way, is activated in response to extracellular or intracellular insults
such as DNA damage. The first evidence for the involvement of
mitochondria in apoptosis was obtained 15 years ago, when
Stanley Korsmeyer's lab showed that the Bcl-2 protein, which was
already known to be an anti-apoptotic protein, was localized at the
mitochondrial membrane and was able to interfere with
programmed cell death. It is now widely accepted that mitochon-
dria play a pivotal role in the regulation of apoptosis. These
organelles are not only required for ATP production, but also act as
a central cell “executioner” by releasing various pro-apoptotic
molecules from their intermembrane space into the cytosol [42].
Pioneering biochemical fractionation and reconstitution studies byWang and collaborators have shed light on this pathway [43,44].
Cytochrome c, a well-known component of the mitochondrial
respiratory chain, appears to be the key protein of the programmed
cell death process [45]. The mechanism of cytochrome c release
has been the subject of intense investigations and different models
have been proposed. Recent studies propose a two-step release in
which the cytochrome c is first detached from the mitochondrial
inner membrane, and then extruded upon permeabilization of the
outer membrane [46]. Once in the cytosol, cytochrome c interacts
with its adaptor molecule Apaf-1 (apoptotic protease activation
factor-1), thereby triggering the ATP/dATP-dependent oligomer-
ization of Apaf-1 [43,47]. Oligomerized Apaf-1 binds to pro-
caspase-9, leading to the formation of the caspase-9 activation
complex, the so-called apoptosome [48]. In turn, activated caspase-
9 triggers proteolytic maturation of pro-caspase-3 and -7
responsible for the cleavage of several proteins, and this finally
leads to the biological and morphological features characteristic of
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(apoptosis inducing factor), Smac/Diablo (second mitochondria-
derived activator of caspases/direct inhibitor of apoptosis-binding
proteinwith a low isolelectric point),HtrA2/Omi (high temperature
requirement protein), and the endonuclease G are also released
from the mitochondrial intermembrane space into the cytosol, and
trigger apoptosis. However, the modes of action of these proteins
are completely different to that of cytochrome c. For example, the
flavoprotein AIF and the endonuclease G operate through a
caspase-independent pathway. They participate in chromatin
condensation and DNA fragmentation in mammalian cells,
respectively [50–53]. On the other hand, Smac/Diablo and
HtrA2/Omi both activate apoptosis by neutralizing the inhibitory
activity of the IAPs (inhibitory apoptotic proteins) that associate
with and inhibit caspases [54]. Thus, the permeabilization of the
mitochondrial outer membrane, allowing the release of intermem-
brane space proteins, appears to be the key step in the apoptotic
process. Currentmodels explainingmitochondrial outermembrane
permeabilization include: (1) the induction of mitochondrial
permeability transition [55,56], (2) the modulation of ions fluxes
and hypotonicity [57], (3) a caspases feed-back loop [58] and
specific caspase-2 engagement to themitochondria [59,60], and (4)
the involvement of Bcl-2 family proteins [61,62]. Presumably,
these mechanisms are dependent on cell type and the nature of the
stimulus.
Like PKB, the Bcl-2 protein has also been shown to play a
role in cancer progression. Bcl-2 was originally cloned from the
t(14;18) translocation breakpoint found in follicular B-cell
lymphomas [63]. However, in contrast to PKB, Bcl-2 does not
promote cell proliferation but rather blocks cell death induced by
various stimuli [64]. Bcl-2 is the founding member of the Bcl-2
family of more than 30 proteins, including both pro- and anti-
apoptotic molecules. Three main subgroups of these proteins
have been defined, in part by structural homologies: (1) Bcl-2-
like survival factors (e.g. Bcl-2, Bcl-XL, Mcl-1), (2) Bax-like
death factors (e.g. Bax, Bak), (3) BH3-only death factors (e.g.
Bid, Bad) [57]. Members of this family are critical checkpoints
in the intrinsic pathway of apoptosis. It has been proposed that
Bcl-2-related proteins act as a “rheostat” regulating sensitivity of
cells to apoptosis. In this scenario, the mitochondrion appears to
be a central, important integrator of Bcl-2 protein activities.
Thus, cell fate depends on the balance between anti- and pro-
apoptotic members of the Bcl-2 family [65,66].
PKB is able to directly or indirectly modulate apoptosis
[21,67]. The direct effects are connected to phosphorylation
events or interactions with cell death actors (Fig. 1), whereas the
indirect regulation of apoptosis is mediated rather through the
transcriptional responses to apoptotic stimuli (Fig. 2). In both
cases, PKB is at the crossroads of several mitochondria-
mediated cell death pathways and is, thus, an important target
for cancer therapy [68,69].
2.1. Direct modulation of apoptosis mediated by PKB
2.1.1. Bcl-2 pro-apoptotic members
Bad, as the first PKB target involved in apoptosis to be
identified (in 1997) [70,71] is a pro-apoptotic member of theBcl-2 family of proteins that binds Bcl-2 or Bcl-XL. In this way,
Bad blocks their anti-apoptotic properties. However, phosphor-
ylation of Bad on Ser136 by PKB releases it from the complex
with Bcl-2/Bcl-XL that is localized on the mitochondrial
membrane and subsequently promotes its association with 14-
3-3 proteins in the cytosol. Thus, by phosphorylating Bad, PKB
inhibits its cell death functions [72].
Bax is a further pro-apoptotic member of the Bcl-2 family that
is regulated by the PKB signalling pathway. The Bax protein
residesmainly in the cytosol of healthy cells, but apoptotic stimuli
induce a conformational change that exposes its N- andC-termini.
This new Bax folding appears to be required for its insertion into
mitochondrial membranes [73], where it forms oligomers causing
cytochrome c release and apoptotic cell death. Overexpression of
active PKB suppresses the relocalization of Bax to mitochondria,
and PKB also inhibits the Bax conformational change, preventing
disruption of the mitochondrial membrane potential and caspase-
3 activation [74]. The mechanism by which PKB suppresses Bax
oligomerization was first reported in two papers published in
2004 and 2005 [75,76]. Both showed that PKB phosphorylates
Bax on Ser184. The phosphorylated form of Bax is found
predominantly in the cytosol where it promotes heterodimeriza-
tion withMcl-1 and Bcl-XL. PKB is the physiological Bax kinase
responsible for abrogation of its pro-apoptotic activities. An
alternative explanation is that PKB directly interferes with the
interaction of Bax with Bid or Bif-1, both of which contribute to
Bax conformational changes [77].
2.1.2. AIF
The apoptosis inducing factor (AIF) is normally confined to
the mitochondrial intermembrane space and is released into the
cytosol upon induction of apoptosis, depending on the cell type
and the nature of the stimulus [78]. Once in the cytosol, mature
AIF translocates to the nucleus, where it induces chromatin
condensation and high-molecular-weight (50-kb) DNA frag-
mentation [79]. Recently, it has been shown that an active form
of PKB blocks ceramide-induced neuronal apoptosis through
inhibition of AIF translocation to the nucleus [80]. However,
ceramide treatment has also been reported to induce PKB
dephosphorylation [81]. The mechanism by which PKB
mediates the inhibition of AIF inhibition needs further investi-
gation but AIF can now be considered to be a promising novel
PKB target.
2.1.3. Htra2/Omi
Htra2/Omi is a serine protease synthesized as a precursor and
localized in the mitochondria [82]. Following apoptotic stimuli,
the N-terminal part of Htra2/Omi is cleaved and the protein is
released to the cytosol, where it induces apoptosis by inhibiting
IAPs (inhibitors of apoptosis) [83,84]. A recent report showed
that PKBα and PKBβ phosphorylate mitochondria-released
Htra2/Omi on Ser212 in vitro and in vivo [85]. This results in
attenuation of Htra2/Omi serine protease activity and decreases
its pro-apoptotic functions. The phosphorylated form of Htra2/
Omi still interferes with but fails to cleave XIAP. PKB may also
inhibit Htra2/Omi release from mitochondria to the cytosol in
response to cisplatin treatment.
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Caspase-9 acts as an initiator of the apoptotic process as part
of the apoptosome complex. It has been reported that PKB
directly phosphorylates human caspase-9 on Ser196, resulting
in its inactivation [86]. However, the phosphorylation site found
in human caspase-9 is not conserved and is not present in other
mammalian species such as mouse, rat and monkey [87]. Thus,
the role of PKB in caspase-9 regulation remains to be clarified.
2.1.5. DNA fragmentation factor (DFF40/CAD)
A caspase-activated DNAse, DFF40/CAD, has been shown to
have a major role in DNA fragmentation, which along with
condensation is a further hallmark of apoptosis. DFF40/CAD
resides in the nucleus as a complex with its specific inhibitor
DFF45/ICAD. Apoptotic activation of caspase −3 and −7 results
in DFF45/ICAD cleavage, leading to active DFF40/CAD nuclease
release [88]. Ebp1, a ubiquitous protein of the cytosol and nucleus,
has been identified recently as a factor contributing to the inhibition
of DNA fragmentation by DFF40/CAD. PKC-dependent phos-
phorylation of Ebp1 has been reported to stimulate its binding to
phosphorylated nuclear PKB in nerve growth factor-treated PC12
cells. The resulting complex interacted with DFF40/CAD,
inhibiting its DNA fragmentation activity and enhancing Ebp1
anti-apoptotic activity. Thus, PKB contributes to the suppression of
apoptosis through an interaction with Ebp1 [89]. However, this
effect appears to be independent of PKB kinase activity.
2.1.6. Acinus
Acinus is a nuclear pro-apoptotic protein activated by caspase
cleavage and involved in chromatin condensation [90]. Recently,
it was shown that PKB phosphorylation of acinus on Ser422 and
Ser573 leads to resistance of acinus to caspase cleavage and
inhibition of chromatin condensation [91]. Moreover, abolishing
phosphorylation of acinus by PKB through mutagenesis,
accelerated its proteolytic degradation and also chromatin
condensation. Thus, PKB may promote cell survival by blocking
acinus nuclear apoptotic effects.
2.1.7. The SAPK pathway
Activation of the stress-activated protein kinase (SAPK)
pathway is thought to trigger mitochondria-dependent apoptosis
in response to many types of stress. SAPK is composed of two
groups of kinases, JNK and p38 MAP kinase. PKB was
reported to phosphorylate three kinases upstream of SAPK,
namely ASK1, MLK3 and SEK1/MKKK4. PKB phosphor-
ylates ASK1 on Ser83 [92], MLK3 on Ser674 [93] and SEK1/
MKKK4 on Ser78 [94]. Phosphorylation results in the
inactivation of these three proteins and promotes cell survival.
2.1.8. Heat-shock proteins
The ubiquitous and highly conserved stress- or heat-shock
proteins (HSPs) are induced in response to a wide variety of
physiological and environmental insults and allow the cells to
survive otherwise lethal conditions [95]. Various mechanisms
have been proposed to account for the cytoprotective functions of
HSPs: (1) by assisting the correct folding of stress-accumulated
misfolded proteins and preventing their aggregation, (2) byinteracting with components of the apoptotic machinery, and (3)
by interfering with the proteasome-mediated degradation of
selected proteins under stress conditions [96]. The HSP family of
proteins comprises several members but only two have been
convincingly reported to play a role in PKB-mediated cell
survival [97,98]. HSP90 has been shown to form a complex with
PKB in vivo. By binding to PKB, HSP90 inhibits the
dephosphorylation of PKB mediated by protein phosphatase 2A
and its sustained activation prevents cell death. HSP27, a small
heat-shock protein found to inhibit apoptosis by binding
cytochrome c released into the cytosol, has been described as a
PKB activator during various forms of stress [99]. In cells
subjected to oxidative stress, PKB is activated gradually and the
association with HSP27 concomitantly increases. In a recent
report, prevention of PKB/HSP27 interaction by anti-HSP27
antibody treatment resulted in inhibition of PKB phosphorylation
on Ser473 and induction of apoptosis [100]. Moreover, it was
shown that HSP27 contributes to the protection of L929 mouse
cells from cisplatin-induced apoptosis by enhancing PKB
activation [101].
2.1.9. GSK-3
The glycogen synthase kinase 3 (GSK-3) has two isoforms,
GSK-3α and GSK-3β, that are inactivated upon phosphorylation
by PKB on Ser21 and Ser9, respectively [102]. Inhibition of
GSK-3 has been found to protect against apoptosis in many
circumstances [103], although themolecular basis for this was not
clearly understood until recently. In 2006, Green and co-workers
showed that GSK-3 induces apoptosis upon interleukin-3
withdrawal by stimulating phosphorylation of the anti-apoptotic
member of the Bcl-2 family, Mcl-1. As a consequence,
ubiquitination of the phosphorylated Mcl-1 was increased,
leading to its degradation by the proteasome and facilitating
cytochrome c release and apoptosis [104]. This clearly demon-
strates the crucial need for PKB regulation, since PKB negatively
regulates GSK-3 activation and, therefore, Mcl-1 stability.
2.1.10. Hexokinases
Cell survival and energy metabolism are closely linked and
PKB appears to be a common mediator of both metabolic and
anti-apoptotic effects of growth factors. Similarly to Bcl-2,
activated PKB is able to maintain mitochondrial integrity by
inhibiting cytochrome c release in mammalian cells [105].
However, unlike Bcl-2, PKB requires the availability of glucose
for these effects [106,107]. These observations led to
investigations of the role of mitochondrial hexokinases as
mediators of PKB anti-apoptotic properties. Hexokinases have a
crucial function in the cellular uptake and utilization of glucose.
They control the first step of glucose metabolism by catalysing
ATP-dependent phosphorylation of glucose to glucose-6-
phosphate [108]. Two hexokinase isoforms, HKI and HKII,
have been shown to specifically bind to the outer mitochondrial
membrane (OMM) at mitochondrial contact sites [109]. Several
reports present mitochondrial hexokinases as downstream
effectors of growth factor- and PKB-mediated cell survival.
PKB is able to block apoptosis-associated hexokinase detachment
from mitochondria [106] and, thus, PKB/hexokinase interaction
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confirmed by the finding that HKI and HKII canmimic the ability
of PKB to inhibit apoptosis [110]. Moreover, like PKB,
mitochondrial hexokinases require glucose for promoting cell
survival and hexokinase association with mitochondria correlates
with PKB ability to maintain OMM integrity [77,111]. Lastly, the
disruption of hexokinase/mitochondria interaction impairs anti-
apoptotic and mitochondrial integrity-promoting functions of
PKB [110]. It would appear that themetabolic regulatory function
of PKB has evolved into an adaptive sensing system involving
mitochondrial hexokinases and a coupling metabolism to cell
survival [112].
2.2. Indirect modulation of apoptosis mediated by PKB
The control of apoptosis execution mediated by PKB also
involves changes in the transcription programme. By regulating
transcriptional factors responsible for the expression of pro- or
anti-apoptotic molecules, PKB also plays a crucial role in
determining cell fate (Fig. 2).
2.2.1. Forkhead family members
It has been shown that PKB is able to directly phosphorylate
Forkhead protein (FoxO) isoforms (FKHR/FoxO1, FoxO2,
FKHRL1/FoxO3 and AFX/FoxO4) and in this way it is res-
ponsible for their nuclear exclusion and inactivation [113,114].
FoxO target genes are important for inhibition of cell survival
and the promotion of apoptosis. For example, FoxO proteins
regulate expression of Bcl-2 family members such as Bim (Bcl-
2 interacting mediator of cell death) or Bcl-6 [115].
2.2.2. Murine double minute 2 (Mdm2)
Mdm2 is an E3 ubiquitin ligase whose expression is induced
by p53. As a feed-back loop, Mdm2 then controls intracellularFig. 2. Indirect modulation of apoptosis. The mediation of apoptosis execution by PK
factors responsible for the expression of pro- or anti-apoptotic molecules, PKB also
activates CREB after its phosphorylation, resulting in the upregulation of anti-apopt
PKB induces I-κBα phosphorylation. Thus, NF-κB is activated and induces expressi
stabilizes Mdm2 and increases Mdm2 ubiquitin ligase activity, leading to a decrease
inhibited by PKB; p73 co-activator YAP is phosphorylated by PKB, after which it int
As a consequence, p73 cannot activate target genes like Bax.levels of the tumour suppressor p53. p53 is a major regulator of
cell death and is commonly inhibited under conditions in which
the PKB pathway is activated [116]. It has been reported that
PKB binds to and phosphorylates Mdm2, allowing its nuclear
import and increasing its ubiquitin ligase activity [117,118].
More recently, Feng et al. showed that PKB is able to inhibit
Mdm2 self-ubiquitination via phosphorylation of Mdm2 on
Ser166 and Ser188. Introduction of a constitutively active form
of PKB into cells induces Mdm2 phosphorylation on these
specific residues and leads to stabilization of the Mdm2 protein.
This strongly suggests that PKB controls the Mdm2/p53
signalling pathway by decreasing Mdm2 proteasomal degrada-
tion [119].
2.2.3. NF-κB
It is well known that control of the inflammatory response
and apoptosis are closely linked to NF-κB activation. Dereg-
ulation of NF-κB activity can lead to the development of
diseases such as autoimmune diseases or cancer [120]. Most of
the time, NF-κB is activated after degradation of its inhibitor, I-
κBα. Firstly, I-κB kinase (IKK) is phosphorylated and activated
and in turn mediates I-κBα phosphorylation, leading to its
degradation by the ubiquitin/proteasome system. Thus, NF-κB
is free and translocates to the nucleus where it activates pro-
survival genes including Bcl-XL, caspases inhibitors [121] and
c-Myb [122]. PKB has been shown to regulate IKK activity by
phosphorylating IKK at the Thr23 residue. This activates IKK,
which then targets I-κBα for proteasomal degradation [61,123].
2.2.4. Cyclic AMP-response element-binding protein (CREB)
There are several reports that CREB transcription factors are
required for the survival of certain cell types [124]. It has been
shown that PKB phosphorylates CREB on Ser133, leading to
CREB activation and the promotion of cell survival throughB also involves changes in the transcription program. By regulating transcription
plays a crucial role in cell fate. PKB phosphorylates and inhibits FoxO and also
otic Bcl-2 family members. Moreover, by phosphorylating and activating IKK,
on of Bcl-2 anti-apoptotic proteins. On the other hand, phosphorylation by PKB
in p53 transcriptional activity. Transcriptional activity of p73 is also indirectly
eracts with 14-3-3 proteins in the cytosol and is then no longer able to bind p73.
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has been demonstrated also that PKB contributes to the
activation of the anti-apoptotic Mcl-1 through a transcription
factor complex containing CREB [126]. Moreover, enhanced
CREB activity mediated by PKB has been reported to increase
Bcl-2 promoter activity and, therefore, to inhibit apoptosis
[127]. Finally, CREB phosphorylation and activation by PKB is
also responsible for an increase in PKB expression, thus
reinforcing PKB anti-apoptotic functions [128].
2.2.5. Yes-associated protein (YAP)
YAP protein has been identified recently as a new PKB
substrate [129]. YAP is phosphorylated on Ser127 by PKB,
after which it binds to 14-3-3 proteins within the cytoplasm.
Consequently, YAP is no longer localized in the nucleus and
cannot function as a co-activator of transcription factors,
including p73. Thus, PKB suppresses YAP ability to promote
p73-mediated transcription of pro-apoptotic genes like Bax.
2.3. PKB isoform redundancy during apoptosis
Three PKB isoforms (PKBα, PKBβ and PKBγ) have been
identified in mammals. They share a high degree of structural
similarity and sequence homology. It is well established that
each isoform plays a unique as well as a common role in cells
[130]. PKBα knock-out mice are growth retarded, PKBβ
knock-out mice develop diabetes-like syndrome, and PKBγ
knock-out mice show reduced brain size [131]. PKB proteins
have crucial functions in preventing cells from apoptosis and
there is evidence that the pro-survival effect of the PKB
isoforms is redundant. For example, PKBα and PKBβ seem to
be dispensable for cell survival in isolated osteoclast precursors,
probably because of the redundant function of PKBγ [132]. It
has been shown also that PKBα and PKBβ are both able to
phosphorylate and inactivate the pro-apoptotic Htra2/Omi [85],
suggesting that the two proteins share common functions
regulating apoptosis. Moreover, in a recent study PKBα/PKBβ
double knock-out mouse embryonic fibroblasts (MEF PKBα/
PKBβ DKO) were viable until 80% of PKBγ was depleted
using siRNA technology [133]. By reintroducing PKBα or
PKBγ into MEF (PKBα/PKBβ DKO), the authors were able to
counteract the apoptotic effects observed in this cell line under
normal or stressed conditions. This suggests that only a small
proportion of active PKB is needed to block apoptosis, although
cells under stress require more PKB to survive. Another exam-
ple of PKB isoform redundancy has been described recently in
Caenorhabditis elegans [134], when it was shown that both
PKBα and PKBβ negatively regulate DNA-damage-induced
apoptosis.
3. New insight into apoptosis: initiation and further
directions
Recent reports that the initiation of apoptosis triggered by
cytochrome c release is coordinated by a class of signalling
proteins initially identified as “mitochondrial-shaping” proteins
strengthens the notion that the same set of signalling proteinsregulates antagonist functions within mitochondria [135–137].
This was originally illustrated in C. elegans, where the anti-
apoptotic Bcl-2 family member CED-9 (Bcl-XL in mammals)
and its antagonist the BH3-only protein egl1 (Bak/Bax) were
shown to regulate mitochondrial shape in cells targeted to die as
well as in healthy cells [138,139]. Among the growing network
of signalling molecules, including GTPases, E3 ligases, AAA
proteases and phosphatases, involved in mitochondria biogen-
esis in mammals, both pro-fission dynamin-related protein 1
(Drp1/DNM1) and pro-fusion optic atrophy protein 1 (OPA1/
mitochondrial genome maintenance 1Mgm1 in yeast) have been
consistently shown to participate in apoptosis. Indeed, upon
apoptosis induction, the tubular and branched mitochondrial
network undergoes intensive remodelling, resulting in its
complete fragmentation [139,140]. The two GTPases Drp1
and OPA1 are central regulators of fission/fusion-dependent
mitochondrial dynamics. The dynamin-related protein member
OPA1, located at the inner membrane and mutated in dominant
optic atrophy, together with the integral outermembrane
(OMM) mitofusins 1 and 2 [Mfn1/FZO1(Fuzzy ognon 1),
Mfn2/FZO2] independently coordinate fusion and tethering of
the mitochondria, respectively. Conversely, the cytosolic dyna-
min-related protein 1 Drp1 functions in association with its
recruiting partner of the OMM, the Fis1 protein (Fis1p/FIS1).
Modulation of mitochondrial dynamics concomitantly with
overexpression of pro-fission protein hFis1 or Drp1 is linked to
increased susceptibility to various apoptotic stimuli. On the other
hand, promotion ofmitochondrial network fusion byDrp1mutant
Drp1K38A or cellular depletion of the pro-fission protein has
been shown to have a protective effect [140,141]. Indeed, effects
on mitochondrial structure by imbalanced fusion/fission may
disrupt the sub-mitochondrial compartmentalization of the very
different enzymatic activities needed to maintain mitochondria
homeostasis and, thus, lead to apoptosis as a secondary indirect
event. Indeed, extensive use of transmitted electron microscopy
and tomography has shed some light on this issue by demon-
strating the prime involvement of internal mitochondria remodel-
ling in apoptosis initiation and regulation.
In fact, most of the mitochondrial pool of cytochrome c (80–
85%) is retained in the cristae of the mitochondria matrix, where
tight juxtaposition of the membrane prevents its release into the
IMS, which is considered to be the upstream event preceding
apoptotic-dependant release of cytochrome c (and other factors
discussed above) from the mitochondria [142,143]. Sequestration
of cytochrome c in the cristae is ensured by the ability of both
IMM integral and IMS soluble OPA1 protein to oligomerize and
maintain the integrity of the cristae junctions [30]. A recent major
breakthrough was the demonstration by Cipolat and co-workers
that the rhomboid protease PARL regulates cytochrome c release
via OPA1-dependent processing [29]. Targeted inactivation of the
PARL gene in mouse leads to severe growth retardation and
cachexia, presumably caused by increased apoptosis, leading to
animal death (8–12 weeks after birth) [30]. Moreover, PARL−/−
cells show hypersensitivity to intrinsic apoptotic stimuli (as
demonstrated by increased kinetics of cytochrome c release)
correlated to the absence of OPA1 oligomers, despite exhibiting
normal mitochondrial morphology and dynamics [29,30]. Thus,
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which is restricted to the IMS, is sufficient to restore a normal
apoptotic response in these cells.
In summary, the involvement of mitochondrial-shaping
proteins in the regulation of apoptosis should be examined
carefully as changes in the complex double-membrane ultra-
structure of the mitochondria may have collateral effects that are
not necessarily a part of the apoptotic process. As illustrated by
the involvement of OPA1 and Drp1 protein in mitochondrial
cristae remodelling, the integration and amplification of the
cytosolic signals into a complex and multi-step intra-mitochon-
drial signalling pathway appears central to the initiation of
apoptosis. In this context, research over the next few years should
increase our mechanistic understanding of the spatial and
temporal parameters influencing the dynamics of PKB anti-
apoptotic properties. Work already initiated has demonstrated the
ability of active PKB to translocate to the OMM or to be actively
imported into the mitochondrial sub-compartment in various cell
systems [8,144,145], suggesting its possible involvement in the
direct regulation of intra-mitochondrial signalling.
4. Conclusions
In the last decade, our understanding of PKB activation and
mechanisms for promoting cell survival has expanded rapidly.
Several PKB substrates involved in apoptosis have been
described and many processes inhibiting cell death have been
identified. In this context, the mitochondrion appears to be the
key organelle in which PKB drives its anti-apoptotic activities.
More precisely, PKB acts at different mitochondrial levels to
sustain cell life: pre-mitochondrial, mitochondrial and post-
mitochondrial. By modulating transcription factor activity or
inhibiting nucleus condensation/fragmentation, PKB interferes
with upstream mitochondrial cell death signals, but it also
maintains mitochondrial integrity by reinforcing the roles of key
players acting on mitochondrial membranes (Bcl-2 family
members). Moreover, caspase activity, which represents
mitochondrial downstream events in the apoptotic process,
can be prevented by PKB in different ways. Recently, several
studies have shown that mitochondria can also be fragmented in
cells that normally undergo programmed cell death, supporting
the notion that mitochondrial remodelling plays an important
role in the process. The function of PKB in this context is still
not clear and further investigations of its possible role as a
modulator of mitochondrial dynamics are required. This could
lead to a major breakthrough in our understanding of PKB
functions in cell survival. Altogether, the recent discoveries
relating to PKB substrates involved in apoptosis, as well as
progress on pharmaceutical compounds that specifically target
PKB, could lead to the generation of powerful tools for cancer
therapy.
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